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ABSTRACT
The aim of this work was the development of a novel drug delivery vehicle termed
nano-in-microparticles (NIMs) to evaluate the magnetic-field dependent targeting of dry
powder NIMs administered endotracheally using an ex vivo and in vivo rodent model. NIMs
are a novel dry powder drug delivery vehicle containing 70% lactose (w/w), 20% SPIONs
(w/w) and 10% fluorescent nanospheres (w/w). Mice were insufflated with NIMs delivery
vehicle in the presence of magnetic field dependent targeting to the left ventral lung after
thoracotomy; controls were insufflated with the NIMs in the absence of magnetic field
dependent targeting. Quantification of deposition of the dye component (drug surrogate) of
NIMS in left and right lung tissue showed an increase in fluorescence to the left lung,
resulting in nearly a 3-fold increase in deposition of dye in NIMS when administered and
targeted to the left lung. Quantification of iron in lung tissue showed significantly more in the
left lung, corroborating deposition of the dye surrogate. The administration of an aerosol
liquid suspension delivery vehicle in the presence and absence of magnetic field dependent
targeting was also evaluated and did not show significance in magnetic field dependent
targeting when compared to dry powder NIMs. Toxicity study results indicate that
doxorubicin-containing NIMs showed more toxicity than the free doxorubicin control, and
that a dose dependent increase in toxicity is observed over time in lung tumor cells exposed
to doxorubicin-containing-NIMS. We conclude that 1) the NIMs vehicle can be targeted
significantly better as a pulmonary drug delivery agent to specific regions of the lung than
liquid suspension and 2) Doxorubicin containing NIMs are more toxic to A549 lung
adenocarcinoma cells as free drug, making NIMs ideal for a targetable inhaled drug delivery
vehicle.
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Concomitantly, we developed a lung cancer animal-imaging model by subcutaneous
xenograft and orthotopic lung implantation of NSCLC adenocarcinoma cells (A549) that
were genetically modified with the human sodium iodide symporter gene (hNIS; SLC5A5)
for the purpose of tumor imaging. Lung tumor growth was quantified using single-photon
emission computer tomography (SPECT) and computed tomography (CT) imaging. hNIS is a
membrane glycoprotein that normally transports iodide in the thyroid, and has the ability to
symport the radiotracer 99mTcO4-. A549 cells were genetically modified with plasmid and
lentiviral vector constructs to stably express hNIS. Modified tumor cells were then implanted
into nude mice to develop two tumor models: the subcutaneous xenograft model and a
xenograft orthotopic tumor model. Tumor progression was longitudinally imaged by
SPECT/CT, and quantified by SPECT voxel analysis. hNIS expression in lung tumors was
quantified using quantitative PCR (qPCR). In addition, hematoxylin and eosin staining and
visual inspection of pulmonary tumors were also performed. Orthotopic tumors induced by
the A549-hNIS-lentiviral vector cell line exhibited a logarithmic increase in SPECT
scintillation over orthotopic tumors induced by the A549 hNIS-plasmid vector cell line and
A549 unmodified control cells in vitro and in the tumor bearing mice models. Furthermore,
orthotopic implantation of tumor cells, injected between the 5th and 6th intercostal rib space of
the left lung achieved a 100% orthotopic tumor take rate showing the replicative precision of
this model. We developed a highly sensitive spatial and temporal lung tumor-imaging model
that could ultimately be used to test the therapeutic efficacy of novel inhaled
chemotherapeutic agents.
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Chapter 1: Introduction and Background
Lung cancer: a 20th and 21st century problem
Lung cancer is responsible for 27% of total cancer deaths in the United States and
is the leading cause of death of all cancers diagnosed in 2014 (Siegel et al., 2014;
American Cancer Society, 2014). Among men, lung and bronchus cancer is the second
leading cancer site, accounting for 14% of total new cancer cases diagnosed and 28% of
the total cancer deaths (American Cancer Society, 2014) (Fig. 1A). Similarly among
women, lung and bronchus cancer is the second leading cancer site, accounting for 14%
of total new cases diagnosed and 26% of the total cancer deaths (American Cancer
Society, 2014) (Fig. 1A). The American Cancer Society estimates 224,210 new cases of
lung cancer in the United States (2014; 116,000 in men and 108,210 in women) (Fig. 1 B,
C). In January 2014, the Morbidity and Mortality Report from The Centers for Disease
Control published that lung cancer incidence rates have dropped 2.6% per year among
men, from 87 cases to 78 cases per 100,000 men from 2005 - 2009. In women, the rate
decreased 1.1% per year, from 57 to 54 cases per 100,000 women. The fastest drop was
among adults aged 35 – 44 years and is attributed to a decline in the number of young
adults smoking in the United States.
While active smoking accounts for 85 - 90% of cases attributed to cause, 10 –
15% of all lung cancers arise in those who have never smoked (Samet et al. 2009; Thun
et al. 2006; Siegel et al. 2014). Interestingly, lung cancer is currently rising among those
non-smoking (Locher et al., 2013). The leading cause of lung cancer in nonsmokers
according to the US Environmental Protection Agency (EPA) is exposure to radon gas.
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Figure 1: Trends in incidence and mortality rates. Graphs depict trends in incidence and
mortality from all cancers diagnosed from 1975 – 2010. Data from the American Cancer
Association and the Surveillance, Epidemiology, and End Results (SEER) Program,
National Cancer Institute 2013, accessed July 16, 2014.
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Radon exposure accounts for approximately 20,000 deaths, or 10% of lung cancer cause
(Krewski et al., 2005). Another 9 - 15% of lung cancer cases are caused by occupational
carcinogen exposure (Field and Withers, 2012), including asbestos (Currie et al., uranium
(Furlow 2014) and iron (Wild, Bourgkard, and Paris 2009)from smelters, blast furnaces
and foundries. Air pollution causes another 1-2% of lung cancer (Cesaroni et al., 2013;
Raaschou-Nielsen et al., 2011). Finally, a small portion (≤1%) of lung cancer occurs in
people with no known risk factors for the disease. Lung cancers in non-smokers often
have certain gene differences in tumors that are different from those from smokers, such
as the TP53 (Mogi and Kuwano, 2011) or p16 (Andujar et al., 2010) tumor suppressor
genes and the K-RAS oncogene (D'Arcangelo and Cappuzzo, 2012) in NSCLC.
The five-year survival rate for lung cancer is 53.5% for cases detected when the
disease is localized within the lungs (Siegel et al., 2014). However, only 15% of lung
cancer cases are diagnosed at an early stage. For lung tumors that have spread to other
organs, the five-year survival rate is a mere 3.9%. Of all patients diagnosed with NSCLC,
less than 10% of patients survive more than 5 years (Mazzone and Mekhail, 2012). Thus,
efforts to detect and treat lung cancer have severe limitations and have failed to
ameliorate lung cancer survival rates despite emerging therapeutics and delivery systems.
There are 2 major types of lung cancer: Small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). Approximately 85-90% of lung cancers are NSCLC
(Syrigos, Nutting, and Roussos, 2006). There are 3 main subtypes of NSCLC: 1)
squamous cell carcinoma, 2) large cell (undifferentiated) carcinoma, and 3)
adenocarcinoma. For this research, I have focused on lung adenocarcinoma because it is
the most prevalent form of NSCLC, accounting for about 85% of all lung cancers
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(Society 2014). Adenocarcinoma is the most applicable cancer for our proposed mode of
therapeutic drug delivery because it is confined to the lung, found in the outer pleural
cavity, and chemotherapy can reach affected tumor areas when administered by the
pulmonary route.
Current therapies for NSCLC
Treatment for NSCLC depends on the stage of the cancer. Surgery and resection
of the tumor and affected areas is a common treatment for NSCLC that has not spread to
nearby lymph nodes. Resection is invasive and often causes impaired lung function postsurgery. Radiation therapy can also be used if surgery is not possible, alone or in
combination with chemotherapy. Platinum-based chemotherapy doublet therapy has
showed modest improvement in patient outcome when compared with the best supportive
care (Schiller et al., 2002). Doublet chemotherapy has become the standard treatment
modality and is the cornerstone treatment for lung cancer. In metastatic disease, treatment
is based on the combination of cisplatin or carboplatin with drugs such as paclitaxel,
doxetaxel, gemcitabine and vinorelbine (Azzoli et al., 2010; Goffin et al. 2010).
Over the last two decades, the development of oncogene-directed targeted
therapies have significantly changed the treatment of NSCLC and quickly becoming a
first-line therapy. The first available targeted therapies for advanced NSCLC were
getfitinib (Kris et al. 2003; Cappuzzo et al., 2005) and erlotinib (Wang, Schmid-Bindert,
and Zhou 2012), both of which are small-molecule tyrosine kinase inhibitors (TKI)
against epidermal growth factors (EGFR) also known as HER 1 or ErbB-1. EGFR in lung
cancer is commonly overexpressed in NSCLC (Jänne and Engelman 2005; Sridhar et al.,
2003; Yang et al., 2014) and has been a motivational factor in the development of EGFR
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TKIs. Phase III clinical trials have demonstrated their antitumor activity for both
getfitinib and erlotinib (Shepherd and Pereira 2005; Thatcher et al. 2005). Both therapies
have been incorporated into treatment for patients after standard first-line chemotherapy.
Limitations to current therapies for NSCLC
Although targeted and tailored therapies are currently being used for NSCLC,
overall lung cancer survival rates have failed to improve for numerous reasons
(Subramanian, 2011). First, conventional lung cancer therapies are systemically
administered. They affect rapidly dividing cancerous cells as well as healthy cells. A
major obstacle to lung cancer treatment is the inability to selectively target and deliver
chemotherapeutics to cancerous cells. Second, effective drug concentrations in solid
tumors is a key parameter for successful treatment. Conventional lung therapies fail to
reach high concentrations at the target tumor site. Instead, drug is administered
systemically instead of regionally and high drug concentrations becomes toxic to vital
organs (Schiller et al. 2002; Minchinton and Tannock 2006). Third, multidrug resistance
(MDR) is a well-characterized broad pattern of cross-resistance to unrelated drugs after
exposure to a single drug. Interestingly, this pattern has been observed in in vitro culture
models and in the clinic. Drug resistance is the main cause of the failure of chemotherapy
in malignant tumors and is usually diagnosed during treatment after a long period of drug
administration. The MDR phenotype can occur as a result of cellular adaptations
including reduced drug uptake, increased drug efflux, alterations in intracellular drug
distribution or inadequate induction of apoptosis (Wangari-Talbot, 2013).
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The Pulmonary Drug Delivery Approach
The development of inhalational agents for oncological use has been limited
(Sharma et al. 2001) in the clinical setting. There is a large amount of published data
regarding aerosol delivery of chemotherapy in preclinical studies. Feasibility of aerosol
delivery has been shown in cancer cell cultures (Azarmi et al. 2008; Tseng et al. 2009;
Koshkina, Yang, and Kleinerman 2013), animal models (Roa et al. 2011; Hershey et al.
1999; Dames et al. 2007; Hasenpusch et al. 2012; Gagnadoux et al. 2008; Rodriguez and
Crabbs 2010; Yi and Wiedmann 2010), and Phase I/II human trials (Otterson et al. 2007;
Otterson et al. 2010; Tatsumura, Yamamoto, and Murakami 1983; Tatsumura et al. 1993;
Zarogoulidis et al. 2013; Lemarie et al. 2011). Most of these publications focus on the use
of nebulized drug delivery vehicles instead of dry powder delivery vehicles.
The chemotherapeutic agent, 5-fluorouracil (5-FU), was investigated in 1968 for
inhalational therapy. Tatsumura et al. (Tatsumura, Yamamoto, and Murakami 1983)
published research that treated patients with inhaled 5-FU preceded by surgery. They
found higher drug concentrations in the tumors than in the surrounding tissue. In a later
study, Tatsumura et al.(Tatsumura et al. 1993) found high 5-FU concentrations in the
main bronchus and adjacent lymph nodes for nearly 4 hours post administration.
Formulation of 5-FU with lipid-coated nanoparticles showed sustained drug release and
enhanced anticancer properties (Hitzman and Elmquist 2006). Otterson et al (Otterson et
al. 2007; Otterson et al. 2010) administered inhaled doxorubicin in a Phase I and later in a
Phase I/II clinical study. They demonstrated the adverse effects of aerosol treatment such
as metallic taste, mild bronchospasm, moderate reduction of pulmonary function, and
pulmonary dose-limiting toxicity. However, none of these studies used a targeting
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mechanism of any sort. Azarmi et al. formulated poly (butylcyanocrylate) nanoparticles
with doxorubicin for inhaled, targeted drug delivery to the lung via encapsulation in
lactose carrier particles made by spray-freeze drying. He showed successful in vitro
uptake into H460 and A549 lung cancer lines and targeting of their drug delivery vehicle
through endocytosis rather than passive diffusion.
Advantages of the Pulmonary Drug Delivery Approach
The direct drug administration of chemotherapeutics and adjuvants to the
respiratory tract by inhalation offers many theoretical advantages over a traditional drug
delivery system (Labiris and Dolovich 2003). 1) Drugs can be delivered regionally
instead of systemically, directly to the disease site. 2) Regional delivery allows for a
lower drug dose to be used resulting in 3) fewer systemic side effects 4) allowing for the
bypass of barriers to therapeutic efficacy such as poor gastrointestinal absorption and
first-pass metabolism of the drug in the liver. 4) The use of a non-invasive “needle-free”
delivery system. 5) Inhalable carriers allow for a wide range of substances to be
delivered, from small molecules to very large proteins (Wolff 1998). 6) The lung has an
enormous absorptive surface area (100 m2) and a highly permeable membrane (0.2 – 0.7
µm thickness) in the alveolar region (Patton and Byron 2007). 7) Large molecules with
low absorption rates can be absorbed in significant quantities due to the slow mucociliary
clearance in the lung periphery resulting in prolonged residency in the lung (Agnew,
Pavia, and Clarke 1981).
In addition, formulations of inhaled drug delivery vehicles as dry powders have
many advantages as well. 1) Dry powders have greater chemical and physical stability
compared to dispersions for nebulization thus increasing their shelf-life. A dry powder is
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more stable than a nebulized suspension and can reach the tumor site without releasing its
payload. The nebulized suspension can prematurely degrade or agglomerate, whereas we
have shown that we can overcome this limitation with a dry powder. 2) Medication as an
inhaled dry powder can be given as a single dose in one breath. This reduces treatment
time and improves patient compliance. 2) Dry powder formulations may not require coldchain storage.
Limitations of the Pulmonary Drug Delivery Approach
A number of acute and latent effects observed in a small number of human trial
studies are still under investigation for inhaled chemotherapy administration. 1)
Pulmonary dose limiting dose toxicity as shown by Otterson et al. (Otterson et al. 2007;
Otterson et al. 2010) 2) Cases where studies have failed to demonstrate the long-term
effects of the chemotherapeutic drug formulations in the lung parenchyma (Darwiche et
al. 2013).
Transportation problems stemming from improperly functioning conducting airways
may lead to impaired respiration and particle transport. 1) Patients with compromised
lung function have impaired respiration through bronchoconstriction, which leads to
inefficient drug delivery to the lung or even impaired pulmonary absorption ability. 2)
Damage to the ciliated epithelium may also limit the mucociliary clearance of particles
impacted in the upper airway, especially in the case of dry powders. 3) Respiratory flow
rate can also affect the dose delivered to the patient, as well as dose reproducibility.
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Physiological Factors Affecting Inhaled Therapeutic Effectiveness
The extent of particle deposition matters largely on the physiological factors of
the patient. The method of inhalation by the patient influences the outcome of particle
deposition in terms of location and degree. The airflow pattern and structure of the
conducting airways will determine the particle deposition in the throat, how much is
swallowed, and in turn, the dose available for lung deposition (Borgström, Olsson, and
Thorsson 2006).
Diseases such as asthma or chronic pulmonary obstructive diseases can obstruct
the airway. An obstructed throat causes recirculation of air in both directions, which
greatly alters flow characteristics (Luo, Liu, and Yang 2007). Patients that suffer from
asthma have constricted or narrowing of the pharyngeal airway. This results in increased
oropharyngeal deposition of an aerosolized dose due to clearance impaction, reducing the
total dose delivered to the lungs (Svartengren et al. 1996).
Use of Dry Powders to Generate a Pulmonary Immune Response
Pulmonary delivery of vaccines has gained major attention for achieving both
mucosal and systemic immunity (Sou et al. 2011). Delivery of macromolecules in the
form of dry powder aerosols to the pulmonary system has been widely suggested as a
promising non-parenteral delivery route that provides improved stability when compared
with conventional liquid formulations (Weers, Tarara, and Clark 2007) (Schüle et al.
2008). An optimum formulation containing NPs as dry powder nanoparticles can result in
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greater stability, ambient storage conditions, and a better immune response compared to
traditional liquid-based vaccines (Kunda et al. 2012).
Muttil et al. prepared PLGA NPs entrapping diphtheria CRM-197 antigen (size
200 ± 50 nm) by the emulsification solvent diffusion and double-emulsion methods. The
NPs were then spray-dried with L-leucine and the resulting spray-dried powders were
delivered in guinea pig lungs to evaluate the immune response following pulmonary and
parenteral immunizations with the dry powders. The highest titer of serum IgG antibody
was observed in guinea pigs immunized by the intramuscular route whereas high IgA
titers were observed for dry powder formulations administered by the pulmonary route.
This demonstrates that pulmonary immunization with dry powder vaccines leads to a
high mucosal immune response in the respiratory tract and sufficient neutralizing
antibodies in the systemic circulation to provide protection against diphtheria (Muttil et
al. 2010). Particle size and surface charge of the material to be delivered plays an
important role in determining the uptake by human dendritic cells (DCs) derived from
blood (Foged et al. 2005). The excipients dissolve upon encountering the respiratory
environment and thereby release the nanoparticles upon phagocytosis by antigen
presenting cells such as dendritic cells, NPs release the antigen intracellularly and elicit
CD8+ and CD4+ T cell responses (Doria-Rose and Haigwood, 2003). Furthermore, the
optimal uptake by DCs occurs when the particle size is ~ 0.5 µm. Uptake of large
particles (~ 1 µm) was greatly enhanced when they displayed a positive surface charge
(Kunda et al. 2012) (Foged et al. 2005).
Micro- and Nanoparticles as Drug Delivery Vehicles
Spherical delivery vehicles are often called particles, capsules, or carriers and can
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range in size from several nanometers to tens of micrometers. Microparticles for inhaled
drug delivery are optimally in the size of 1 – 3 um to achieve alveolar deposition (Gerrity
et al. 1979).
Depending on the target delivery region, particles should exhibit desirable particle
size distribution ideally with aerodynamic diameters (da) of 5-10 µm for airways and 1-5
µm for deep lung delivery with a standard density of 1 g cm-1. Particles less than 0.5 µm
(NPs) are driven by diffusion and are most likely to be exhaled, hence they are therefore
often encapsulated and delivered within dry powder microparticles.
Brief History of Magnetic Particle Targeting
Magnetic iron oxide has been used to impart a magnetic moment to particles in
the field of biotechnology since the 1970s (Kakar, Batra, and Singh 2013). Kakar
provides a very thorough review of the insights that magnetic particle systems have
provided for biomedical application. Gilchrist et al. published a paper in 1956 on the
selective inductive heating of lymph nodes after injection of 20 – 100 nm sized magnetite
particles into the lymph nodes near surgically removed cancer (Gilchrist et al., 1957).
This was a seminal paper using hyperthermia to thermally ablate tumor cells. Meyers et
al. described how magnetic carriers were able to accumulate small iron particles when
intravenously injected into the leg veins of dogs using a large, externally applied horse
shoe magnet (Meyers, Cronic, and Nice, 1963).
Defined spherical magnetic microspheres containing albumin were made for the
first time in the 1970’s for tumor therapy and as magnetic resonance contrast agents
(Widder, Senyei, and Ranney 1979). Many attempts have been made to develop magnetic
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drug targeting methods but none have progressed to clinical trials (A. K. Gupta and
Gupta 2005; Häfeli 2004; Babincova and Babinec 2009). An example of a magnetic
targeted carrier drug platform was the FDA-approved was FeRx, Inc (San Diego, CA)
which contained up to 80% of metallic iron with the remaining comprised of activated
carbon (Rudge et al. 2000). The systemic application of magnetic nanoparticles proved
difficult because of their rapid clearance from the blood via the RES, but improvements
in functionalization using polyethylene glycols (PEG) has overcome this limitation.
Superparamagnetic Iron Oxide Nanoparticles (SPIONs)
Superparamagnetism is a phenomenon where magnetic materials exhibit a
behavior similar to paramagnetism at temperatures below the Curie or the Neel
temperature (Sadhukha, Wiedmann, and Panyam 2013). SPIONs are small synthetic
Fe3O4 particles with core sizes ranging between 5 nm and 99 nm in diameter. SPIONs
consist of a single (individual) magnetic domain of elements that can be aligned in the
presence of an external magnetic field allowing for magnetic-field-dependent targeting,
hyperthermia induced cancer-cell killing or MRI resonance imaging. SPIONs have
unique physical and chemical features such as a large surface area to mass ratio, which
make them ideal for ligand attachment binding or for the delivery of cargo payload.
Formulation of Inhalable Dry Powders
The process of spray drying is used to create fine dry powders for pulmonary
delivery. The spray drying technique has been well recognized since the 1990s (Chan and
Chew 2003). We use the B-290 mini-spray dryer in our lab, manufactured by the
company Buchi. Spray drying is a pharmaceutical manufacturing process used to produce
respirable particles in the solid state.
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Figure 2A shows a schematic of the B-290 and Figure 2B details the mechanics of
the spray drying process. First, the inlet air of the spray dryer is heated to average
temperatures ranging between 50 °C to 185 °C, depending on the materials being spray
dried, with a maximum of 220 °C (Figure 2B – circle 1). Next, using a two-fluid nozzle,
droplets are formed. Conductive heat is exchanged between the drying nitrogen gas and
the sample
in the
Mini
Spray droplets
Dryer B-290
Technical data sheet

drying chamber (Fig. 2B – circle 3). The dry powders are

collected in the particle collection chamber attached to the cyclone (Fig. 2B – circle 4).

The Mini Spray Dryer B-290 is the world leading laboratory scale Spray Dryer since many years.
It is designed to visualize your Spray Drying process for wide range of applications in various
fields such as pharma, materials, chemistry, food, feed, beverages, etc. It allows working with
acids, organic solvents or mixtures of aqueous- and organic solvents safely in combination with
the Inert Loop B-295 and the Dehumidifier B-296.

A

Functional principle
Step 1 - Heating:
Heat the inlet air to the desired temperature
(max. 220 °C)

B

Step 2 - Droplet formation:
Two-fluid nozzle for the B-290 and.
Step 3 - Drying chamber:
Conductive heat exchange between drying gas
and sample droplets.
Step 4 - Particle collection:
Cyclone technology
Step 5 - Outlet filter:
Collection of finest particles to protect the user
and the environment.
Step 6 - Drying gas:
Delivered by aspirator
Functional
principle ofof
the
sample
feedB-290
dispersion
Figure 2:
A) Schematic
the
Buchi
Spray dryer and B) step-wise mechanism of
The Mini Spray Dryer has a integrated two-fluid nozzle: Compressed gas (normally air or N2) is used to
disperse the liquid body into fine droplets which are subsequently dried in the cylinder.

the spray drying process.
1.
2.
3.
4.
5.
6.

Feed solution
Peristaltic pump
Two fluid nozzle
Connection for cooling water
Connection for compressed spray gas
Automatic nozzle cleaning system

Compared to other methods of powder manufacturing like milling or lyophilization,
spray drying yields dry powders with good aerodynamic properties (e.g. flow and
13
Functional principle of the closed mode with the Inert Loop B-295

dispersability) and offers more control over their dry physicochemical properties because
variables like atomization, drying dynamics and liquid properties can be fine tuned.
Operation variables can be manipulated through interrelated parameters such as the inlet
air temperature, the drying air flow rate, the liquid feeding rate, the pressure of atomizing
air, as well as percent solids in the solution (Cal and Sollohub 2010).
Dry powders can be formulated with various excipients (co-polymers or sugars,
e.g. manitol, trehalose, or maltodextrin) for controlled release (O'Hagan et al. 1991;
O'Hagan et al., 2004). Spray drying excipients such as leucine or polymorphic forms of
drugs results in corrugated particles that have highly and improved dispersion behavior
(Hoppentocht, Hagedoorn, et al. 2014; Son et al. 2011; Son et al., 2012). Ester derivatives
of trehalose can increase the lipophilicity, reducing the extent or rate of crystallization of
spray dried powders, with a goal of sustained drug release (Davidson et al. 2003).
Factors Influencing Inhaled Microparticle Deposition
There are two primary modes of pulmonary aerosol administration: nasal and oral
inhalation. Microparticle deposition in the respiratory tract is dependent on multiple
factors:
1) Particle size: Particle size and its distribution are determined by the mass median
aerodynamic diameter (MMAD) and geometric standard deviation (GSD),
respectively.
2) Particle shape: Particles that are long and fibrous particles, such as asbestos, are
more likely to deposit and penetrate the alveoli because they orient parallel to air
flow streamlines. A particle with a greater aspect ratio can potentially be
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deposited deeper in the deep lung leading to a more efficacious therapeutic effect
(Ally, Kappl, and Butt 2012).
3) Particle density: Particle density refers to the mass per unit volume of the particle
itself. Liquid particles and earth-matter particles have a density equal to that of
their parent material. Smoke and fume particles may have apparent densities
significantly less than that of their chemical composition because of the large void
spaces in there highly agglomerated structure. By inserting “pores” into particles
by decreasing density (large porous particles), dispersion properties are improved
by reducing van der Waals forces and is beneficial for pulmonary delivery
(Crowder et al. 2002; Edwards et al., 1997).
4) Particle airflow velocity: The inhaled air follows through the nose or mouth – a
torturous path of branching airways in the lung. Flow is cyclical and reverses
many times a minute. At its peak, it may be turbulent in the trachea. As the
Reynolds number decreases with increasing lung depth, airflow becomes
increasingly laminar (Lippmann, Yeates, and Albert, 1980). Increasing air
velocity increases impaction deposition, but decreases sedimentation and
diffusion by decreasing residence time.
5) Tidal volume: The inhaled air at the start of each breath goes deeper into the lung
and remains longer than air inhaled later in the breath. The deeper the air goes and
the longer this air resides, the greater its depletion of inhaled particles.
6) Inter-patient physiological variations: Significant differences in respiratory tract
anatomy can affect flow rate including the diameter of the airway. The diameter
of the airway affects the particle as it contacts the airway surface. The surface of
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the mucous layer defines the effective diameter of the conducting airways. A
normal patient has a mucus layer that is ~5 µm thick; a patient with bronchitis has
a much thicker mucus layer which causes increased small airway particle
deposition by impaction and turbulent diffusion (Labiris et al., 2003).
7) Inhaler design: Differences in inhalers can lead to variable amounts of emitted
dose to a patient, based on resistance from the inhaler.
Mechanisms Governing Particle Deposition
There are three generally accepted mechanisms by which particle deposition in the
airway occurs:
1) Inertial impaction is the main deposition mechanism for particles > 3 µm,
accumulated in the upper trachea bronchial regions. Inertial impaction occurs
during passage through the oropharynx and large conducting airways if the
particles possess a certain mass and velocity. Hyperventilation can also influence
deposition by impaction.
2) Sedimentation by gravitational force occurs in the smaller bronchi, the
bronchioles, and the alveolar spaces where the airways are small and have low air
velocity. Sedimentation is influenced by breath holding, which increases
residence time and therefore deposition (Li and Ahmadi, 1995). Sedimentation is
less effective than diffusion when particles are < 0.5 µm (Lippmann, Yeates, and
Albert 1980).
3) Diffusion impacts particles in the range of 0.5 – 1.0 µm and is based on Brownian
motion (Lippmann, Yeates, and Albert 1980). Diffusion depends only on particle
size and not on particle density or shape.
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In most cases, the first three deposition mechanisms occur most frequently.
4) Interception occurs when the trajectory of a particle comes in contact with the
bronchial bifurcation, hence is significant only for fibrous particles and must be a
significant linear size and shape compared to the airway diameter because
aerodynamic drag can affect orientation within the airway.
5) Electrostatic mobility can influence enhanced respiratory tract deposition.
Particles carry a certain charge (e.g. freshly fractured mineral dust particles) and
can induce charge on the surface of the airways. Most aerosols have small
amounts of charge, however deposition due to electrostatic mobility is usually
non-significant in comparison to the first three mechanisms discussed.
Aerodynamics of Dry Powder Aerosols
The distribution and the deposition sites of inhaled particles is strongly dependent on
their aerodynamic diameters (Lippmann, Yeates, and Albert 1980). Airflow in the
respiratory system is complex and has been understood mainly from experimental studies
using physical models of lung airway. In the average adult, airflow is turbulent in the
upper airways. Airflow becomes more laminar, as indicated by Reynold’s number,
starting at generation 16 (as the generation number increases, airways become smaller).
Administration of Dry Powders In Vivo
Dry powders are delivered using a dry powder insufflator (DPI) (Penn-Century
Inc.) attached to a commercially available syringe. Vaccine liquid droplets are
administered using a Penn Century IA-1C Liquid Microsprayer Aerosolizer attached to a
FMJ-250 High Pressure Syringe (Penn-Century Inc., Wyndmoor, USA) (Sakagami 2006;
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Hoppentocht, Hoste, et al. 2014; Duret et al. 2012). Both devices are available
commercially.
Hoppentocht et al. (Hoppentocht, Hoste, et al. 2014) investigated the dispersion
efficiency of dry powders with the DP-4M Insufflator™ by comparing particle sizing
using RODOS dry powder sizing machine. He found many limitations of the DP-4M
Insufflator™ such as variability in dispersion efficiency and in the dose delivered to the
rodent. Two hundred µL of air, based on the Penn Century recommendation, was
insufficient to adequately disperse dry powers in mouse lungs. We also observed this
limitation and further discuss about the device in subsequent chapters.
A nose-only aerosol exposure chamber can be used to take advantage of a rodents’
natural breathing mechanism to inhale dry powders. A drawback of this aerosolization
method is that aerosols can deposit in the nasopharynx cavity in the rodent, thereby
becoming a subject of mucociliary clearance. This aerosolization device also requires the
delivery of large volume of particles and a significant amount of powder can be wasted
because of nasopharyngeal deposition.
Forces Acting on Dry Powders
All forces acting on dry powders were referenced from the book “Particulate
Interactions in Dry Powder Formulations for Inhalation” (Zeng, Martin, and Marriott,
2000).
1. Electrostatic Force (Coulombic): Electrostatic properties of formulation
component materials play an important role in dry powder inhalation products.
Fine powders exert charge on other particles and tend to be highly cohesive.
Electrostatic charges can arise from the contact of an uncharged particle with
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either a negatively or positively charged particle transferring electron and ions
among particles. When two charged particles are brought together, they will
experience attraction or repulsion depending on their electrical signs. The
electrostatic charge distribution of the particles affects the efficiency of drug
delivery by influencing both the transport and deposition of inhaled particles
(Balachandran, Machowski, and Gaura 1997) (Beleca et al. 2010).
2. Drag force: Drag force is the predominant force acting on particles in the
conducting airways. Drag force is due to static pressure gradients in the flow.
(Dunber, Hickey, and Holzner 1998).
3. Buoyancy force: This force is caused by the Saffman lift force (a result of the
velocity gradient of the air or fluid), the Magnus force (caused by particle contact
and rebound from the conducting airway wall) and centrifugal force (affected by
the mass and the diameter of the drug particle).
4. Friction: Forces of friction may play a role at the initiation of powder dispersion
and to a lesser extent, during aerosol delivery (Podczeck 1997).
5. Dispersion Forces (Van der Waals force): These forces are present in fine dry
powders causing clumping behavior, an example of a cohesive force. The major
force between uncharged particles is Van der Waals force.
Particle Characterization
1. Size and size distribution: The determination of aerodynamic diameter by measuring
the mass median aerodynamic diameter (MMAD) is one of the most important
characterization parameters in terms of particle deposition by impaction and
sedimentation. MMAD and geometric standard deviation (GSD) are determined by
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cascade impaction studies. Fine particle fraction (FPF) is also determined using the
impactor, and is defined as the percentage of particles in the respirable size range of 1
– 5 µm (Telko and Hickey, 2005).
2. Moisture content: Hygroscopicity is the intrinsic tendency of a material to take on
moisture from its surroundings (Telko and Hickey, 2005). Moisture uptake and loss
can result in local dissolution and recrystallization, leading to irreversible aggregation
through solid bridge formation, which can adversely affect aerosol generation and
lung deposition (Braun, Oschmann, and Schmidt 1996). Moisture uptake can be
quantified using a Karl Fischer (KF) colometric titration. Dynamic Vapor Sorption
(DVS) can also be used to determine moisture uptake.
3. Glass transition (Tg): The crystalline or amorphous state of materials can be
determined by differential scanning calorimetry (DSC).
4. Drug release and dissolution properties: Drug release profiles are critical for inhaled
drugs in order to evaluate the pharmacokinetic profile and hence the bioavailability of
the drug.
5. Surface characteristics: Electron microscopy (SEM/TEM) is used to determine
corroborate particle size and determine physical surface characteristics morphology.
6. X-ray diffraction: XRD can be used to determine bond lengths and bond angles
defined by intermolecular spacing, which is directly related to crystalline properties
of the material (Brittain, 1995).
7. Determination of metal content: Inductively Coupled Plasma – Optical Emission
Spectrometry can be used to determine amounts of metal in a drug delivery system,
for example iron.
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Brief History of the Subcutaneous Xenograft Animal Model
The most commonly used animal model is a tumor xenograft in immunodeficient
mice. The term “xeno” has greek origin meaning from a foreign place. In the case of lung
cancer, a lung cancer cell or tissue is placed in a region other than the lung; usually in a
flank or shoulder region. Xenografts initiated through the injection of tumor cells from
cell culture or through transplantation of a small tumor mass.
Multiple types of tumor installation methodologies exist. Xenograft tumor models
are most commonly used in immunodeficient mice (Olive et al, 2006). Xenograft models
can be initiated through the subcutaneous or intravenous injection of tumor cells from
cell culture or tissue transplantation. Xenograft transplants may be orthotopic, meaning
that the tumor is placed in the site it would be expected to arise naturally in the host:
human lung cancer cells placed in the mouse’s lung. Orthotopically implanted xenograft
tumor models can be initiated through surgical transplantation of a small tumor mass or
by injection of tumor cells from cell culture through intravenous injection or intratracheal
injection.
An allograft mouse tumor system, also known as a syngeneic model, consists of
cancerous cells or solid tumors that are transplanted into a host mouse, derived from the
same genetic background as a given mouse strain (eMICE, NCI, nih.gov). Since the
cancer tissue and the recipient mouse share ancestry, the transplant is not rejected by the
host’s immune system. An advantage of a syngeneic model is that the host immune
system is normal, which may more closely represent a translational tumor
microenvironment. A disadvantage is that the transplanted mouse tissue will not fully
represent a human tumor.
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Orthotopic Animal Model and Clinical Relevance
In orthotopically-induced xenograft models human cells injected (or human tissue
implanted) in the appropriate organ or tissue of origin. Orthotopic lung cancer models can
be initiated multiple ways: using endobronchial, intrathoracic, or intravenous injection of
tumor cell suspensions. McLemore developed the first orthotopic lung cancer model in
1987 by implanting either human lung cancer cells or fragments of tissue into the lung of
nude mice by endobronchial injection (McLemore et al., 1987). An intrathoracic injection
model was used and resulted in moderate tumor take rate – 35% of fresh primary human
lung tumor specimens and 66% using cell inoculum.
Advantages of orthotopic tumor models include 1) Improved tumor take rate 2)
Enhanced invasive and metastatic properties to the mediastinal lymph nodes. 3) Tumors
arise in the organ-specific site providing a better representative host-tumor
microenvironment. 4) Provides relevant pharmacokinetic and pharmacodynamics features
more characteristic of human cancer than s.c. implanted tumors.
Disadvantages of orthotopic tumor models include 1) Animal lifetime is often
shortened due to virulent tumor growth 2) Tumors imaging requires equipment that is
expensive and may not be easily accessible 3) Tumors imaging is more time intensive
than using digital calipers for s.c. xenografts 4) Orthotopic models are more costly to
produce than s.c. models because imaging machinery is required. 5) The installation
technique requires practice for tumor reproducibility.
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Thesis Aims, Hypotheses and Expected Outcomes
The long-term goal of this research is two-fold: 1) to target a novel drug delivery
vehicle containing a therapeutic agent to the respiratory tract of a healthy animal model
2) to develop an animal orthotopic imaging model using a modified symporter-A549 cell
to longitudinally image resulting tumor burden in the same animal. The central
hypothesis of this project is that magnetically responsive nano-in-microparticles (NIMs)
in the presence of magnetic-field-dependent-targeting will be retained in specific regions
of the respiratory tract and achieve high drug concentrations in lung regions.
Concomitantly, an orthotopic tumor model exploiting the sodium iodide (NaI) symporter
(NIS) mechanism will allow for longitudinal SPECT/CT imaging of tumor burden. We
tested our central hypothesis and accomplished the overall objective of this proposal by
pursuing the following specific aims:

Specific Aim 1: Formulate, characterize and optimize an inhalable and magnetically
responsive drug delivery dry powder containing doxorubicin (termed nano-inmicroparticles; NIMs) and develop a proof-of-concept in vitro tracheal mimic inhalation
delivery system utilizing magnetic-field-dependent-targeting and retention of NIMs.
I hypothesized that by using the spray drying technique, a novel magnetically
responsive dry powder drug delivery vehicle could be formulated for pulmonary
administration. This formulation contains the active pharmaceutical ingredient
doxorubicin, SPIONs, and the excipient lactose. Expected outcomes: These studies could
demonstrate that by optimizing spray drying parameters and formulation component
concentrations, the resulting dry powders will be of the correct mass median aerodynamic
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diameter, geometry, morphology, charge and magnetic susceptibility for pulmonary
administration. I also hypothesized that aerosolized NIMs will be targeted and retained in
specific regions of respiratory tract influenced by magnetic-field-dependent-targeting.
Expected outcomes: These studies could demonstrate, by the mechanism of magnetic
targeting and inertial-impaction, that NIMs will be deposited and retained in a human
tracheal mimic model and an ex vivo rat model.

Specific Aim 2: Target magnetically responsive NIMs to specific regions of the
respiratory tract in healthy rats.
I hypothesized that pulmonary administration of NIMs could allow magneticfield-dependent-targeting in a healthy mouse model. Expected outcomes: These studies
could demonstrate that NIMs will be delivered and targeted to the left lung of the
respiratory tract using a Dry Powder Insufflator™ in the presence of an externally placed
permanent magnet. Dry powder NIMs could be compared to the administration of an
aerosolized and targeted liquid suspension, again, in the presence and absence of
magnetic-field dependent targeting.

Specific Aim 3: Develop a preclinical orthotopic tumor model for the purposes of
longitudinal tumor imaging using SPECT/CT.
I hypothesized that an orthotopic tumor model exploiting the sodium iodide (NaI)
symporter (NIS) mechanism could allow for longitudinal SPECT/CT imaging of tumor
burden. Expected outcomes: These studies demonstrate that by developing an orthotopic
tumor using A549-NIS modified cells, the tumor will sequester 99mTc allowing for
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SPECT/CT tumor burden imaging. Ultimately this will allow me to investigate the effects
of inhaled therapeutic agents in the same animal over a longitudinal period of time.
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Chapter 2:

Novel Preparation and Characterization
of Magnetic Nano-in-Microparticle
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INTRODUCTION
Lung cancer is the leading cause of cancer mortality worldwide, with 1.4 million people dying
from the disease each year, as of 2008 (1). Despite advances in surgery and treatment, the 5-year
survival rate from 2001-2007 was 15% and has remained largely unchanged for decades (2). These
statistics are due, in part, to a conventional drug delivery system that neither adequately delivers
nor maintains sufficient drug concentration near solid lung tumors (3), leading to adverse effects
in healthy tissues. Clearly, there is an unmet medical need in the field of cancer therapy to selectively deliver chemotherapeutics to lung tumors and minimize side effects observed in healthy
tissues as well as to achieve effective therapy.
OBJECTIVE
We formulated and characterized microparticles containing Fe3O4 superparamagnetic iron oxide
nanoparticles (SPIONs) and the chemotherapeutic agent doxorubicin in a lactose matrix.
A proof-of-concept cylindrical glass tube was used to mimic the conducting airways of humans.
In conjunction with an external permanent magnet, magnetically responsive nano-in-microparticles
were directed and retained in a site-specific region inside the tube. Previously, Dames, et al. (4)
targeted nebulized droplets containing SPIONs and pDNA, a therapeutic mimic, to specific lobe
regions in a mouse lung. Although significant deposition was shown in the magnetized lobe,
separation of pDNA from SPIONs during the delivery process was observed.
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METHODS
Formulation of Inhalable Magnetic Microparticles
A suspension containing 77% lactose, 20% SPIONs, and 3% doxorubicin in ddH20 (% w/w) were
spray dried using a Büchi mini-spray dryer B-290 to achieve nano-in-microparticles dry powders
(Büchi Corporation, Flawil, Switzerland). Spray drying parameters were as follows: inlet temperature 170 ± 2°C, outlet temperature 103 ± 2°C, aspirator rate 100%, and atomization air flow rate of
742 NL/h (equivalent to a spray rate of 60 mm). The yield was calculated as the ratio of the mass
of solids collected after spray drying to the amount of solids in the feed suspension. Carrier control
particles were manufactured containing 5% lactose only (% w/v) in ddH2O, made into a solution
and spray dried as previously stated.
Microparticle Characterization
The hydrodynamic and aerodynamic size and particle characteristics of the nano-in-microparticle
dry powders were determined by laser diffraction, cascade impaction and electron microscopy.
Energy-dispersive x-ray spectroscopy (EDS) via scanning electron microscopy (SEM) was used to
elementally analyze Fe on the particle surface, whereas, inductively coupled plasma (ICP) quantified the amount of Fe loading in the microparticle.
Proof-of-Concept Tracheal Mimic Tube Study
A cylindrical borosilicate glass tube (two-centimeter diameter by 25-centimeter length) was designed
to mimic the conducting airways of the human respiratory tract. Two different formulations were
administered: the aforementioned nano-in-microparticle dry powder formulation, and a nebulized
liquid suspension. Both contained a fluorescent dye as a surrogate for doxorubicin. For our in vitro
investigation, the highest magnetic grade commercially available neodymium permanent magnet
(grade 52, Δ B < 0.58 T) was used. This was placed on the external vertical axis of the tube to
achieve targeting of the magnetically responsive nano-in-microparticle dry powders to a specific
region of the tube. When conducting in vivo experiments, we plan to use a higher magnetic flux
gradient as reported in the literature (4). An insufflator and microsprayer (Penn Century) were
used to aerosolize the dry powders (n = 3) and liquid suspension, respectively. Relative fluorescence
intensity was quantified using the Carestream Molecular Image Station 4000 MM Pro.
RESULTS AND DISCUSSION
TEM and SEM images of the nano-in-microparticle dry powder containing SPIONs and doxorubicin indicated the microparticle to be spherical in shape (Figures 1A and 1B). The geometric
diameter of the microparticle was 1.6 µm as determined by SEM imaging. TEM images suggested that SPIONs are uniformly distributed throughout the microparticle delivery vehicle. SEM
reveals the rough outer surface of individual microparticles due to the protrusion of the SPIONs
from the microparticle surface (Figure 1C). An average geometric diameter of 1.6 µm was measured
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with laser diffraction, and corroborated with SEM. The aerodynamic particle size characterization
was determined using a next generation cascade impactor (NGI) and showed a mass median aerodynamic diameter (MMAD) of 3.27 µm, administered using the Penn Century insufflator at a
flow rate of 15 L/min, simulating compromised lung function. The average fine particle fraction
of the microparticles was 96% with a geometric standard deviation (GSD) of ±1.69 µm. The theoretical powder yield was 60.9%. EDS and ICP showed the microparticle surface composition to
be 16.08% ± 0.5 Fe and 7.44% ± 0.3 Fe, respectively, compared to the theoretical 20% (w/w) Fe
loading in the microparticle. Based on this data, we suggest differential SPION partitioning to the
outer microparticle surface versus the inner microparticle matrix. Proof-of-concept tracheal tube
studies showed significant spatial deposition of the nano-in-microparticle dry powders in regions
experiencing a strong magnetic flux (Figure 2A). This correlates the amount of drug delivery
vehicle that could be deposited to a specified location using our delivery method and aerosolized
dry powders. Quantitative fluorescence analysis showed increased deposition of aerosolized dry
powders (mean = 430, SE = 101) near the magnet based on greater fluorescence intensity, compared
to the aerosolized liquid formulation (mean = 211.0) (Figure 2B). Therefore, more therapeutic
could be directed and deposited in specific lung tumor regions with a dry powder formulation than
a liquid suspension.

Figure 1.

A) SEM micrograph of blank lactose dry powder with a smooth external morphology. B) TEM
micrograph of the outer edge of a particle incorporating electron dense SPIONs in a lactose
matrix. C) SEM micrograph of the rough external morphology of magnetically responsive dry
powder.
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A) The retention of a fluorescent surrogate marker in an aerosolized dry powder formulation
compared to aerosolized liquid suspension. B) Quantitative fluorescence intensity of the
compared formulations.

CONCLUSIONS
The formulation and characterization of a novel nano-in-microparticle dry powder was performed.
This work is novel because a magnetic dry powder containing a chemotherapeutic agent can be
directed to specific regions of the lung more efficiently compared to aerosolized liquid suspensions
containing SPIONs. The solid matrix of a dry powder will allow a better association between the
chemotherapeutic agent and SPIONS, thus preventing the separation of the drug from the SPIONs
during the inhalation process. This was demonstrated in a proof-of-concept tracheal tube study,
assessed by relative fluorescence. Magnetic dry powder microparticles have nearly twice the fluorescent intensity and will therefore better accumulate in a specific region compared to the magnetic
aerosolized liquid suspension. Accordingly, the aerosolized liquid suspension showed decreased
fluorescence, due to the premature separation of the drug surrogate dye from the SPIONs before
reaching the region of interest. Therefore, targeting magnetically responsive powders containing a
chemotherapeutic agent could lead to efficient targeting to lung tumor regions. This novel delivery
system could minimize the side effects observed in healthy tissues due to the chemotherapeutic
agent, and has great potential for inhalation therapy in the future.
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Preparation and Characterization of Novel Magnetic Nano-inMicroparticles for Site-Speciﬁc Pulmonary Drug Delivery
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ABSTRACT: We propose the use of novel inhalable nano-in-microparticles
(NIMs) for site-speciﬁc pulmonary drug delivery. Conventional lung cancer therapy
has failed to achieve therapeutic drug concentrations at tumor sites without causing
adverse eﬀects in healthy tissue. To increase targeted drug delivery near lung
tumors, we have prepared and characterized a magnetically responsive dry powder
vehicle containing doxorubicin. A suspension of lactose, doxorubicin and Fe3O4
superparamagnetic iron oxide nanoparticles (SPIONs) were spray dried. NIMs
were characterized for their size and morphological properties by various
techniques: dynamic light scattering (DLS) and laser diﬀraction (LS) to determine hydrodynamic size of the SPIONs and
the NIMs, respectively; next generation cascade impactor (NGI) to determine the aerodynamic diameter and ﬁne particle
fraction (FPF); scanning (SEM) and transmission (TEM) electron microscopy to analyze particle surface morphology; electron
dispersive X-ray spectroscopy (EDS) to determine iron loading in NIMs; inductively coupled plasma atomic emission
spectroscopy (ICP-AES) and superconducting quantum interference device (SQUID) to determine Fe3O4 content in the
microparticles; and high performance liquid chromatography (HPLC) to determine doxorubicin loading in the vehicle. NIMs
deposition and retention near a magnetic ﬁeld was performed using a proof-of-concept cylindrical tube to mimic the conducting
airway deposition. The hydrodynamic size and zeta potential of SPIONs were 56 nm and −49 mV, respectively. The
hydrodynamic and aerodynamic NIM diameters were 1.6 μm and 3.27 ± 1.69 μm, respectively. SEM micrographs reveal
spherical particles with rough surface morphology. TEM and focused ion beam−SEM micrographs corroborate the porous
nature of NIMs, and surface localization of SPIONs. An in vitro tracheal mimic study demonstrates more than twice the spatial
deposition and retention of NIMs, compared to a liquid suspension, in regions under the inﬂuence of a strong magnetic gradient.
We report the novel formulation of an inhaled and magnetically responsive NIM drug delivery vehicle. This vehicle is capable of
being loaded with one or more chemotherapeutic agents, with future translational ability to be targeted to lung tumors using an
external magnetic ﬁeld.
KEYWORDS: pulmonary delivery, magnetic microparticles, inhalable dry powders, SPIONs, lung cancer therapy, spray drying

1. INTRODUCTION

chemotherapeutics. However, it has been associated with side
eﬀects.6
A major unmet medical need in the ﬁeld of cancer therapy is
to selectively deliver chemotherapeutic agents to lung tumors.
The objective is to minimize side eﬀects observed in healthy
lung tissues as well as to achieve eﬀective therapy. A phase I/II
study of inhaled doxorubicin combined with oral cisplatin and
docetaxel-based therapy for advanced non-small cell lung
cancer showed the eﬃcacy of inhaled therapy. Although
seven evaluable patients responded to the combined inhaled
and oral therapy, dose-limiting pulmonary toxicity was observed
in two patients due to a lack of drug-tumor targeting.7,8 This

Lung cancer is the leading cause of cancer mortality worldwide,
with 1.4 million people dying from the disease each year, as of
2008.1 Lung cancer accounts for more deaths than breast,
prostate, colon, liver and kidney cancers combined.2 In the
United States alone, 160,000 people died of lung cancer in
2010.3 Despite the use of new chemotherapeutic agents for
lung cancer, the average patient ﬁve-year survival rate is 5−15%
and has remained largely unchanged for decades.1
These statistics are due, in part, to conventional drug delivery
systems that neither deliver nor maintain suﬃcient drug
concentration near solid lung tumors,4 leading to adverse
eﬀects in healthy tissues. The lung oﬀers a unique and
challenging route for drug delivery with high absorption and
surface area, ca. 100 m2.5 Inhaled drug delivery is widely used
for diseases such as asthma, COPD and cystic ﬁbrosis and has
shown promise as an alternate delivery method for lung cancer
© 2013 American Chemical Society
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nanospheres (w/w). Nanospheres were used in the NIM
formulation, rather than a soluble dye, to avoid redistribution of
free dye following deposition in unmagnetized regions. Spray
drying parameters were the same for nanospheres and
doxorubicin-containing NIMs and were as follows: inlet
temperature 170 ± 2 °C, outlet temperature 103 ± 2 °C,
aspirator rate 100%, pump ﬂow rate of 10% and air ﬂow rate
742 L/h. Control lactose particles were prepared by spraying a
5% lactose solution (w/v) in ddH2O using the above
parameters. When spray drying doxorubicin and SPIONs, the
spray dryer was isolated in a walk-in chemical hood that was
vented to outside air to prevent exposure to toxic vapors.
Chemotherapeutic-resistant PPE was worn when handling
doxorubicin and NIMs.
2.3. Microparticle Characterization. 2.3.1. Yield and
Encapsulation Eﬃciency of Doxorubicin. NIM yield was
calculated as the ratio of the mass of solids collected after spray
drying to the amount of solids in the feed suspension. The
percentage encapsulation eﬃciency (EE) and percentage
doxorubicin loading in NIMs were determined using eqs 1
and 2, respectively:

study showed the beneﬁt of delivering agents directly to the
lung with diminished systemic side eﬀects.
Researchers have used Fe3O4 superparamagnetic iron oxide
nanoparticles (SPIONs) as a means to target drugs to speciﬁc
regions of the lung in animal models to mitigate the toxicity
observed in healthy lung tissues.9−11 If successful, this approach
will lead to improved tumor targeting, minimize the side eﬀects
observed in healthy tissues due to the chemotherapeutic agent,
and maximize the therapeutic outcome. Targeted pulmonary
drug delivery using SPIONs will also signiﬁcantly lower the
total drug dose required to achieve therapeutic response at the
tumor site, thus further alleviating the side eﬀects observed in
healthy tissues.
Previously, Dames, et al.11 and Rudolph et al.12 targeted
nebulized suspension containing SPIONs and pDNA, a
therapeutic mimic, to speciﬁc regions in a mouse lung.
Although signiﬁcant deposition of SPIONs was shown in the
magnetized lobe, separation of pDNA from SPIONs during the
delivery process was observed. Nebulized formulations used in
these studies lead to separation of the drug surrogate from the
SPIONs before reaching the intended target site. We propose
formulating and characterizing an inhalable dry powder vehicle
containing SPIONs and a chemotherapeutic agent. This novel
approach overcomes the natural deposition mechanism of
inhaled aerosol liquid droplets in the lungs that is limited by
targeting of aerosols to the central and peripheral airways but
not to local regions of the lung.
The objective of this study was to formulate and characterize
nano-in-microparticles (NIMs) containing SPIONs and the
chemotherapeutic agent doxorubicin in a lactose matrix. NIMs,
the ﬁrst of their kind formulated in a dry powder form, will
prevent premature separation of the chemotherapeutic agent
and SPIONs.13

% EE =

actual weight of doxorubicin in NIMs × 100
theoretical weight of doxorubicin in NIMs

% doxorubicin loading
actual weight of doxorubicin in NIMs × 100
=
NIMs weight

(1)

(2)

2.3.2. SPION Characterization: Hydrodynamic Size and
Zeta Potential. Hydrodynamic size (D50) was determined
using dynamic light scattering (Zetasizer Nano ZSP, Malvern
Instruments Ltd.). The samples were prepared by dispersing 1
μL [50 mg/mL] of SPIONs in 1 mL of ddH2O (n = 9). The
zeta potential of SPIONs was characterized by dispersing 0.5
μL [50 mg/mL] of SPIONs in 1 mL of ddH2O (n = 9),
expressed as size distribution by average intensity.
2.3.3. NIM Hydrodynamic Size. The volume median
diameter (Dv 0.5) of the NIMs was determined by laser
diﬀraction using the cuvette disperser (Helos/KF-OM,
Sympatec GmbH, Germany). Brieﬂy, 5.0 mg of NIMs was
suspended in 1 mL of acetonitrile and gently vortex-mixed. A
200 μL aliquot of this suspension was added dropwise to the 6
mL cuvette containing 5 mL of acetonitrile. Measurements
were taken for 10 s using the R3 lens in triplicate.
2.3.4. In Vitro Aerosolization Studies (Aerodynamic
Diameter). The aerodynamic size of the spray dried NIMs
containing dye was determined using a Next Generation
Impactor (model 170 NGI, MSP Corporation, Shoreview,
MN). NIM samples (6 mg) were aerosolized using a model
DP4 dry powder insuﬄator for rat (Penn Century, Inc., USA).
A pump (Copley Scientiﬁc, Nottingham, U.K.) was operated at
a ﬂow rate of 30.0 L/min for 10 min. Following aerosolization,
particle deposition was measured by gravimetric method from
collection cups. The percent cumulative mass fractions were
plotted versus log aerodynamic diameters. The mass median
aerodynamic diameter (MMAD) was estimated by linear
interpolation that links the curve points at 50% deposition.
The ﬁne particle fraction (FPF; stage 3 to stage 7, i.e. <6.4 μm)
was calculated as a percentage of total emitted dose (n = 3).
2.3.5. NIM Morphology and Cross Sectional Analysis. To
determine particle size, surface morphology and elemental
analysis, NIMs were visualized using a high-resolution scanning

2. EXPERIMENTAL SECTION
2.1. Materials. Alpha-D-(+)-lactose monohydrate Respitose
ML-001 was a gracious gift from DMV-Fonterra Excipients
GmbH & Co. KG (Goch, Germany). FluidMAG-UC SPIONs
with a hydrodynamic diameter of 50 nm were gifted and
purchased from Chemicell GmbH (Berlin, Germany). FluoroMax Green Fluorescent Polymer nanospheres (0.025 μm
diameter) were purchased from Thermo Fisher Scientiﬁc.
Adriamycin (doxorubicin) was purchased from Selleck
Chemicals, LLC (Houston, TX). A Gemini-NX 5 μm C18
110 A 150 × 4.6 mm HPLC column was purchased from
Phenomenex (Torrance, CA). OmniSolv acetonitrile, anhydrous, was obtained from EMD Chemicals (Gibbstown, NJ),
and all other reagents were of analytical grade and used as
received. Borosilicate glass tubes (20 mm × 120 mm) were
fabricated by Scientiﬁc Glass Co. Ltd. (Albuquerque, NM). A
commercially available neodymium−iron−boron (NdFeB)
permanent cylindrical magnet (grade N52, 22 mm long × 20
mm in diameter) was purchased from Applied Magnets (Plano,
TX).
2.2. Preparation of Inhalable Magnetic Microparticles.
NIMs containing ﬂuorescent nanospheres or a chemotherapeutic agent (doxorubicin) were prepared by spray drying.
A suspension containing 78.2% lactose, 20% SPIONs and 2.8%
doxorubicin (w/w) in double distilled water (ddH2O) was
spray dried using a mini-spray dryer B-290 with a standard twoﬂuid nozzle (0.7 mm diameter) (Büchi Corporation, Flawil,
Switzerland). NIMs were also formulated with a ﬂuorescent
nanosphere drug-surrogate; the drug was replaced with 4.0%
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Figure 1. Tracheal mimic tube study. A tracheal mimic tube was ﬁtted with an inhaler spacer and connected to vacuum pump mimicking breathing
inspiration, determined by a ﬂow meter at 15 L/min. A neodymium magnet was placed in a region of interest, and formulations of either NIMs or
liquid suspension were administered.

concentrations of 2 and 14 μg/mL were prepared by dispersing
NIMs into a suspension, separating the SPION component
using a magnetic gradient, and transferring supernatant to
HPLC vials. The HPLC system consisted of a 1260 Inﬁnity
Agilent LC (Agilent Technologies, Santa Clara, CA).
Integrations, calculations, and plotting of chromatograms
were performed with a Chemstation computing integrator
(Agilent Technologies, Houston, TX). A C18 HPLC column
was used, and the mobile phase was prepared by mixing
acetonitrile and water, adjusted to pH 3.0 with phosphoric acid,
at 72/28 (v/v) proportions. Doxorubicin eluted at 7.2 min with
a ﬂow rate of 1 mL/min. The UV detector was set at a
wavelength of 254 nm. The HPLC apparatus was operated at
room temperature.
2.3.8. SPION Magnetization Measurement. Magnetic
properties were measured with an MPMS-7XL SQUID
Susceptometer (Quantum Design, San Diego, CA) integrated
to a Physical Properties Measurement system (PPMS,
Quantum Design, San Diego, CA). The ac susceptibility
measurements were conducted in the temperature range from 4
to 300 K with nominal magnetic ﬁeld of 20 kOe. These
measurements allowed us to calculate the magnetic moment of
the SPIONs as well as the concentration of SPIONs in the
NIMs.
2.3.9. Permanent Magnet Characterization. The cylindrical permanent magnet (2.5 cm length × 2 cm diameter) was
characterized using a Bell-5180 series Hall eﬀect gauss/
teslameter and an STD18-0404 axial gaussmeter probe (Sypris
Test and Measurement, F.W. Bell, Orlando, FL). The Hall
eﬀect gaussmeter was used to measure the ﬂux density (B) at
increasing distances from the surface of the magnet. A ruler was
taped parallel to the magnet, and the ﬂux density was measured
with the axial gaussmeter probe in 1 mm increments from a
distance of zero to 30 mm from the magnet. Because magnetic
force is proportional to the magnetic ﬁeld gradient (ΔB/Δx, in
units of G/mm), the gradient was determined by dividing ΔB,
the change in the ﬂux density between each successive
measurement, by Δx, the change in distance between each
successive measurement. The magnetic ﬁeld gradient measurements were used to indicate the relative strength of the
magnetic attractive force on the NIMs at diﬀerent positions for
the subsequent tracheal mimic tube study.
2.4. Proof of Concept Tracheal Mimic Tube Study.
Cylindrical borosilicate glass tubes were designed and fabricated
to mimic the conducting airways of the human respiratory tract.
The dimensions of the tube were similar to those of a human
male adult (20 mm diameter × 200 mm length × 1 mm

electron microscope energy dispersive X-ray spectrometry
(EDS-SEM) (JEOL 5800LV). Brieﬂy, NIMs were deposited
onto a small piece of silicon wafer using double-sided magnetic
adhesive tape and examined in the SEM at 0.3−20 kV. Using
the focused ion beam SEM (FIB-SEM), electron-transparent
slices of the NIMs were cut to reveal a cross-section of the
microparticle. For transmission electron microscopy (TEM,
JEOL 200CX TEM operated at 200 kV), NIMs were uniformly
suspended in acetonitrile and 10 μL droplets were mounted on
copper grids covered with holey carbon ﬁlm. Samples were also
analyzed by energy dispersive X-ray spectroscopy (EDS) for
SPION loading in NIMs.
2.3.6. Iron Content Determination. To evaluate concentrations of Fe in NIMs, samples were analyzed using inductively
coupled plasma atomic emission spectroscopy (ICP-AES,
Perkin-Elmer Elan II, Waltham, MA). The internal standard
was iron (Fe) at mass 55.845. The analysis was performed
comparably to method US EPA 200.8. Exactly 10 mL of the
standards, samples, and QC samples were spiked with 1 mL of
100 mg/L Fe as internal standard to correct for drifts in the
signal that may be caused by sample matrix, viscosity of the
solution, and/or peristaltic pump (sample) pulsing. The system
was calibrated using NIST traceable calibration standards
(stock solution) and QC solutions (stock solution). The system
is sensitive down to the parts per billion (ppb) level. Three
milligram NIM samples were taken for measurement and
digested, using 2 mL of nitric acid, at 90 °C. After digestion was
completed, digests were brought up to 10 mL ﬁnal volume and
transferred into ICP plastic tubes. Results were then calculated
using the starting weight and the ﬁnal volume after digestion.
Results were expressed as μg/g of Fe and then converted to
ppb based on the standard curve. Fe was calculated based on
the basis of the molecular ratio of Fe3O4. Samples were run in
duplicate.
2.3.7. Doxorubicin Content Determination Using HPLC.
We adapted an HPLC method reported by Mikan et al.14 and
Urva et al.15 A stock standard of 65 μg/mL was prepared by
placing 0.65 mg of doxorubicin into a 10 mL volumetric ﬂask
and diluted in pH 3.0 ddH2O to a total volume of 10 mL. A
working standard of 20 μg/mL was prepared by transferring
appropriate amounts of stock doxorubicin in a 5 mL volumetric
ﬂask and diluted in pH 3.0 water to a total volume of 5 mL.
Both stock and working doxorubicin solutions were stored at 4
°C. To create a standard curve, doxorubicin standards with
concentrations of 0.078, 0.156, 0.31, 0.63, 1.25, 2.5, 5, 10, and
20 μg/mL were prepared by accurately transferring appropriate
volumes of working doxorubicin solution to HPLC vials. NIM
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Figure 2. Hydrodynamic size and stability characterization of SPIONs. SPIONs are a component of the NIM drug delivery vehicle. (A) The
transmission electron microscopy (TEM) micrograph shows monodisperse 50 nm diameter single-domain Fe3O4 nanoparticles. (B) Dynamic light
scattering (DLS) shows a D50 of 56 nm. (C) Zeta-potential shows nanoparticle charge of −49 mV.

Figure 3. SEM images of (A) lactose particles. (B, C) NIMs containing SPIONs, doxorubicin and lactose. (D) A cross-section of a single NIM
ablated with a focused ion beam. (E) TEM images of electron-dense SPIONs concentrated toward the outer surface of NIMs. (F) A magniﬁed
version of E showing the distribution of SPIONs.

3. RESULTS
3.1. NIM Formulation. NIMs were formulated by spray
drying doxorubicin and SPIONs in a lactose matrix. For the
purpose of drug delivery and bioavailability to tumors, NIMs
were characterized on the basis of size, surface morphology and
magnetic properties. SEM and TEM micrographs indicate
NIMs to be spherical in shape with a diameter of 1.6 μm
(Figure 3C and Figure 3E, respectively). TEM micrographs
revealed increased electron dense (black) areas indicating the
presence of iron atoms. Cross-sectional analysis by TEM shows
that SPIONs are preferentially distributed on the outer surface
of the NIMs (Figure 3E). SEM micrographs revealed a rough
outer surface due to SPIONs protruding from the lactose
matrix (Figure 3C). The surface area of NIMs may be
inﬂuenced by the extent of the surface roughness. This is an
important characteristic of dry powers when mitigating drug−
drug particle agglomeration formation.16
3.2. Characterization of SPIONs: Hydrodynamic Size,
Zeta Potential, and TEM. SPIONs had an average radius of
56 ± 6 nm (Figure 2B) and a density of 2.5 g/cm3. SPIONs
had an average zeta potential of −49 mV (Figure 2C) and
confer colloidal stability against aggregation. TEM micrographs
of SPIONs showed magnetite crystals on the order of 6 nm that
are combined to form a single-domain 50 nm core (Figure 2A).
3.3. Yield, Encapsulation Eﬃciency and Doxorubicin
Loading. The theoretical powder yield was 60.9% based on a

thickness). Two diﬀerent formulations were examined: NIMs
and a nebulized liquid suspension. Both formulations contained
the green ﬂuorescent nanospheres as a surrogate for
doxorubicin. Brieﬂy, 5.0 mg of NIMs was weighed for each
run; for the preparation of the liquid suspension 5.0 mg of the
NIMs were suspended in 3 mL of water to have equal
proportions of the nanospheres and SPIONs. The permanent
magnet was placed on the external vertical axis of the tube to
achieve retention of the NIMs near the magnet (Figure 1).
The magnetic retention of the NIMs was examined by
placing the magnet at 0 and 4 mm from the tube based on the
magnetic strength characterized earlier. These two distances
were measured from the outer surface of the glass tube
(thickness 1 mm). Aerosol generators (model DP-4 dry powder
insuﬄator and model IA-1C liquid suspension microsprayer
(Penn Century, Inc., Philadelphia, PA, USA)) were used to
aerosolize the NIMs and the liquid suspension, respectively (n
= 3) (Figure 1). The glass tube was connected to a vacuum
source that was adjusted to a ﬂow rate of 15 L/min. Relative
ﬂuorescence intensity was quantiﬁed using the Carestream
Molecular Image Station 4000 MM Pro using excitation and
emission wavelengths of 488 and 508 nm, respectively. Student
t tests were used to quantify statistical signiﬁcance (Graphpad
prism, La Jolla, CA).
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Figure 4. Quantiﬁcation of Fe3O4 in NIMs. (A) Schematic depicting cross-section NIMs and SPION localization. (B) ICP-AES chromatogram of
Fe3O4 loading in NIMs. (C) EDS/SEM Fe depth analysis. (D) EDS/TEM Fe depth analysis. (E) Hysteresis curve shows superparamagnetism and
demonstrates the total electromagnetic unit (emu), enabling the calculation of Fe3O4.

Figure 5. A cylindrical glass tube was designed to mimic the conducting airway of the human pulmonary tract. (A) Magnetic gradient
characterization of a permanent magnet used to direct and retain NIMs to a region of interest. The magnet was characterized over a distance of 30
mm and ﬁt with the function 1/x3. (B) The targeting and retention of a ﬂuorescent dye with and without a magnet using NIMs. (C) The targeting
and retention of a ﬂuorescent dye with and without a magnet using a liquid suspension. The magnetic retention of the NIMs was examined by
placing the magnet at 0 and 4 mm from the tube. These two distances were measured from the outer surface of the glass tube (thickness 1 mm). (D)
The NIMs formulation is 2.4 times more ﬂuorescent in a magnet region of interest (p = 0.0154).

mass balance performed on the solids (SPIONs, doxorubicin,
lactose) and NIMs before and after spray drying, respectively.
Using HPLC, % EE was quantiﬁed in NIMs to be 57%.
Doxorubicin eluted with a retention time of 7.2 min.
Theoretically, NIMs contained 2.8% (w/w solids) doxorubicin,
and actual doxorubicin loading was quantiﬁed to be 1.6%. The
doxorubicin loss is attributed to the spray drying process; small
particles of doxorubicin (which have a characteristic red color)
were visually observed trapped in the ﬁlter of the machine.
3.4. NIM Characterization. The average hydrodynamic
NIM diameter was 1.6 μm using laser diﬀraction. This size
correlates with the size assessed using SEM (Figure 3B). A
MMAD of 3.27 μm was obtained using a NGI. The
aerodynamic diameter takes the density of the NIMs into

account and is fundamental to particle deposition in the lung
and hence for inhaled drug delivery. The average ﬁne particle
fraction (FPF) (≤6.4 μm) of the NIMs was >90%, and the
geometric standard deviation (GSD) was ±1.69.
3.5. Permanent Magnet Characterization. Single and
two combined permanent magnets were characterized for their
magnetic ﬁeld strength. The magnetic ﬁeld strength on the
surface of the single magnet was 0.58 T. Magnetic ﬁeld strength
did not increase when two permanent magnets were combined
(data not shown). Magnetic ﬁeld lines are parallel to the surface
of the magnet and diverge with increasing distance, resulting in
a weaker ﬂux density at larger distances; the magnetic force acts
on the NIMs when they enter this region of diverging magnetic
ﬁeld. The direction of the force moves magnetic objects from
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magnetic NIMs containing SPIONs and doxorubicin, by the
process of spray drying. NIMs can be guided to a region of
interest in a tracheal tube with strategic placement of an
external magnet. Inhalable dry powders will allow higher doses
of drug to be delivered to cancerous lung regions without
increasing side eﬀects observed in surrounding healthy tissues,
compared to a liquid suspension. Using this novel delivery
method, we do not expect to overcome oropharyngeal
deposition. This delivery method will only localize drug near
the target region that does not impact the upper regions of the
respiratory tract.
4.1. Formulation of a Novel Inhalable NIMs Delivery
Vehicle. NIMs were formulated using pulmonary-compatible
lactose rather than a biodegradable polymer. This is to allow for
the immediate release of drug from the vehicle after deposition
and to minimize the patient contact time with the magnetic
ﬁeld. After NIM deposition at the target site, the NIM will
disintegrate quickly in the lung parenchyma to release drug that
will diﬀuse into the target tumor mass. Neither doxorubicin nor
SPIONs are conjugated to the delivery vehicle thus eliminating
any limitations on the release of bound drug near the target site.
4.2. Characterization of NIMs. NIMs exhibit a rough
outer surface, as seen from the SEM images (Figure 3B,C).
This facilitates a beneﬁcial disaggregation of particles when
administered as a dry powder.16 Currently, dry powder ﬂow
and dispersion are improved by incorporating larger particles
(50−100 μm) as carriers19 to facilitate disaggregation of dry
powders during inhalation. Should NIM ﬂow or dispersion be a
problem, the addition of carrier particles would be considered.
The ﬂow dynamics of the NIMs after inhalation can also aﬀect
the drug deposition and would require further studies. A logical
next step, and our next pursuit, will involve the administration
of NIMs in animal models to investigate the targeting
capabilities in the upper and lower respiratory tract.
NIMs can be designed to modulate drug release after the
particles have been guided to the targeted lung regions in the
future. If this concept is successful, NIMs can also be used to
deliver doublet chemotherapeutic agents since doublet therapy
is the cornerstone of treatment for lung cancer. Future studies
also need to investigate the eﬀect of SPIONs on cellular uptake
and pulmonary toxicity in animal models, since surface
properties of SPIONs are known to aﬀect the cellular uptake
and cytotoxicity. However, the biodegradability and biocompatibility of SPIONs have been proven for many years in the
clinical setting as a contrast agent in magnetic resonance
imaging.20,21
4.3. Magnetic Properties of Aerosolized NIMs. The
small magnetic moment of individual SPION in an aerosolized
liquid droplet cannot be guided easily in the presence of an
external magnet. However, when SPIONs are assembled
together in NIMs,16 the net magnetic moment of aggregated
SPIONs is large enough to be manipulated with a medically
compatible external magnet. In addition, droplets containing
nanosized SPIONs for inhaled drug delivery are easily exhaled
due to their small size; therefore encapsulating the SPIONs into
micrometer sized NIMs will help to resolve this problem. The
combined magnetic moment of the SPIONs present in the
NIMs may allow the particles to be retained at the target site
until the NIMs disintegrate therefore releasing the drug. In
addition, NIMs could also be retained at the target site by
entrapment from lung mucus and cilia.
A 28% decrease in the ﬂuorescence intensity of NIMs was
observed when the magnet was placed 4 mm away from the

regions of lower ﬂux density to regions of greatest ﬂux density
(i.e., the surface of the magnet). This study also shows that the
geometry and orientation of the magnet is critical for signiﬁcant
deposition of the NIMs near the magnet.9 Figure 5A shows that
the magnet was characterized over a distance of 30 mm with
decreasing magnetic gradient strength (G/mm).
3.6. Magnetization Measurement. A SQUID is a
sensitive magnetometer that is used to measure extremely
small magnetic ﬁelds, and with this device we measured the
magnetic moment of NIMs. Susceptibility curves were obtained
to provide the speciﬁc magnetization (s) in emu/g at a
particular magnetic ﬁeld strength. This is related to the
susceptibility through the equation χ = (s*ρ)/H where ρ is the
particle density. The zero coercivity and the reversible
hysteresis behavior indicate the superparamagnetic nature of
the SPIONs (Figure 4E). The speciﬁc saturation magnetization
for the NIM formulation was 8 emu/g. This value is below the
saturation magnetization known for bulk Fe3O4 (Ms = 92 emu/
g) as expected given that lactose does not contribute to the
magnetic moment. The magnetization measurement suggests
that the NIMs are approximately 9% Fe3O4 by weight. The
magnetization was corrected by the diamagnetic response of
the sample-holder, and normalized by sample mass.
Using ICP-AES, elemental Fe in NIMs was 7.67%. When
converting this to magnetite, Fe3O4 was calculated to be 10.6%
by weight, in good agreement with the Fe3O4 fraction obtained
from the magnetization measurements (9%). EDS-SEM and
EDS-TEM quantiﬁed Fe on the NIM surface, and Fe3O4 was
calculated to be 16 ± 0.5% and 19 ± 0.5%, respectively (Figure
4C,D). These numbers are further understood knowing that
EDS-TEM has a depth resolution of 50 nm whereas EDS-SEM
penetrates an average sample depth of ∼1 μm.17 TEM
micrographs (Figure 3E) qualitatively supported this observation that SPIONs are less densely distributed/localized in the
center of the NIMs. Thus EDS-SEM quantitates a lower
amount of Fe3O4 given this analytical tool penetrates the
sample more deeply than EDS-TEM.
3.7. Proof of Concept Tracheal Tube Study. Magnetic
retention of NIMs containing ﬂuorescent nanospheres was
quantiﬁed in relation to its ﬂuorescence intensity (Figure
5B,C). Quantitative ﬂuorescence analysis showed a 2-fold
increased deposition of aerosolized NIMs at 0 mm (mean =
534.97, SD = 131.17) near the magnet based on greater
ﬂuorescence intensity, compared to the aerosolized liquid
formulation at 0 mm (mean = 221.67, SD = 26.70) (t = 4.054,
p = 0.0154, df = 4, two-tailed Student t test) (Figure 5B,C,D).
Control studies of untargeted NIMs (absence of magnetic
targeting) qualitatively show no mean ﬂuorescence over
background in the region of interest (Figure 5B,C).
Quantitative ﬂuorescence analysis showed increased deposition
of NIMs at 4 mm (mean = 385.65, SD 30.15), compared to the
aerosolized liquid formulation (mean 277.30, SD = 88.16)
(Figure 5D). A 28% decrease in the ﬂuorescence intensity of
NIMs was observed when the magnet was placed 4 mm away
from the tube compared to 0 mm.

4. DISCUSSION
This research proposes the use of regional chemotherapy by the
pulmonary route with the intent of increasing drug exposure
near a solid tumor. Despite inhaled drug delivery being used for
respiratory diseases for over 30 years,18 targeted drug delivery
to speciﬁc regions of the lung has not been adequately
explored. We show here, for the ﬁrst time, the formulation of
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This study brings about new perspectives for speciﬁc disease
treatment by increasing delivery of chemotherapeutic agents to
the tumor mass and reducing unwanted drug-related side
eﬀects in nondiseased tissue. In conclusion, SPIONs with very
high saturation magnetization were successfully encapsulated in
NIMs by spray drying. These novel formulations have the
potential to be targeted to speciﬁc regions of the lung using an
external magnet.

tube compared to 0 mm. This decrease in ﬂuorescence, and
therefore magnetic force, is a challenge that needs to be
addressed since the magnetic ﬁeld has to penetrate a larger
distance if this targeting mechanism is to be applied in humans.
Since the magnetic gradient decreases with the distance to the
target tissue, the main limitation of this delivery mechanism
could relate to the strength of the external ﬁeld that can be
applied to the patient to obtain the necessary magnetic
gradient; however, high ﬁeld gradient electromagnets are being
used in animals for magnetic targeting22 and substantial ﬁeld
gradients are also used in MRI imaging. Further studies are
needed to validate the safety of the strength of an external
magnet as it relates to magnetic nanoparticles.
The magnetization s-curve of NIMs loaded with 9% w/w
Fe3O4 is shown (Figure 4E) and has negligible coercivity, and
consequently no remanence was observed once the magnetic
ﬁeld was removed, indicating the superparamagnetic behavior
of the SPIONs. Localization of SPIONs on the NIM surface
was qualitatively and quantitatively observed. Surface analytical
techniques were used to understand the elemental depth
proﬁles of SPIONs in NIMs. EDS analysis is based on the beam
voltage which is applied to the sample; a lower voltage will
excite electrons to a lesser depth in the sample allowing for the
quantiﬁcation of elemental Fe composition. Both EDS-TEM
and EDS-SEM analysis were used to determine the distribution
of SPIONs in the NIMs from the surface to the interior of the
particles (Figure 4C,D). Uncoated SPIONs were chosen for
this formulation to exploit the superparamagnetic properties of
the core iron oxide nanoparticles, since coating leads to loss of
magnetic strength23 per volume. However, coating SPIONs
with a polymer is known to prevent aggregation and to provide
colloidal stability to the suspension. In our study, the
suspension containing SPIONs, drug and lactose was
adequately stirred prior to and during the spray drying process,
to prevent aggregation of SPIONs.
4.4. Proof-of-Concept Tracheal Mimic and NIMs
Targeting. Dames et al.11 and Hasenpusch et al.24 have
proven the feasibility of magnetic aerosol delivery using
nebulized SPIONs and a drug surrogate to target speciﬁc
lung regions in mice using an external permanent magnet. A
drawback of this delivery system was that the drug surrogate
separated from the magnetic carrier during pulmonary delivery
resulting in premature release of the surrogate in the upper
respiratory tract. This separation would result in a lower
amount of the drug surrogate reaching the target site in a liquid
suspension. We demonstrated a similar result in the tracheal
mimic experiment as seen by a uniform nanosphere distribution
in the tube of a liquid suspension formulation (Figure 5C). In
contrast, the NIM formulation showed signiﬁcant spatial
deposition of dye only in regions experiencing a strong
magnetic force (Figure 5B). The targeting of NIMs resulted in
a ﬂuorescent intensity that was 2.4 times more than that of the
liquid formulation near the magnet at 0 mm distance (Figure
5D). It is to be noted that the tracheal mimic experiment
exhibits the in vitro targeting and retention of dry powders for a
proof of concept idea, and the aerosol particles were assumed
to be carried by a laminar airstream, consistent with other
published literature.9,10 However, we do expect turbulence to
be generated when NIMs are near the magnetic ﬁeld. Guiding
NIMs containing SPIONs to a speciﬁc lung lobe will be
challenging because it is more complex than the single tube we
have used in this study.
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INTRODUCTION
Pharmaceutical aerosols are of growing interest in the field of therapeutic drug delivery. Recently,
inhaled pharmaceuticals have gained preclinical trial attention for the treatment of lung cancer
[1, 2]. A major obstacle in lung cancer treatment is the ability to selectively deliver chemotherapeutics to lung tumors, therefore minimizing side effects observed in healthy tissues. There have
been several different approaches to site-specific targeted drug delivery [3-5] using magneticfield-dependent-targeting. This research attempts to improve upon previous drug delivery studies
using a targeted and inhaled dry powder approach.
METHODS
Nano-in-microparticles (NIMs) were formulated and characterized containing Fe3O4 superparamagnetic iron oxide nanoparticles (SPIONs) and a far-red fluorescent probe (Invitrogen
Molecular Probes, FluoroSpheres®) in a lactose matrix. NIMs were characterized for size and
magnetic strength. An ex vivo pilot study was conducted to target NIMs to the right lung lobe in
healthy rats, in the presence or absence of a magnetic field. Total radiance (fluorescence intensity)
was qualitatively and quantitatively analyzed to assess NIMs deposition and retention.
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Formulation of Inhalable Magnetic Microparticles
A suspension containing 70% lactose (DMV-Fonterra Excipients, Respitose, ML001), 20% SPIONs
(Chemicell, fluidMAG-UC/A, 0.050 mm diameter) and 10% Fluorospheres (Invitrogen Molecular
Probes, 660 nm excitation and 680 nm emission, 0.024 mm diameter) (% w/w) was spray dried
using a Büchi mini-spray dryer B-290 to achieve NIMs dry powders (Büchi Corporation, Flawil,
Switzerland). Spray drying parameters were as follows: outlet temperature 100 ± 4°C, inlet temperature 170 ± 2°C, aspirator rate 90%, and atomization air flow rate of 742 NL/h (equivalent to
a spray rate of 60 mm). Powder yield was calculated as the ratio of the mass of solids collected
after spray drying to the amount of solids in the feed suspension. Carrier control particles were
formulated containing 5% lactose only (% w/v) in ddH2O, made into a solution and spray dried as
previously stated.
Microparticle Characterization
The hydrodynamic and aerodynamic size and particle characteristics of NIMs were determined by
laser diffraction, cascade impaction and electron microscopy. Internal particle characteristics were
determined by focused ion beam ablation (FIB) and visualized by Transmission electron microscopy (TEM). The magnetic strength of NIMs was assessed by inductively coupled plasma atomic
emission spectroscopy (ICP-AES), energy-dispersive x-ray spectroscopy (EDS) was used for
elemental analysis, and surface morphology via scanning electron microscopy (SEM).
Ex Vivo NIM Magnetic-Field-Dependent Targeting in Rat Lungs
The overall pulmonary deposition of fluorescent, magnetic NIMs was targeted to rat lungs by
insufflation (Penn Century, Dry Powder Insufflator, DP-4) in the presence of a neodymium
permanent magnet (Applied Magnets, grade 52, D B < 0.58 T). Rats (n = 3) were sacrificed, and
lungs lobes with trachea (attached) were excised. Five puffs of air were administered to the lungs
by insufflation to counteract lung collapse. A permanent magnet was placed at a distance of 1 µm
from the right lung tissue. A total of ten milligrams of fluorescent NIMs powder was insufflated
intratracheally. An IVIS Lumina II imager following intratracheal delivery imaged NIMs powder
deposition. Fluorescent regions of interest (trachea, right lung lobe and left lung lobe) were quantified.
RESULTS AND DISCUSSION
SEM micrographs indicate NIMs to be spherical in shape (Figure 1A and 1C) with a rough
external surface (Figure 1B, NIM rendering). An average geometric diameter of 1.6 µm was measured
with laser diffraction, and corroborated with SEM. The aerodynamic particle size characterization was determined using a next generation cascade impactor (NGI) and showed a mass median
aerodynamic diameter (MMAD) of 3.2 µm, administered using the Penn Century insufflator at a
flow rate of 15 L/min simulating compromised lung function, as this targeted delivery vehicle is for
lung cancer patients. The average fine particle fraction (FPF) was > 90% with a geometric standard
deviation (GSD) of ± 1.7 µm. The theoretical powder yield was 58%.
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Figure 1.

A) SEM micrograph showing rough surface morphology of NIMs; B) Cartoon depiction of
NIMs surface and interior SPION distribution; and C) FIB-TEM ablated micrograph showing
NIM cross-section.

Using ICP-AES, Fe3O4 was calculated to be 10.6% by weight. EDS-TEM and EDS-SEM
quantified Fe on the NIM surface, and Fe3O4 was calculated to be 19 ± 0.5% and 16 ± 0.5%,
respectively. EDS-TEM has a spatial resolution of 50 nm, whereas EDS-SEM penetrates an average sample depth of ~ 1 µm. EDS-TEM quantitates a higher amount of Fe3O4 given this analytical
tool penetrates the sample at a shallower depth than EDS-SEM.
Table 1.
Magnetic-field-dependent accumulation of NIMs in rat lungs.

A four-fold increase in magnetic-field-dependent accumulation of NIMs was seen in the
magnetized lung (right lobe) over the unmagnetized lung (left lobe) (Table 1 and Figure 2A).
NIM deposition in the trachea remained high which could be attributed to the method of delivery
(insufflation) (n = 3, Table 1, Figure 2). The insufflated NIM dry powders were widely distributed
in the pulmonary tract of the rat when magnetic targeting was not applied (Figure 2B). No fluorescence background was seen in control lungs (no treatment, unmagnetized) (Figure 2C). Lactose
has an intrinsic tendency to take up moisture (a hygroscopic property). When passing through the
humid environment of the airways, this results in increased particle size [6] and therefore more
proximal NIM deposition (increased radiance intensity) and non-magnetic-field accumulation in
the trachea (Figure 2A and 2B).

40
Copyright © 2013 VCU

4

A Pilot Study Targeting Nano-in-Microparticles in Rat Lungs Ex Vivo – McBride and Muttil

Figure 2.

A) The deposition of targeted NIMs to the right lung lobe; B) untargeted NIMs deposited in both
lung lobes and trachea; and C) control lungs, no treatment.

CONCLUSION
This pilot study showed approximately a four fold magnetic-field-dependent accumulation of
NIMs containing SPIONs and FluoroSpheres in the right lung lobe of rats ex vivo. By aligning
NIMs in one direction using a magnetic field, microparticles would become randomly oriented
with airway flow, leading to a higher probability of deposition in the targeted lung lobe [7].
Investigational method development for dry powder pulmonary insufflation in animals is particularly relevant for aerosol delivery as it closely mimics clinical use in humans.
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NIMs Deposition Analysis - A Rat lung Pilot Study
An ex vivo pilot study was conducted to target NIMs to the right lung in healthy
rats, in the presence or absence of a magnetic field. Deposition was quantified by
fluorescence intensity (excitation 660 nm; emission 680 nm) of the rat lungs left lung,
right lung and trachea for an exposure time of 20 seconds. A region of interest (ROI) was
drawn around the left lung, right lung, trachea and background with area remaining
constant (2.5 cm2). Fluorescence was measured and expressed as units of radiance
efficiency:
Radiance efficiency =  

  (!/!"#/!"^!/!")
!"/!"

Targeting Efficiency Ratios As A Means to Analyze Fluorescence
In addition to comparing fluorescence intensity, data were further analyzed by
calculating and comparing targeting efficiency ratios (Chen et al. 2002). Targeting
efficiency was calculated as follows: in the numerator, fluorescence intensity of the left
lung, right lung or trachea (I individual) was divided by the sum of the fluorescence
intensities of the three tissues (I sum) in the denominator (Equation 1).
Targeting efficiency ratio =  !

!!"#!$!#%&'   (!.!.    !"#$  !"#$)
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The key issue in this analysis was to determine whether a ratio was high or low in
order to conclude whether magnetic field dependent targeting was significantly increased
or decreased to the right lung, in comparison to the untargeted left lung.
In the following chapter, Inductively Coupled Plasma – Optical Emission
Spectroscopy (ICP-OES) will be used to quantify the deposition of iron in the lung from
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either the dry powder NIMs vehicle or a liquid suspension vehicle (liquid suspension
vehicle was used by Dames, et al. 2007 and Hasenpusch et al. 2012). An analysis strategy
was needed to empirically corroborate the results of ICP-OES (iron deposition in the
targeted lung) and the IVIS Lumina II Imager (dye deposition in the targeted lung). We
believe that the ratio analysis method, in addition to reporting fluorescence (radiance
efficiency) allows for a more objective comparison of raw fluorescence values of the ex
vivo targeting pilot study data and subsequent in vivo targeting study data. Targeting
efficiency ratio comparisons help normalize and compare values with minimal data
manipulation. In the future in vivo targeting study, expressing fluorescence and iron
deposition in terms of targeting efficiency ratios allowed us to best corroborate these
analytical methods, ultimately allowing for more meaningful data comparison.
Statistical Analysis
Statistical analyses were performed using Windows SPSS version 16 (SPSS Inc,
Chicago, IL, USA). Paired t-tests with bonferroni correction were used to compare two or
more groups of independent data. The significance level was set at α = 0.05. Descriptive
statistics were also employed if data were not statistically significant.
Results
Fluorescence intensity was quantified in the presence and absence of magnetic
field dependent targeting, reported as mean intensity ± SEM. In the absence of magnetic
field dependent targeting (no magnet placed on either lung), fluorescence intensity was
similar in both the right and left lungs (8.34 x 107 ± 8.89 x 106 right lung; 9.89 x 107 ±
2.02 x 107 left lung) (Fig. 3C). In terms of targeting efficiency ratios, in the absence of
magnetic field dependent targeting, 20% NIMs deposition was observed in the right lung
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versus 23% NIMs deposition in the left lung. This resulted in an absolute difference of
3% deposition to the left lung. Therefore, no preferential deposition of NIMs was
observed in the right or left lungs.
A 3.9 fold increase in fluorescence (drug surrogate) was observed in the right lung
compared to the left lung from the administration of dry powder NIMs (right lung mean:
1.71 x 109 ± 4.73 x 108; left lung mean: 4.36 x 108 ± 7.60 x 107, P = 0.057, n = 3) (Fig.
3A). Using the targeting efficiency ratio, a 20% increase in fluorescence from NIMs was
observed in the right lung versus 4% NIMs deposited in the left lung (Table 3.1).
Significantly more fluorescence was quantified in the right lung of rats that had been
exposed to an external magnetic gradient (1.71 x 109 ± 4.73 x 108) during insufflation
than compared to the control mice in the absence of magnetic targeting (8.34 x 107 ± 8.89
106 right lung; P = 0.0035) (Fig. 3 A, B).
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Figure 3. Deposition of the Model Drug Surrogate in the Lungs of Rats upon NIMs
Dry Powder Administration A) Comparison of magnetic dependent targeting in the
right lung, left lung and trachea in the presence and absence of targeting, quantified by
average fluorescence intensity. Differences in fluorescence intensity are significant
comparing the right lung in the presence of magnetic targeting and the right lung in the
absence of magnetic targeting (**P = 0.0035, n = 3). B) Comparison of fluorescence
targeting and deposition between the right (magnetized) and left lung (unmagnetized; *P
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= 0.057, n = 3). C) Comparison of fluorescence deposition in the absence of targeting of
right and left lung (not significant). D) Comparison of between right lungs (P = 0.076, n
= 3). E) Comparison between left lungs (neither lung magnetized) (*P = 0.055, n = 3).
Discussion
Rats were chosen for this pilot ex vivo targeting study for a number of reasons:
1) Although mortality or safety data is scantly published using dry powder
inhalers in rodent models, previous literature reported that rats observed a 3% mortality
rate versus a 9% mortality rate in mice (Guillon et. al., 2012) when dry powders were
administered using the Insufflator™ or Microsprayer™ instrument (Morella et al., 2009).
We previously observed that if mice were over stimulated when endotracheally intubated
with the Dry Power Insufflator™ or Microsprayer™, laryngeal spasms and death could
occur, a result of reflex adduction of the vocal cord.
2) We felt rats would serve as a better translational model than mice in
determining targeting efficiency of magnetically responsive dry powders because of their
larger scale trachea and lungs.
3) Intubation of a rat trachea is easier in a bigger rodent model. Our goal was not
to achieve maximum NIMs dose delivery, but to target the NIMs to a specific lung as
efficiently as possible.
Hasenpusch demonstrated a two-three fold higher accumulation of their model
drug, fluorescein, in the lung region of mice that had been exposed to an external
magnetic gradient during nebulization compared to the untargeted mice without any
exposure to a magnetic gradient (Hausenpusch et. al., 2012). In Hasenpusch’s study, the
deposition rate of iron was found to increase 2.1-fold in the right lung exposed to the
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magnetic field compared with the left lung (control) independent of the nebulization
device (nose-only (NOIS) inhalation system and a whole body delivery chamber
(WBIC)). We demonstrated a 5-fold higher accumulation of our model drug in the lung
region of rats that had been exposed to an external permanent gradient during insufflation
compared to the control rat without any exposure to a magnetic gradient.
Hasenpusch observed that there was no significant difference in fluorescein
deposition, nor luciferase activity in the analysis of transgene expression, when
comparing the left and right lobes in the presence of magnetic field dependent targeting
of mice. In comparison, we saw 4-fold higher accumulation of our model drug in the lung
region of rats that had been exposed to an external magnetic gradient during insufflation.
Fluorescein deposition increased not only in the magnetized lung lobe but also in
the non-magnetized control lung lobe; they concluded that the influence of the magnetic
gradient was strong enough to increase deposition of aerosol droplets in the right lungs
exposed to the magnetic field but weak enough to avoid rapid clearance of the SPIONs
by mucociliary clearance or phagocytosis. There are two proposed implications of
increased deposition to the untargeted lung: beneficial deposition to the untargeted lung
and unbeneficial uncontrolled deposition to the untargeted lung. Many diseases are
restricted to segregated areas of the lung so it could be advantageous to attain high
deposition concentrations in the diseased parts of the lung, while leaving the healthy
tissue unaffected making uncontrolled deposition to the untargeted lung unbeneficial.
I propose a different theory: Fluorescein was not bound to the SPIONs but free in
solution allowing for premature dissociation from the delivery vehicle before it reached
the intended target site, causing rapid tissue biodistribution of fluorescein after reaching

48

the lung surface. A dry powder delivery system would overcome the limitation of a
weakly interacting delivery vehicle with its drug. Encapsulation of the candidate drug
into a liposome was suggested, but this option likely will result in a similar problem
because liposomes inherently leak cargo (Torchilin et. al., 2005). Hasenpusch’s
experiments were conducted using either a NOIS or WBIC inhalation delivery system
and it is known that a large amount of delivery vehicle is lost in the nose and mouth of
the animal, further observed by Hasenpusch et al.
With this study, we have shown that dry powder NIMs can be reliably
administered and targeted to a specific lung in the presence of magnetic field dependent
targeting in an animal model ex vivo. In addition, we have shown that NIMs, unlike other
aerosol delivery systems, do not prematurely separate during the delivery process and can
be targeted and retained in the lung of a rat ex vivo.
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Chapter 4: In vitro Pulmonary Delivery and Targeting of a Magnetically Responsive
Dry Powder Nano-in-Microparticles

Abstract
The aim of this study was to evaluate the magnetic field-dependent targeting of
dry powder nano-in-microparticles (NIMs) administered endotracheally using an in vivo
healthy rodent model. NIMs are a novel drug delivery vehicle containing 70% lactose,
20% SPIONs and either 10% fluorescent nanospheres or 1.6% doxorubicin (percentages
expressed as w/w solids) ( McBride et al., 2013;Tewes et al., 2014). Mice were
insufflated with 2.0 mg NIMs delivery vehicle in the presence of magnetic field
dependent targeting to the left lung after thoracotomy; controls were insufflated with
NIMs in the absence of magnetic field dependent targeting. Quantification of deposition
of the fluorescent dye component (drug surrogate) of NIMS in left and right lung tissue
showed an increase in fluorescence intensity to the left lung (1.4 x ± 0.26) x 108 radiance
efficiency (RE), n = 3; right lung: (0.52 ± 0.23) x 108 RE, n = 3, P < 0.01, expressed in
units of average relative efficiency (RE) ± SEM). Differences in mean intensity were
analyzed by ratios, resulting in a significant increase in deposition of NIMS when
administered endotracheally and targeted to the left lung compared to the right lung.
Quantification of iron showed significantly more deposition in the left lung compared to
the right lung (left lung: 1520 ± 579 mg/L iron, n = 3; right lung: 186 ± 112 mg/L iron, n
= 3, P < 0.005). In contrast to dry powder NIMs, the administration of an aerosol liquid
suspension of NIMs in the presence and absence of magnetic-field dependent targeting
was also evaluated and did not show increased deposition in response to magnetic

50

targeting to the left lung. In vitro cytotoxicity study results indicate that doxorubicincontaining NIMs were more toxic to A549 lung adenocarcinoma cells than the free
doxorubicin control. In addition, a dose dependent increase in cytotoxicity was observed
over time in lung tumor cells exposed to doxorubicin-containing-NIMs. We conclude that
1) Doxorubicin-containing NIMs are more toxic to A549 lung adenocarcinoma cells
compared to free drug and 2) dry powder NIMs vehicle can be magnetically targeted
significantly better as a pulmonary drug delivery strategy to specific regions of the lung
compared to a NIMs liquid suspension, thus making dry powder NIMs an ideal tool for
targeted inhaled drug delivery.

Introduction
Lung cancer is the second most commonly diagnosed cancer in both men and
women, and has the highest mortality rate compared to all other cancers (World Health
Organization, 2007; Siegel et al., 2014; Society, 2014). Pharmaceutical aerosols have
become a field of growing interest to the field of therapeutic drug delivery (Patton and
Byron, 2007; Hickey, 2013) gaining preclinical trial attention for the treatment of lung
cancer (Otterson et al., 2007; 2010; Albert Einstein College of Medicine of Yeshiva
University, 2014; Memorial Sloan-Kettering Cancer Center, 2014; Eleison
Pharmaceuticals LLC, 2014). For example, a phase I/II study of inhaled doxorubicin
combined with platinum-based therapy was administered to twenty-eight patients with
advanced non-small cell lung cancer (Otterson et al., 2010). Pulmonary delivery has been
used to treat local pulmonary diseases such as asthma, microbial infections, as well as
systemic diseases, but its application to the treatment of cancer is also giving promising
results, specifically, with the use of inhaled micro- and nanocarrier-mediated drug
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targeting for cancer therapy (Tomoda et al., 2009; Roa et al., 2011). Most recently,
inhaled dry powder insulin was approved by the FDA for the treatment of type 1 or 2
diabetes (Santos Cavaiola and Edelman, 2014; Traynor, 2014).
Conventional chemotherapy administered intravenously for lung cancer damages
both healthy and tumor cells, and accumulates in the liver, kidney and spleen, with a
lower drug endpoint concentration available in the lung milieu. Inhalable chemotherapy
can reduce systemic insult to healthy cells and organs by delivering drugs directly to the
lungs thus achieving adequate concentration near the tumor mass (Shim and Williams,
1980; Lewinski et al., 2008).
The lung is a unique organ for drug delivery. Lungs are well suited for
administration of inhaled chemotherapeutic agents due to their large surface area, thin
alveolar epithelium, easily permeable membrane and extensive vasculature, which allow
substantial and fast drug absorption for local and systemic efficacy (Johnson et al., 2002;
Sakagami, 2013).
Inhalational chemotherapy was first described by Shevchenko and Resnik in 1968
and tested in dogs and subsequently in 58 patients, of which antitumor efficacy was
observed in 24 patients (Shevchenko and Resnik, 1968).This trial established the
feasibility of administering chemotherapy by inhalation, but failed because it was as toxic
to healthy cells as cancer cells. A variety of chemotherapeutic agents have been evaluated
in preclinical and clinical trials including cisplatin (Hao et al., 2014), mitomycin, 5fluorouracil (Tatsumura et al., 1993), and adjuvants (Huland et al., 2003; Yi and
Wiedmann, 2010).
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Although inhaled drugs have existed for over 50 years, drawbacks such as
difficulties with formulation, administration, uniform dosing, compliance and stability of
inhaled drugs have limited their clinical success. Delivery vehicle formulation plays an
important role in producing an effective inhalable medication. Limited clinical efficacy
and significant dose-limiting pulmonary toxicity have represented two critical barriers
restricting progress in the therapy of advanced lung cancer (Hershey et al., 1999;
Otterson et al., 2007; 2010).
Magnetic-field dependent targeted delivery of drug-containing vehicles to specific
regions of the model airways in vitro has been demonstrated previously by us and others
(Dames et al., 2007; Xie et al., 2010; McBride et al., 2013; Tewes et al., 2014). The aim
of this study was to evaluate the magnetic-field dependent targeting of dry powder nanoin-microparticles (NIMs) administered endotracheally into the lung of healthy mice.
Using a novel inhaled dry powder drug delivery, this research attempts to improve the
targeting of chemotherapeutic agents relative to previous magnetic-field based delivery
strategies.

Materials and Methods
Materials
Alpha-D-(+)-lactose monohydrate Respitose ML-001 was a gift from DMVFonterra Excipients GmbH & Co. KG (Goch, Germany). FluidMAG-UC SPIONs with a
hydrodynamic diameter of 50 nm was purchased from Chemicell GmbH (Berlin,
Germany). Fluorescent dye-containing NIMs were formulated with Molecular Probes®
FluoSpheres® Carboxylate-Modified Nanospheres (F8783, 0.02 µm, dark red
fluorescent, excitation 660 nm and emission 680 nm, Molecular Probes®, Life
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Technologies, Thermo Fisher Scientific, Inc. Waltham, MA, USA).
Formulation and Characterization of the Dry Powder Nano-In-Microparticles
(NIMs) Delivery Vehicle
Spray drying was used to prepare the NIMs delivery vehicle as previously
described (McBride et al., 2013). Briefly, a suspension containing approximately 78.4%
lactose, 20% SPIONs and 1.6% doxorubicin (Selleck Chemicals, LLC, Houston, TX,
USA) (w/w) for in vitro viability and toxicity studies and 70% lactose, 20% SPIONs and
20% fluorescent nanosphere (drug surrogate) for animals studies was spray dried in
double distilled water (dd H2O; 2.5% solution w/v feed concentration) using a B-290
mini-spray with a standard two-fluid nozzle (0.7 mm diameter; Büchi Corporation,
Flawil, Switzerland), as previously described (McBride et al, 2013). Spray drying
parameters were as follows: inlet temperature 170 ± 2°C, outlet temperature 103 ± 2°C,
aspirator rate 100%, and an atomization air flow rate of 742 NL/h (equivalent to a spray
rate of 60 mm). Carrier control particles were formulated containing 5% lactose only (%
w/v) dd H2O, made into a solution and spray dried, as previously stated.
Dry Powder NIMs Particle Sizing
Dry powder particle size was measured by laser diffraction using a Mastersizer
3000 analyzer (Malvern Instruments Ltd, Worcestershire, UK) attached to a drydispersion accessory device (Aero S, Malvern Instruments). A pressure of 4 bars was
used for the Venturi dispenser and a feed rate vibration of 90% was used during the
measurements. The refractive index of the sample was taken to be the average of the
NIMs components multiplied by the percent (w/w) contained in the formulation: 70%
w/w lactose (1.35), 20% SPIONs (2.42) w/w and 10% fluorescent nanospheres (1.52) for
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an average of 1.58. The results were expressed in terms of D [4,3] (the volumetric mean
diameter) and Dv50 (volumetric mean diameter). All samples were analyzed in triplicate
and are expressed as mean ± standard deviation.
In Vitro Cytotoxicity Studies
Human lung adenocarcinoma cancer cells (ATCC® CCL-185™) (American Type
Tissue Culture, Manassas, Virginia, USA) were exposed to NIMs dry powder and its
components (doxorubicin; lactose; SPIONs). These novel formulations were tested for
viability using the CytoTox96® Non-Radioactive MTS (3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay (Promega, Madison,
Wisconsin, USA) and the CytoTox96® Non-Radioactive lactate dehydrogenase (LDH)
cytotoxicity assay (Promega, Madison, Wisconsin, USA) were cultured with Ham’s
F12K (Kaighn’s) medium and supplemented with fetal bovine serum (FBS), 5% Lglutamine, 3% antimycotic, and 3% antibiotic (Life Technologies, Grand Island, NY,
USA).
Briefly, NIMs were dispersed in F12K non-supplemented media and FBS
yielding concentration of 1000 µg/mL, 100 µg/mL, and 10 µg/mL. The same protocol
was used to generate doxorubicin solutions with concentrations of 30 µg/mL, 3 µg/mL,
and 0.3 µg/mL; lactose solutions concentrations of 770 µg/mL, 77 µg/mL, 7.7 µg/mL;
and SPIONs solution concentrations of 200 µg/mL, 20 µg/mL, 2 µg/mL. Prior to
exposure, A549 cells were washed with fresh media and 100µL of the aforementioned
suspensions/solutions (NIMs; doxorubicin; lactose; SPIONs) were pipetted in triplicate
for exposure periods of 1, 8, 24, 48 hours.
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MTS Viability Assay
CellTiter 96® Aqueous One Solution Reagent was mixed according to the
manufacturer’s instructions. In brief, at time periods of 1, 8, 24, 48 hours post-exposure,
120 µL of MTS reagent mixed with media at a ratio of 1:6 and aliquoted into each well of
a black optical bottom 96-well plate and incubated at 37°C and 5% CO2 for 3 hours to
maximize the development of formazan salt. Absorbance was measured at a wavelength
of 490 nm. Results were plotted as absorbance over time with respect to increasing
amounts of doxorubicin contained in the NIMs (0.03 µg, 0.3 µg and 3.0 µg).
LDH Toxicity Assay
The CytoTox96® Non-Radioactive Assay was mixed according to the
manufacturer’s instructions. At time periods of 1, 8, 24, 48 hours post-exposure, 80 µL of
media was aspirated from each well and spun at 10000 rpm for 10 minutes to settle any
SPIONs or cells. 50uL of each sample supernatant was plated into wells of a black optical
bottom 96-well plate, followed by 50uL of reagent substrate. The plate was incubated in
the dark at room temperature for 30 minutes. Fifty microliters of stop solution was added
to each well. Absorbance was measured at 490 nm and results were plotted as absorbance
over time with respect to increasing amounts of doxorubicin contained in the NIMs (0.03
µg, 0.3 µg and 3.0 µg).
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Magnetic Field Dependent Targeting In Vivo Animal Studies
Animals
Male balb/c mice (6-8 weeks old; Jackson Laboratory, Sacramento, CA, USA)
were used for the in vivo magnetic-dependent targeting studies. All rodents were housed
in a temperature and light cycle controlled facility, and their care was under the
guidelines of the National Institutes of Health and an approved institutional animal care
and use committee protocol (IACUC protocol number 11-100747-HSC) at the University
of New Mexico.
Targeting of Dry Powder NIMs Compared to NIMs liquid suspension in Murine
Lungs
Mice were anesthetized with xylazine/ketamine by intraperitoneal injection. Dry
Powder Insufflators™ are specifically developed for pulmonary drug administration to
mice and variants suitable for rats, guinea pigs and larger animals exist.
A dry powder Insufflator™ for mouse (DP-4-M; Penn-Century Inc., Wyndmoor,
PA, USA) was attached to a 1 ml disposable plastic syringe that was used to
endotracheally administer the dry powder NIMs. The insufflator delivery tube (cannula)
was inserted gently into the trachea of the animal, proximal to the carina, until the curve
of the cannula was positioned approximately 5 mm from the incisors. The mouse left
lung was surgically exposed by thoracotomy and a commercially available
neodymium−iron−boron (NdFeB) permanent cylindrical magnet (grade N52, 22 mm long
× 20 mm in diameter; Applied Magnets, Plano, TX) was centered above, with edge
perpendicular to the upper section of the left lung (Fig.1A). This permanent magnet was
previously characterized to have a magnetic field of 0.58 Tesla (McBride et al., 2013).
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The dry powder vehicle was administered using the syringe with an air volume of 500 µl
for total of 10 puffs (10 actuations). A liquid suspension delivery vehicle was
administered using the MicroSprayer® aerosolizer (1A-1C; Penn-Century) for mouse and
was attached to a hand-operated, high-pressure syringe (FMJ-250; Penn-Century). Mice
were endotracheally intubated with the MicroSprayer® and 50 µL saline containing 2.0
mg of NIMs (w/v solids) was administered directly into the airways in the presence of the
magnetic field. Control mice were treated using the same dry powder NIMs and liquid
suspension regime in the absence of magnetic-targeting. To prepare the liquid suspension
delivery vehicle, NIMs were dissolved in saline to prepare a liquid suspension that
contained equivalent amounts of the fluorescent dye (or drug) and SPIONs. Two
thousand micrograms (2.0 mg) of dry powder NIMs were mixed in 50 µl of saline to
prepare a single dose suspension for in vivo administration. Mice were euthanized
humanely; lungs and trachea were removed en bloc, separated (Fig. 1B), and
fluorescence and iron deposition were quantified in the respective tissue.
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Figure 1: Magnetic-field-dependent lung targeting study A) Position of the
neodymium-iron-boron magnet during magnetic-field-dependent targeting. The magnet
was positioned in the upper quadrant of the left lung. B) Orientation of imaged trachea,
right lung, and left lung. Accumulated SPIONs are markedly visible in trachea and left
lung (black arrows).
Fluorescence Quantification
Dry powder NIMs and liquid suspension NIMs in the presence of magnetic fielddependent targeting were administered endotracheally with or without magnetic targeting
to the left lung. Individual lung lobes and trachea were excised and imaged immediately
for fluorescence measurement (excitation: 660 nm; emission: 680 nm) with an exposure
time of 10 seconds using a Caliper IVIS Lumina II (Caliper Life Sciences). A region of
interest (ROI) was drawn around the trachea, left lung, right lung, and background. The
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ROI area was kept constant at 2.5 cm2 and fluorescence expressed as units of average
radiance efficiency (RE) (p/sec/cm2/sr)/(µW/cm2).
Targeting efficiency ratio was calculated by determining ratios of the fluorescence
intensity (FI individual) of ROIs from an individual tissue (e.g. left lung) in the numerator,
divided by the sum of fluorescence intensity (FI sum) of the three ROI areas in the
denominator (Equation 1).

Targeting Efficiency Ratio =

!"!"#!$!#%&'
!"!"#

Iron Quantification In Murine Lungs and Trachea
Inductively coupled plasma optical emission spectroscopy (ICP-OES) was used to
measure iron (ferrous) content in mouse lungs. Briefly, tissue was digested with 0.5 ml
nitric acid (HNO3) at 105 °C for 1 hour and vortexed until completely dissolved (protocol
modified from Niazi et al. 1993)(Niazi et al., 1993). After cooling, the samples were
brought up to a known volume with 18.1 megaohm MilliQ water and vortexed. Samples
were analyzed with a PerkinElmer Optima 4300 DV ICP-OES. The recommended
wavelength for iron was used (Fe(II)-λ-259.939 nm). A blank and range of calibration
standards were used to establish a five-point calibration curve (0.1 ppm to 25 ppm
(mg/L). Endogenous iron was analyzed in untreated lungs (n = 3). Calibration and
instrument verification samples (ICV – integrity check values) were incorporated before
and after analyzing the samples, as well as periodically throughout the measurements.
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Statistical Analysis
Statistical analyses were performed using Windows SPSS version 16 (SPSS Inc,
Chicago, IL, USA). Paired t-tests with bonferroni correction were used to compare two or
more groups of independent data, respectively. The significance level was set at α = 0.05.
Descriptive statistics were also employed if data were not statistically significant. A
power calculation post hoc was run using the free program G*power (Dusseldorf,
Germany) (Faul et al., 2007; 2009). For in vivo animal experiments with equivalent
sample sizes with an effect size of n = 3, the power was calculated to be > 0.95.

Results and Discussion
Microparticles for pulmonary delivery have been previously prepared by spray
drying lactose as the main bulking agent (Sham et al., 2004, McBride et al., 2013). Spray
drying nanoparticles (SPIONs in our case) with a lactose matrix would decrease the
residence time of NIMS in the lung tissue after inhalation due to its solubility in the lung
fluid. This would allow the immediate release of the drug and potentially decrease the
chance of NIMs being phagocytosed by alveolar macrophages thus enhancing the
bioavailability of the drug payload (Bailey and Berkland, 2009)
Dry Powder NIMs Formulation and Characterization
NIMs were previously characterized for particle size, zeta potential, morphology,
iron and drug loading (McBride et al., 2013). The particle size was measured by laser
diffraction using a Mastersizer 3000 Aero S dry powder disperser and in triplicate. The
average D4,3 was 3.86 µm ± 0.24 µm and the average D50 (volumetric median diameter)
was 2.71 ± 0.04 µm, with a span of 2.25, which expresses the distribution width. These
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results are fairly typical in that the D4,3 is greater than the D50 (the volume-basis median
value) (Horiba Scientific, 2012). NIMs were sized for optimal pulmonary delivery in the
size range 1 – 5 µm (Gerrity et al., 1979). The advantage of encapsulating SPIONs into
larger micron-sized NIMs will also overcome the disadvantage of the nanoparticle being
exhaled when administered by the pulmonary route due to their small size (Hickey 2014).
The doxorubicin loading was previously quantified to be 1.6% (w/w) in the NIMs
using HPLC. In addition, Fe3O4 was calculated to be 10.6% (w/w) in the NIMs using
ICP-AES (McBride et al., 2013).
Viability of A549 cells exposed to NIMs quantified by the MTS assay
The MTS assay was used to analyze the viability of A549 lung adenocarcinoma
cells when exposed to NIMs. We hypothesized that doxorubicin-containing NIMs would
be as toxic to A549 cells compared to free doxorubicin alone.
Figure 2 compares tumor cells treated with free doxorubicin solution versus free
doxorubicin solution, lactose alone, and SPIONs alone. The viability of A549 control
cells (n = 3) was 2.468 ± 0.007 at 1 hour, 2.380 ± 0.133 at 8 hours, 2.651 ± 0.025 at 24
hours, and 2.735 ± 0.004 at 48 hours. Three doxorubicin dose levels were compared.
When A549 tumor cells exposed to 0.03 µg free doxorubicin solution were compared to
cells exposed to NIMs containing 0.016 µg doxorubicin, cells exposed to NIMs (2.706 ±
0.108, n = 3) were as viable as untreated A549 cells (2.735 ± 0.004, n = 3) after 48 hours
of exposure (Fig. 2A), showing similar rates of killing. A549 cells treated with free
doxorubicin (2.524 ± 0.011, n = 3) were 7% less viable after 48 hours of exposure than
cells exposed to NIMs or untreated A549 cells (Fig. 2A).
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Figure 2. MTS viability assay of A549 cells exposed to doxorubicin-loaded-NIMs
delivery vehicle MTS assay measuring viability of A549 lung adenocarcinoma cells
exposed to a) 1 µg NIMs containing 0.016 µg doxorubicin compared to 0.03 µg free
doxorubicin and b) 10 µg NIMs containing 0.16 µg doxorubicin compared to 0.3 µg free
doxorubicin and c) 100 µg NIMs containing 1.6 µg doxorubicin compared to 3.0 µg free
doxorubicin.

Concomitantly, A549 cells exposed to 0.3 µg free doxorubicin solution were
compared to cells exposed to NIMs containing 0.16 µg doxorubicin. Interestingly, cell
viability was reduced 17% when exposed to NIMs (0.16 µg doxorubicin; 1.743 ± 0.157, n
= 3) versus free doxorubicin (0.3 µg doxorubicin; 1.439 ± 0.046, n = 3) after 48 hours of
exposure, even though the NIMs vehicle contained 46.67% less doxorubicin than the
doxorubicin solution (Fig 2B). With a 10-fold increase in NIMs and free doxorubicin
concentration exposure at 48 hours exposure (1.6 µg doxorubicin in NIMS; 3.0 µg free
doxorubicin), a slight loss in cell viability was observed for free doxorubicin over NIMs.
Cell viability was significantly reduced when exposed to NIMs (1.6 µg doxorubicin;
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1.155 ± 0.014, n = 3) versus free doxorubicin (0.3 µg doxorubicin; 0.908 ± 0.046, n = 3)
after 48 hours of exposure (Fig. 2C). However, there was an overall reduction in cell
viability in both doxorubicin alone and NIMs, compared to controls. A549 cells exposed
to solutions of controls (lactose alone and SPIONs alone) were viable over the entire 48
hour experimental time course. We conclude that neither lactose alone nor SPIONs alone
decreased cell viability.
At 1 and 8 hours post-exposure, the tumor cell death rate was essentially equal
with both the NIMs and free doxorubicin treatments. At time points beyond 8 hours, an
increase in cell death was observed for the NIMs treated cells (0.16 µg doxorubicin)
compared to free doxorubicin (0.3 µg) treatment.
Cytotoxicity of A549 Cells Exposed to NIMs Quantified by the LDH Assay
The LDH assay was used to analyze NIMs toxicity when exposed to tumor cells
(Fig. 3). LDH released from damaged cells oxidizes lactate to pyruvate, which promotes
conversion of tetrazolium salt (INT) reagent to a purple formazan product, a watersoluble molecule with absorbance at 490. The amount of LDH released is proportional to
the number of cells damaged or lysed (Haslam et al., 2000; Lewinski et al., 2008). We
hypothesized that the doxorubicin-containing-NIMs would be as toxic as free
doxorubicin alone.
Figure 3 compares tumor cells treated with free doxorubicin solution versus the
doxorubicin loaded-NIMs, lactose alone, and SPIONs alone. Increased absorbance
signifies low cell viability or lactate dehydrogenase leakage from the cell membrane.
When A549 tumor cells exposed to 0.03 µg free doxorubicin solution were compared to
cells exposed to NIMs containing 0.016 µg doxorubicin, cells exposed to NIMs (0.552 ±
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0.080, n = 3) were as toxic as tumor cells treated with free doxorubicin (0.425 ± 0.002, n
= 3) after 48 hours of exposure (Fig. 3A).

Figure 3. LDH cytotoxicity assay of A549 cells exposed to doxorubicin-loaded-NIMs
delivery vehicle. LDH assay measuring toxicity of A) 1 µg NIMs containing 0.016 µg
doxorubicin compared to 0.03 µg free doxorubicin and B) 10 µg NIMs containing 0.16
µg doxorubicin compared to 0.3 µg free doxorubicin and C) 100 µg NIMs containing 1.6
µg doxorubicin compared to 3.0 µg free doxorubicin to A549 lung adenocarcinoma cells.

Likewise, when A549 tumor cells exposed higher dose of free doxorubicin
solution (3.0 µg) were compared to cells exposed to NIMs containing (1.6 µg
doxorubicin) (1 µg NIMs containing 1.6% doxorubicin), cells exposed to NIMs (1.146 ±
0.045, n = 3) were as toxic as tumor cells treated with free doxorubicin (1.046 ± 0.068, n
= 3) after 48 hours of exposure (Fig. 3C). Having shown that NIMs express more toxicity
than the free doxorubicin control, despite containing 46.7% less doxorubicin, we attribute
the increased toxicity of NIMs to be a synergistic effect of increased cellular uptake of
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SPIONs and ROS production, coupled with greater cytotoxic effects of doxorubicin
(Jones et al., 2011). SPIONs alone were found to be non-toxic to A549 cells. While bare
iron oxide nanoparticles exert some toxic effects, coated SPIONs have been found to be
nontoxic (Shim and Williams, 1980; Lewinski et al., 2008). SPIONs are composed of
simple iron oxides that are biodegradable and their safety has been previously
demonstrated by being used as diagnostic agents in humans in imaging of the lung
(Stahlhofen and Möller 1993, Polyakt and Friedman 2009).

Magnetic-Field-Dependent Targeting for Particle Deposition Visualization
Dry powder NIMs containing fluorescent nanospheres were endotracheally
insufflated in the presence of magnetic field dependent targeting to the left lungs of mice.
Fluorescence associated with NIMs was detected in the mouse trachea, left lung and right
lung.
A proof of concept magnetic-field dependent targeting study was conducted to
optimize dry powder pulmonary delivery, and to show the feasibility of NIMs targeting in
a healthy ex vivo rat model. Although the data was non-significant (P = 0.057), this study
showed feasibility of magnetic field dependent targeting of the NIMs delivery vehicle to
one lung over the other. Dry powder NIMs were targeted 3.9 fold more to the right lung
than the left, and provided insight into dry powder NIMs formulation optimization, as
well as optimization of the use and dispersion and delivery of dry powders from the DP4R insufflator device.
In control animals that were not administered NIMs, both lungs exhibited little to
no background fluorescence intensity (1.69 x106 ± 2.77 x 105 RE). In the presence of
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magnetic field dependent targeting with NIMs, significantly higher fluorescence units of
radiance efficiency was detected in the left lung (1.42 ± 0.26) x 108 RE; (5.2 ± 2.3) x 107
RE in the right lung, P < 0.01) as shown in Figure 4D, or 2.7-fold more deposition to the
left lung than the right. We achieved slightly better targeting than Dames et al., 2007 who
observed a two-fold higher dose of pDNA in the magnetized right lung than the
unmagnetized left lobe. When NIMs were administered to the lungs in the absence of
magnetic field dependent targeting, intensity averages were similar in both the left and
right lung (6.12 ± 3.0) x 107 RE; right lung: (5.79 ± 2.4) x 107 RE.
Significantly more fluorescence was quantified in the trachea for dry powder
NIMs than liquid suspension. We attribute this pitfall to the DP-4M insufflator delivery
tool. Hoppentocht et al. recently published data stating that the recommended 200 µL air
volume did not provide adequate dispersion or emitted dose to administer dry powders in
mice lungs (Johnson et al., 2002; Huland et al., 2003; Yi and Wiedmann, 2010;
Sakagami, 2013; Hoppentocht et al., 2014). We confirmed this observation and showed
that a larger pulsed air volume of 500 µL was required for adequate NIMs dispersion in
in the lung. However, a higher air volume could have led to significant powder deposition
in the trachea (Fig 4 B, D). The insufflator deposits the dry powder in the respiratory tract
based on firm plunging of the syringe, which is necessary for the proper aerosolization
and delivery of NIMs into the lung (Morello et al. 2009). The high velocity air stream
generated by the syringe (attached to the insufflator) would lead to powder deposition in
the upper conducting airways and the main tracheal bifurcation due to inertial impaction.
Dry powder NIMs exiting the insufflator delivery tube had enough momentum to follow
its trajectory until it collided with the tracheal wall (Mortensen et al. 2014). However,
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NIMs that did not impact on the upper respiratory tract were available for magnetic
targeting deeper into the lung lobes as shown in Figure 4D. We believe that using an
existing passive dry powder inhaler that will allow slow and deep inspiration would
mitigate the upper respiratory tract deposition of our NIMs.
We relied on information from the Penn Century manufacturer with respect to the
emission velocity of the liquid suspension and the dry powder, but did not test this. The
syringe volume (1 ml) and force used to dispense the liquid or powder from the
instrument were maintained during the experiment.
Neither an increase nor decrease in the mass of the dose administered had a
profound effect on the dispersion efficiency. An average of 2.0 mg NIMs (w/w solids)
was loaded into the insufflator; based on gravimetric analysis, an average of 0.4 – 0.6 mg
dry powder NIMs was administered. This suggests that limitations of the dose should not
be based entirely on weight, but rather on the basis of powder properties and air volume
for optimal powder dispersion and deposition. Therefore, it is necessary to optimize
dispersion efficiency of the dry powders before using the insufflator.
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Figure 4: Effect of magnetic-field-dependent targeting by fluorescence
quantification of in murine lungs A) Control, no treatment lungs show no fluorescence
background (n = 1). The trachea is oriented in upper half of image; right lung is oriented
on left side of image; left lung is oriented on right side of image. B) Dry powder NIMs
vehicle and the liquid suspension vehicle in the absence of magnetic-field-dependent
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targeting (n = 3). C) Dry powder NIMs vehicle in the presence of magnetic-fielddependent targeting (n = 3). D) Liquid suspension vehicle in the presence of magneticfield-dependent targeting (n = 3).
	
  

	
  

Figure 5: Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension A)
Comparison of fluorescent dye in dry powder NIMs and liquid suspension in left and
right lungs (targeted to left lung) in the presence of magnetic-field-dependence targeting
and B) in the absence of magnetic-field-dependent targeting. C) Fluorescence differential
between vehicles in the presence and absence of targeting. D) Fluorescence quantified in
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left lung of NIMs (presence and absence of targeting) and liquid suspension (presence
and absence of targeting).
Effect of Magnetic-Dependent Targeting As Iron Quantification Using ICP-OES
Inductively coupled plasma optical emission spectroscopy (ICP-OES) is an
analytical tool used to detect trace metals and is also commonly used for iron oxide
nanoparticle quantification (Taylor et al, 2014; Chertok et al, 2010; Cole et al, 2011; Sun
et al, 2006; Moroz et al 2002; Huang et al, 2009; Wuang et al, 2006, Xie et al, 2008;
Simbert et al, 2007; Graczyk et al, 2014). Our goal was to use this technique to accurately
quantify nanoparticle iron in the lung and tracheal tissue after magnetic-dependent
targeting of the NIMs or liquid suspension vehicle.
One drawback of ICP-OES is its inability to distinguish between endogenous and
exogenous sources of iron. We compensated for this shortcoming by quantifying and
subtracting endogenous iron in untreated left and right lung tissues, as well as tracheal
tissue (n = 3). All data are presented as mean ± SEM unless otherwise noted. The
standard curve had an R2 value of 0.99975. The left lung was found to have an average
iron concentration of 156.0 ± 3.1 mg/kg, the right lung 135.0 ± 16.3 mg/kg iron, and the
trachea 88.2 ± 11.4 mg/kg iron.
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Figure 6: Iron accumulation and effect of magnetic-field-dependent targeting:
corroboration of iron and dye components from the delivery vehicle A) Accumulation of
iron measured by ICP-OES to the left/right lung and trachea, targeted with NIMs vehicle.
B) Accumulation of iron measured by ICP-OES to the left/right lung and trachea,
targeted with the liquid suspension vehicle. C) Comparison of differences: fluorescence
and iron to the left lung in the presence and absence of magnetic targeting and
administration of NIMs dry powder vehicle. D) Comparison of differences: fluorescence
and iron to the left lung in the presence and absence of magnetic targeting and
administration of the liquid suspension.
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In the case of targeted NIMs to the left lung, more iron was quantified in the left
lung (1520 ± 579 mg/kg) than the right lung (186 ± 112 mg/kg) (P < 0.005, n = 3), an 8.2
fold more difference, showing corroborative evidence that dry powder NIMs were
targeted to the left lung over the right lung. In contrast, iron quantified in the left and
right lungs with liquid suspension targeting did not show significant targeting (left lung
394 ± 141 mg/kg, right lung 232 ± 53 mg/kg). In the absence of magnetic targeting,
variable amounts of iron were found in the left and right lungs with both the dry powder
NIMs and liquid suspension vehicles.
Corroboration of Targeting By Comparing Targeting Efficiency Ratios
Furthermore, targeting efficiency was calculated by taking the ratios of intensity
quantified by fluorescence and by ICP-OES in the left lung, right lung, and trachea,
respectively, and divided by either the sum of the total fluorescence intensity or intensity
given by ICP-OES of the three ROI areas. Quantification of fluorescence or iron was
analyzed by comparing fluorescence or iron targeting efficiency ratios (e.g.
iron/fluorescence in left lung divided by the sum of fluorescence/iron in left lung, right
lung and trachea). The key issue was to determine whether a ratio was significantly high
or low in order to conclude whether magnetic field dependent targeting was increased or
decreased to the left lung, significant to the untargeted right lung.
Corroborating fluorescence and iron data, similar outcomes are seen when
comparing the differences between left and right lung of NIMs in the presence and
absence of magnetic targeting (fluorescence accumulation of NIMs, average differential
of fluorescence in left and right lung in the presence of targeting 30% ± 6%; iron
accumulation of NIMs, average differential of iron in left and right lung in the presence
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of targeting 30% ± 5%) (Figure 6C). In the absence of magnetic targeting, iron and
fluorescence data corroborate each other (fluorescence accumulation of NIMs, average
differential of fluorescence in left and right lung in the absence of targeting 1% ± 9% to
left lung; iron accumulation of NIMs, average differential of iron in left and right lung in
the absence of targeting 1% ± 2% to right lung) (Figure 6C).
Significantly more NIMs (61% ± 7%) than liquid suspension (28% ± 3%) were
deposited in the trachea. Stopping or inertial force (Fs) is constantly acting on all particles
(NIMs and liquid suspension) in a field of gravity, which results in a stationary particle
settling velocity (UTS) leading to particle contact with airway walls by sedimentation
(Hershey et al., 1999; Frijlink and de Boer, 2004; Faul et al., 2007; Otterson et al., 2007;
Faul et al., 2009; Otterson et al., 2010). We propose that both dry powder NIMs and
liquid suspension impinge on the tracheal walls, but the liquid suspension continues to
move down the trachea, therefore less iron accumulation was observed.
Although magnetic targeting of drugs using NIMs could be used for many
diseases impacting the lung, localized tumors stands to benefit most significantly from
this targeting mechanism and will be the focus of our future studies. We will be targeting
our dry powder NIMs in an orthotropic lung cancer mice model developed in our
laboratory to demonstrate NIMs ability to cause tumor regression when delivered by the
pulmonary route.
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Conclusion
Combination chemotherapy for lung cancer by the pulmonary route has shown
promise in a Phase I/II study, however, its effectiveness was limited due to potential
pulmonary dose-limiting toxicity to healthy tissues. Therefore, the ultimate goal of this
targeted drug delivery vehicle is to carry high drug payloads of one or more
chemotherapeutic agents to specific regions of the lung and minimize toxicity to healthy
tissues that are not affected by cancer. Delivery of magnetically responsive NIMs to
specific regions of the lung will be advantageous for the treatment of non-metastasized
solid lung tumors, and this work provides the foundation for targeted drug delivery in
rodent models of lung cancer.
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Chapter 5: A longitudinal, orthotopic mouse model using modified A549-hNIS
human adenocarcinoma cells and SPECT/CT imaging

Abstract
We have developed a murine lung cancer imaging model by subcutaneous
xenograft and orthotopic lung implantation of human lung adenocarcinoma cells (A549)
that were genetically modified with the human sodium iodide symporter gene (hNIS;
SLC5A5) for the purpose of tumor imaging. Lung tumor growth was quantified using
single-photon emission computer tomography (SPECT) and computed tomography (CT)
imaging. The radiotracer Tc-99m pertechnetate (99mTcO4-) was selected for its short halflife (6 hours) and rapid clearance from the body. hNIS is a membrane glycoprotein that
normally transports iodide (I-) in the thyroid, and has the ability to symport the I- analog
99m

TcO4-. Here, we have exploited the hNIS mechanism through genetic modification of

lung cancer cells to sequester the radiotracer 99mTcO4- in a lung tumor mouse model for
the purpose of longitudinal SPECT/CT imaging.
Methods: A549 cells were genetically modified with plasmid and lentiviral vector
constructs to stably express hNIS. Modified tumor cells were then implanted into nude
mice to develop two tumor models: the subcutaneous xenograft model and the orthotopic
xenograft tumor model. Tumor progression was longitudinally imaged by SPECT/CT,
and quantified by SPECT voxel analysis. hNIS expression in lung tumors was quantified
using quantitative PCR (qPCR). In addition, hematoxylin and eosin staining and visual
inspection of pulmonary tumors were also performed.
Results: Orthotopic tumors (n = 6) induced by the A549-hNIS-lentiviral vector cell line
exhibited a logarithmic increase in SPECT scintillation over orthotopic tumors induced
76

by the A549 hNIS-plasmid vector cell line (n = 6) and A549 unmodified control cells in
vitro and in the tumor bearing mice models. No significant uptake was observed in cells
infected with the plasmid DNA vector expressing hNIS. Orthotopic implantation of
tumor cells, injected between the 5th and 6th intercostal rib space of the left lung achieved
a 100% orthotopic tumor take rate showing the replicative precision of this model.
Conclusion: We developed a highly sensitive spatial and temporal lung tumor-imaging
model. Through stable incorporation of the hNIS gene in A549 cells, a tumor model was
developed and imaged longitudinally allowing for SPECT/CT imaging and precise tumor
burden quantification at multiple time points across the study. This tumor model could
significantly improve the quality of imaging data by avoiding inter-animal variation,
reducing imaging invasiveness, and allowing long-term longitudinal monitoring of the
same animal treated with new anti-cancer drugs. Ultimately, this model allows each
animal to be used as its own control leading to improved study significance and a
reduction in study animals.
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Introduction
Animal tumor models are the preclinical standard for the evaluation of potentially
useful cancer chemotherapeutic agents; however, drawbacks exist in animal models(Curt,
1994). Some of these drawbacks include the use of large cohorts of animals, variability in
tumor size between animals, and the inability to precisely follow tumor growth and
metastasis (Olive and Tuveson, 2006; Phalen et al., 2008).
Genes encoding for the transport of membrane proteins have emerged as an
innovative strategy for non-invasive visualization of longitudinal tumor growth in
preclinical animal models. Reporter gene imaging is based on vector-mediated
overexpression of a transgene in host tissue which encodes for a protein that is normally
not present in the target area(Miyagawa et al., 2005; Riesco-Eizaguirre and Santisteban,
2006). The feasibility of noninvasive imaging using PET or SPECT/CT and radiolabeled
reporter probes has been demonstrated in small animals(Inubushi et al., 2003) and in
large animals (Bengel et al., 2003; Dobrucki and Sinusas, 2009).
Xenograft tumor models are most commonly used in immunodeficient mice
(Olive and Tuveson, 2006) and multiple types of tumor instillation methodologies exist.
Xenograft models can be initiated through the subcutaneous or intravenous injection of
tumor cells from cell culture or tissue transplantation. Xenograft transplants may also be
orthotopic, meaning that the tumor is placed in the site where it would be expected to
arise naturally in the host: human lung cancer cells placed in the mouse lung.
Orthotopically implanted lung xenograft tumor models can be initiated through surgical
transplantation of a small tumor mass or by injection of tumor cells from cell culture
through intravenous injection, intratracheal injection or by surgical implantation. We
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have established an orthotopic tumor model which simulates the clinical and pathological
features of human lung cancer, similar to other published literature (Yamaura et al., 2000;
March et al., 2001; Kang et al., 2010; Li et al., 2011).
The hNIS is a plasma membrane glycoprotein that mediates active iodine uptake
in tissues such as thyroid, salivary glands, gastric mucosa, and lactating mammary glands
(Tazebay et al., 2000). hNIS-mediated iodide uptake is an active transport process that
occurs against the electrochemical gradient in negatively charged iodine anions (Fig. 1)
(Chung, 2002; Dohán et al., 2003). Here, we propose the implantation of hNIS modified
A549 human lung cancer cells into immune compromised mice (athymic nude nu/nu
mice) to develop a longitudinal lung cancer animal-imaging model (Fig. 1). We show the
development of an innovative preclinical tumor animal model using A549 lung
adenocarcinoma cancer cells that were modified to express the human sodium iodide
(Na+I-) symporter (hNIS) for reporter gene imaging. These cells enabled the development
of subcutaneous and orthotopic xenograft lung cancer animal models and their tumor
burden radioimaging, for the ultimate purpose of novel chemotherapeutic evaluation and
assessment of tumor response.
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Figure 1: Schematic of the vector-mediated overexpression of a transgene in a host
cell encoding for a protein that is normally not present in the host cell. Plasmid DNA and
lentiviral vectors expressing the hNIS gene were transfected or transduced to genetically
modify A549 cells.
We have constructed plasmid DNA and lentiviral vectors expressing the hNIS
gene. These vectors were transfected or transduced to genetically modified A549 cells.
Cells were characterized for hNIS expression and implanted as a either a subcutaneous
xenograft or orthotopic xenograft model to the lung. Resulting tumors were imaged using
SPECT/CT and algorithmically quantified. We hypothesize that lung cancer cells
expressing the hNIS gene will allow selective radioimaging of vector-modified cells in an
orthotopic lung cancer animal model, thus providing a preclinical in vivo model to
evaluate the efficacy of novel chemotherapeutic formulations.
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Materials and Methods

Cell lines
The human epithelial carcinoma cell line CCL-185 A549 was purchased from
American Type Culture Collection (ATCC, Manassas, VA). A549 cells and genetically
modified cells were cultured in F-12K nutrient mixture (kaighn’s modification) 1x media
from Invitrogen (F-12K) (Grand Island, NY) supplemented with 5% fetal bovine serum
(FBS) and 1% penicillin-streptomycin from Invitrogen (Grand Island, NY). Cells were
maintained at 37°C under an atmosphere of 5% CO2.
Creation of the plasmid DNA vector and cell transfection
The A549-pDNA cell line was generated encoding the hNIS gene. Primers were
designed based on the cDNA sequence SLC5A5 (Entrez Nucleotide, National Center for
Biotechnology Information, Bethesda, MD) to form a 1932 basepair insert into the
multiple cloning site of the pIRES2DsRedExpress vector. This modified vector was then
transfected into CCL-185A549 cells using the FuGene 6® reagent (Promega, Madison,
WI) according to the manufacturer’s protocol. Modified cells were plated in serial
dilution resulting in a cell density of 106 to 10 in 10 mm plates. Cells were treated for
selection with 500 µg/ml of G418 Sulfate antibiotic (VWR, Radnor, PA, USA) for 2
weeks. Clones were screened for 99mTcO4- activity. Those cells with highest activity were
chosen for subsequent characterization studies.
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Creation of the lentiviral vector and cell transduction
The A549-hNIS lentiviral cell line was generated using a lentiviral vector that
encodes the sodium iodide gene driven by a household gene (PGK) promoter or strong
viral (SF) promoter, both being eGFP-positive. The lentivirus was produced in 293T
cells; A549 cells were then infected with the virus-containing medium. After infection,
fresh F-12K medium was added to allow cells to recover for 24 to 48 h. Clones were
screened for eGFP activity by flow cytometry and those with the highest activity were
chosen for follow up in vivo studies.
In vitro hNIS –mediated Radioactive 99mTcO4- uptake assay
A549 lung adenocarcinoma cells stably expressing the plasmid hNIS vector were
plated 24 hours before the start of the assay at a cell density of 1 x 106/well in a 12 well
plate. One hour prior to the start of the uptake assay, cells were counted by
hemocytometer using 0.4% solution of trypan blue (HyClone™ Trypan Blue Stain, GE
Healthcare Life Sciences, Logan, Utah, USA) and cell counts were recorded. Cells were
treated with 1.0 microcurie of 99mTcO4- (Cardinal Health, Albuquerque, NM) for 1 hour
at 37°C with 5% CO2. Cells were washed twice with cold PBS (Invitrogen, Grand Island,
NY). One mL of 20mM sodium acetate (Sigma-Aldrich Corporation, St. Louis, MO) in
PBS was added to each well, incubated at room temperature for ten minutes and
supernatant removed. Then 1 mL of 0.1 M NaOH (Sigma-Aldrich Corporation, St. Louis,
MO) was added to each well to de-adhere and lyse cells. The cell lysate was collected
and radioactivity was counted by a gamma counter (Wallac Wizard 1470-005, Perkin
Elmer). For each sample, 99mTcO4- activity (counts) emitted was divided by the number
of cells in each well to normalize data. Experiments were performed in triplicate. Cells
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were screen for 99mTcO4- activity. Those cells with highest activity were chosen for
subsequent in vivo studies.
Animals
Male, 6-week old, athymic nude mice (Nu/Nu) (Harlan Sprague Dawley, Inc.,
Indianapolis, IN, USA) were housed and maintained in specific pathogen-free conditions
in a facility approved by the American Association for Accreditation of Laboratory
Animal Care under National Institutes of Health Guidelines. Food and water were
provided ad libitum to the animals in standard cages. All experiments were performed in
accordance with the guidelines of the Institutional Animal Care and Use Committee, at
the University of New Mexico under IACUC protocol number HSC100853.
Implantation and development of subcutaneous xenograft lung tumors
Modified A549-hNIS cells (3 x 106 cells in 100 µl) were suspended in 1:1 F 12K
media and matrigel (BD Biosciences, San Jose, CA, USA) per injection site. Only cell
suspensions with >90% viability determined by trypan blue exclusion was used to inject
the cell inoculum. Mice were anesthetized by continuous flow of 3% isofluorane and
cells were injected subcutaneously (s.c; 25 gauge, 5/8’’ needle). Each animal received 4
tumor injections; one each in the a) left anterior lateral thoracic wall b) right anterior
lateral thoracic wall c) left posterior lateral aspect of the flank d) right posterior lateral
aspect of the flank (Kyriazis and Kyriazis, 1980).Tumor growth was monitored with a
digital caliper, and their volume was estimated according to the following formula: V =
(S2 x L)/2, in which S and L are the smaller and larger measures of the tumor,
respectively (Tomayko and Reynolds, 1989)(data not shown, for monitoring purposes).
Animals were observed for 45 to 60 minutes after tumor inoculation, until fully
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recovered.
Implantation and development of orthotopic xenograft lung tumors
Modified A549-hNIS cells (3 x 106 cells in 100 µl) were suspended in 1:1 F 12K
media and matrigel per injection site. Mice were anesthetized by continuous flow of 3%
isofluorane (2.5% LPM oxygen), shaved, and a 5 mm skin incision was made to the left
chest, ~ 5 mm below the scapula. A needle (25 gauge) containing cells was quickly, at an
angle of approximately 45°, advanced to a depth of 5 mm in the mediastinum of the left
lung between the 5th and 6th intercostal rib space (protocol modified from Ichite et.
al.(Ichite et al., 2009) and Saha, et al.(Saha et al., 2010)). Animals were observed for 45
to 60 minutes after tumor inoculation until fully recovered.
SPECT/CT imaging
Tumors were imaged using single-photon emission computed tomography
(SPECT) and computed tomography (CT) (NanoSPECT/CT, Mediso USA, LLC, Boston,
MA). Mice were anesthetized with 3% isofluorane (2.5% LPM oxygen) in an anesthesia
induction chamber and injected by tail vein with 1 millicurie of

99m

TcO4-. Mice were

placed on a heated bed (37°C) for 30 minutes of SPECT imaging followed by 15 minutes
of CT imaging. Mice remained anesthetized at 2% isofluorane (2.5% LPM oxygen)
during the entire imaging process and were monitored to ensure proper recovery from the
anesthesia.
Tumor histology
Lungs and trachea bearing tumors were removed en bloc. During lung fixation, it
was important to prevent lung collapse, deflation, and disruption of lung structures and to
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avoid fixation artifacts, which could lead to alveolar wall thickening, hypercellularity,
change in shape or volume, and blood in the lungs (van Kuppevelt et al., 2000).
Therefore, a canula was inserted into the trachea and fixed with a ligature. The lungs
were fixed by gentle infusion of the fixative (10% formalin) through the cannula by
continuous release of fixative under pressure for 20 minutes (Braber and Verheijden,
2010). The final fixative pressure was defined as the height of the fixative reservoir
above the surface of the fixative in which the lungs were immersed. Tissues were stored
in 10% formalin until processing, and then embedded in paraffin. Seven-micron sections
were sliced in a sagittal plane and stained with hematoxylin and eosin. Tumor samples
were analyzed for histological changes including the presence of tumor necrosis,
apoptosis, mitotic activity and cytologic atypia.
Analysis of SPECT/CT and data processing
An automated library-based segmentation routine robust to high-density lung
tissue was used to segment the lungs from the CT image data, with manual QC and
intervention as necessary. For the SPECT and CT data, separately, the Otsu method
(Otsu, 1979) was applied within segmented lung regions of interest to calculate a tumor
threshold. Lung voxels where intensity exceeded the threshold were classified as tumor
voxels. The final tumor region was defined as the intersection of the modality-specific
tumor regions.
Statistical Analysis
Data were presented as the mean and 95% CI, and the statistical significance of
differences in mean values was assessed by a one-way ANOVA and Dunnett’s multiple
comparisons post hoc test. The differences in radioactivity uptake (expressed in units of
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percent injected does of per gram of tissue (%ID/g)) were considered significant at values
of P < 0.05.
Results
In vitro expression of hNIS in modified cell lines
Plasmid and lentiviral-vector mediated hNIS expression was characterized for
stable integration in A549 cells. An in vitro hNIS–mediated radioactive
assay was used to characterize

99m

99m

TcO4- uptake

TcO4- uptake of A549-pDNA vector cells lines.

99m

Tc

uptake analysis of transiently transfected A549 cells (unstable incorporation of hNIS into
the A549 cell genome) compared to A549 cells (untransfected cells) showed 124-fold
higher

99m

TcO4- uptake in transiently transfected A549 cells, and was used as positive

control of hNIS expression. Untransfected A549 cells showed no hNIS activity. Thirtyfour cell lines were characterized for stable hNIS incorporation. Of those, two cell lines
were chosen (named A549-pDNA clone 1 and A549-pDNA clone 2; abbreviations used
going forth) for increased hNIS expression and

99m

TcO4- uptake activity (Fig 1C), and

further used for in vivo studies.
Lentiviral vectors using two different promoters were also used to infect A549
cells. Flow cytometric analysis showed that for the housekeeping gene (PGK) as well as
for the strong viral (SF) promoter, all cells were positive for eGFP. The SF promoter
results in a 4-fold stronger mean fluorescence intensity signal compared to the
housekeeping gene promoter (Figure 1A). Flow cytometric analysis showed 30.6% hNIS
positive cells for household gene (PGK) promoter and 73.0% hNIS positive cells for the
SF promoter. The SF promoter further resulted in a 2.9-fold stronger MFI signal than the
household gene promoter (Fig. 1B) therefore the lentiviral vector cells containing the SF
86

promoter (named A549-LV clone, and abbreviation used going forth) were used for in
vivo studies.
Quantitative PCR (qPCR) was used to compare hNIS expression of A549-pDNA
clone 1, A549-pDNA clone 2, and A549-LV clone relative to A549 vehicle absent of the
hNIS gene. A549-LV vector-mediated clone expressed 2067-fold more gene expression
than vehicle. A549-pDNA vector-mediated clone 1 and A549-pDNA clone 2 expressed
14-fold and 21-fold more hNIS than A549 vehicle (Fig 1D). Based on qPCR results, we
hypothesized that the A549-lentiviral vector using the SF promoter would best sequester
99m

TcO4- in lung cancer cells in an in vivo tumor model.

	
  

Figure 2: Characterization of lentiviral and pDNA vector-mediated hNIS expression
in A549 lung cancer cells. A) PGK and SF promoter lentiviral clones characterized by
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eGFP percent positive and mean fluorescence intensity B) hNIS expression
characterization of PGK and SF promoter lentiviral clones C) pDNA vector clones
characterized by in vitro uptake of 99mTcO4- D) Comparison of hNIS expression of
mRNA in lentiviral and pDNA vector-mediated cells.
SPECT/CT imaging of subcutaneous xenograft tumors and hNIS expression
Tumors were allowed to grow for a total of 47 days and imaged by SPECT and
CT at two time points: 18 days (time point 1) and 47 days (time point 2). Phantom images
show orientation of s.c. xenograft tumor placement and overall tumor growth,
qualitatively determined by CT imaging (Fig. 3A). At time point 1, only the A549-LV
tumor was observed (Fig. 3B). Again, at time point 2, only the A549-LV tumor was
observed (Fig. 3C) even though A549 control, A549-pDNA clone 1, A549-pDNA clone
2 and A549-LV tumors were quantifiably present both visually and by CT (Fig. 4A).
After sacrifice at time point 2, radioactivity was determined in the tumor tissue by
SPECT voxel analysis (Fig. 3B) and showed significantly more activity in the A549-LV
tumor compared to the A549 control tumor, and A549-pDNA clone 1 and 2 tumors (p <
0.01, n = 6) even though the tumor size was an average of 200 mm3 for all tumors (Fig.
4A).
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Figure 3. Subcutaneous xenograft tumor quantification A) Orientation of xenograft
Figure
50 : Day 47
tumors as shown by phantoms images on a CT image: upper L: A549 control, lower L:

A549-lentiviral clone, upper R: A549-plasmid clone 1 and upper L: A549-plasmid DNA

Tc-99m Xenograft
Tumor Study
clone 2 B) SPECT/CT first imaging time point (day 18 tumor growth) (n = 6) C)

SPECT/CT second imaging time point (day 47 tumor growth) (n = 7; representative
image)
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Figure 4: SPECT analysis of subcutaneous injected xenograft tumors at the end of
the study (day 47) A) Tumor volume quantification using CT analysis. B) Percent
injected dose 99mTcO4- per gram of tumor tissue. C) mRNA hNIS expression of tumors.
One-way ANOVA and Dunnett’s multiple comparisons post hoc test (p < 0.01, n = 6),
error bars graphed as mean with 95% CI.
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Quantification of hNIS expression by qPCR
We further corroborated hNIS expression by qPCR of mRNA from excised
tumors (Fig. 4C). Interestingly, A549-pDNA tumors had very low levels of hNIS
expression. A549-LV tumors expressed an average of 4.8 fold more hNIS than A549pDNA tumor 1, and 27 fold more hNIS expression than A549-pDNA tumor 2.

SPECT/CT imaging of orthotopically-induced xenograft tumors expressing hNIS
Like the s.c. xenograft tumor model, orthotopically-induced xenograft tumors
were imaged by SPECT/CT at 2 time points (day 18 and 36). SPECT images show
minimal radioactivity for A549-LV tumors at imaging time point 1 (Fig. 5 A, upper right
panel). A significant increase in radioactivity is seen at time point 2 (Fig. 5 B upper right
panel). No radioactivity is observed for A549-pDNA tumors 1 or 2 at either imaging time
point even though CT detected similar tumor volume among all groups (Fig. 5C). We
observed a 25 fold increase in 99mTcO4- radioactivity (% ID/g) in the A549-LV tumor
compared to other tumor groups (Fig. 5D). When quantifying hNIS expression of mRNA
from excised tumor tissue, the A549-LV tumor group exhibited a 13.8 fold higher hNIS
expression over the A549-pDNA tumor group (data not shown).

91

Figure 5: Tumor scintillation of orthotopically-injected xenograft tumors compared
to A) Tumor volume quantification on day 18: A549 control, lentiviral-A549, plasmid
DNA-A549 clone 1 and plasmid DNA-A549 clone 2. B) Orthotopic xenograft tumor
volume quantification on day 36. C) Comparison of tumor growth between saline control,
A549 control, A49-pDNA clones and lentiviral-A549 clone groups, as measured by CT.
D) Percent injected dose 99mTcO4- per gram tumor tissue for all animal groups day 36.
**** p < 0.0001, error bars graphed as mean 95% CI.
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Primary tumors in mice confirmed by histological analysis
To confirm SPECT/CT detection of tumor burden and the presence of tumor
tissue in mice, we performed histological analysis of H&E stained tissues. Tumor tissue
induced by s.c. xenograft transplantation of A549-pDNA and A549-LV modified cells
lines showed areas of invasive adenocarcinoma tissue growing nests of cells of solid
pattern (Fig. 6 A-D). No metastasis was found in mice with s.c. xenograft transplantation.
Tumor tissue induced by orthotopic xenograft transplantation to the lung using
A549-pDNA vector and A549-LV vector-modified cell lines showed primary tumors in
the left lung (Fig. 7 A – C). We saw widespread nodules and tumors preferentially
invading and extensively disseminated along the pleura. Metastases were observed in the
pleural cavity as well as the right lung. No metastases were observed in any other organs
of the mouse. Purulent neutrophilic exudate fluid was also observed in the pleura due to
inflammation and was creamy and yellow in appearance compared to normal thin serous
fluid.
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Figure 6: Representative H&E histological images of xenograft tumors of A) A549
controls; no genetic modification. B) A549 – pDNA clone 1 C) A549 – pDNA clone 2
D) A549 – Lentivirus clone. Montage images are 4x magnification. Inset images are 40x
magnification (n = 3).
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Figure 7: Histopathological analysis of orthotopically-induced tumor tissue
A) Representative H&E montage images depicting primary tumors (4x magnification) of
saline control, A549 control, A549-pDNA clone 1, A549-pDNA clone 2, and A549-LV
clone. B) Inset images comparing tumor and normal tissue (40x magnification) C)
Dissected specimen showing solitary nodule (as shown by arrow) n = 6 per group.
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Discussion
Animal models are the preclinical standard for the evaluation of potentially useful
cancer chemotherapeutic agents. These models are essential for understanding the fates,
effects, pharmacokinetic and pharmacodynamic interactions of novel drugs. Although
drugs may be metabolized differently in animal models and humans, these data provide a
baseline to assess drug efficacy in a preclinical animal model. Our hypothesis was that an
innovative preclinical model could be developed using modified A549 human lung
adenocarcinoma cells expressing the hNIS gene to enable non-invasive, longitudinal
imaging of tumor burden. For this purpose, we constructed and characterized genetically
modified lung cancer cell lines expressing the human hNIS gene and developed
subcutaneous and orthotopic implanted xenograft tumors that could be longitudinally
imaged by SPECT/CT to evaluate tumor growth. We took advantage of the hNIS
mechanism to concentrate a radiotracer to tumor-specific regions and showed that hNISA549 modified cells sequestered 99mTcO4- in the orthotopically-induced xenograft lung
cancer animal model.
The major finding of this work was that the significantly more hNIS expression
and 99mTcO4- uptake was observed in A549-lentiviral-vector-mediated tumors in
subcutaneous xenograft and orthotopically-implanted xenograft tumor models. To track
the uptake of the radioiodine tracer 99mTcO4- by the human hNIS-modified tumor,
SPECT/CT was used to longitudinally image tumors over a 47-day period. Tumors were
imaged at two time points, at 18 days and 42 days growth, and showed significant growth
in tumor volume based on injected dose of 99mTcO4- per gram of tissue. Orthotopically96

induced xenograft A549-LV tumors expressed 99mTcO4- activity by 200 fold more than
A549 control tumors. These findings are significant because they illustrate a new
methodology that allows for precise tumor growth monitoring in a single mouse over
multiple imaging time points without sacrificing animals throughout the study.
The second major finding of this study is that using algorithmic modeling of
SPECT scintillation, tumor volume was empirically quantified to determine precise
tumor burden compared to bio-distribution of 99mTcO4- and H&E analysis by traditional
animal sacrificing. The longitudinal imaging of tumor burden in this animal model will
overcome drawbacks of having more animals to be sacrificed at multiple time points to
evaluate tumor growth. In addition, this animal model will allow for precise tumor
burden quantification over multiple imaging time points.
S.c. xenograft tumors in nude mice are the most common method of transplanting
human tumor material. Recently some authors have questioned the accuracy of xenograft
tumor data when applied to human drug trials (Syrigos et al., 2006). Orthotopicallyinduced xenograft models have advantages over s.c. xenograft models such as improved
tumor take rates and enhanced invasive and metastatic properties, which are especially
important for lung cancer because the organ-specific site provides tumor cells with the
most appropriate milieu to evaluate the efficacy of novel therapeutics.
The SPECT/CT imaging method is advantageous over bioluminescence imaging;
specifically, its signal is not limited by depth of tumor in the animal and it is better suited
for identifying 3D localization of tumors (Deroose et al., 2007). Also, voxel number and
intensity can be precisely quantified allowing for extremely accurate tumor burden
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quantification, which is important when using an orthotopically-induced xenograft tumor
model, as tumors cannot be manually measured by caliper (Ayers et al., 2010).
Limitations of this research are that SPECT/CT imaging and voxel quantification
are costly and not widely available. Development and execution of the orthotopic tumor
model is time-consuming and expensive, but more clinically relevant to human lung
cancer. Also, the plasmid DNA vector-mediated expression of the hNIS gene was very
low compared to lentiviral-vector medicated expression. Decreased hNIS gene expression
in tumor progression has been related to dysregulation or epigenetic mechanisms.
Transcriptional downregulation of the hNIS gene is caused by methylation of the hNIS
DNA sequence in critical regulatory regions and maybe reversed by the application of
chemical demethylation through the inhibitor of deacetylase (Nakamoto et al., 2000; Guo
et al., 2010). Improved efficiency of baculovirus-mediated hNIS reporter gene imaging in
lung adenocarcinoma cells was shown with sodium butyrate treatment (Guo et al., 2010).
Stable incorporation of the hNIS gene, as shown by the lentiviral transduction method, is
crucial for 99mTcO4- uptake in vivo.
The hNIS gene has many advantages as an imaging reporter gene due to the wide
availability of its substrate radioisotopes like 99mTcO4-, as well as their well-understood
metabolisms and clearance mechanisms. In addition, hNIS is unlikely to interact with the
underlying cell biochemistry, and iodide is not metabolized in most tissue, therefore
ameliorating background signal. We have demonstrated significant increase of 99mTcO4uptake in mice injected with modified cells orthotopically, over a 200-fold increase,
compared to mice injected with A549 cells alone.
Conclusion
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We have constructed plasmid DNA and lentiviral vectors expressing the hNIS
gene. These vectors were transfected or transduced to genetically modify A549 cells.
Cells were characterized for hNIS expression and implanted as a subcutaneous xenograft
or orthotopic model to the lung. Resulting tumors were imaged using SPECT/CT and
algorithmically quantified. This tumor model could significantly improve the quality of
imaging data by avoiding inter-animal variation, reducing imaging invasiveness, and
allowing long-term longitudinal monitoring of the same animal treated with novel anticancer drugs.
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Future Directions and Outstanding Questions
Dissolution Studies
The efficacy and systemic exposure of inhaled drugs depends on the site of
deposition, the rate and extent of absorption of the inhaled particle, and the
physicochemical properties of the drug formulation. Developing an appropriate
dissolution method for the in vitro assessment of inhaled NIMs is a key step in
establishing any meaningful in vitro / in vivo correlations. The in vitro dissolution method
must be optimized to be sufficiently sensitive to detect differences in critical
compositional or processing variables (Sood et al, 2009; McConville, J.T., 2000). The
purpose of this dissolution study would be to identify a relevant in vitro dissolution
screening method to predict the in vivo drug release properties of spray dried NIMs. A
number of issues remain in order to understand the deposition of drugs and dissolution
rates of novel inhaled delivery vehicles in the lungs. For in vitro testing, considerations
for a number of test parameters include:
•

The dissolution rate of the excipient lactose

•

Water, the medium composition

•

Flow rates

•

Dissolution pump type of a Type IV dissolution bath system

In Vivo Delivery and Targeting of NIMs to an Orthotopic Tumor Model
To bring full circle the testing of inhaled and targeted NIMs therapy with the
sodium iodide symporter tumor imaging model, a cohort of mice could be induced with
orthotopic lung tumors using hNIS lentiviral vector modified-A549 cells, as previously
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shown. Based on the development of the orthotopic tumor model, we expect A549-LV
orthotopic tumors to grow to a significant size within 15 – 20 days, accurately quantified
by CT/SPECT.
Three treatments would be given: 1) Intravenous (IV) chemotherapeutic
(doxorubicin or cisplatin) to understand tumor regression from a systemic drug delivery
perspective. 2) Insufflated NIMs treatment containing the same intravenous
chemotherapeutic agent given IV, in the absence of magnetic targeting. 3) Insufflated
chemotherapeutic-containing NIMs treatment with magnetic field dependent targeting.
We expect to understand tumor growth rate kinetics, and pharmacokinetic parameters of
inhaled chemotherapeutics including liberation, absorption, distribution, metabolism and
excretion of the three treatments.
•

Do NIMs appear to cause more inflammation in the lung than the
equivalent systemically administered dose?

The current best device to administer dry powders to rodents is the Penn Century
Insufflator™. Compared to inhalation towers, tracheal insufflation delivers a more
reproducible and predicable emitted dose. From our experience and others (Duret et al,
2012; Hoppentocht et al. 2014), the insufflator is an unreliable delivery strategy and even
the best-planned and executed experiment has a high probability of failure. As better
tools are developed to administer dry powders to animal models, we hope to reconcile
some of the following issues:
•

Reproducibility and precision of dose emitted

•

Flow properties of the dry powders emitted

•

Anti-aggregation and anti-clogging properties
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APPENDICES
Spray drying SOP for nano-in-microparticles (NIMs) containing dye
Aim: To spray dry NIMs (10.0% dye, 20.0% SPIONs, 70.0% lactose) (% w/volume) for in vivo
magnetic-field-dependent targeting (left mouse lung)
Spray drying plan:
1. 20 ml batch of 3% lactose (3% total solids)  for control purposes
a. To verify that spray dryer works correctly, to characterize and optimize particle
size
2. 20 ml batch of NIMs containing dye (2.5% total solids)  yields approximately 250 mg
dry powder
Materials:
• FluoroSpheres® fluorescent microsphere far red dye, 10.0% (w/volume) of total
microparticle
o Fluorospheres®-Carboxylate Modified Microspheres
o Nominal bead size: 0.02 µm
o Dark red fluorescent (633 emission)
o 2% solids (concentration: 0.02 g/ml)
o 4 ml dye purchased from Life Technologies rec’d 2/10/14
o Product Number: F-8783
o Life Technologies (Molecular Probes®) from Carlsbad, CA
•

SPIONs, 20.0% (w/volume) of total microparticle
o 50 nm diameter
o [50 mg/ml] stock concentration
o FluidMAG- UC/A, catalog # 4114-5
o Synthesized 11/25/11 from Chemicell GmbH, Berlin, Germany

•

Lactose, 70.0% (w/volume) of total microparticle
o Gift from DMV Fonterra Excipients
o Product name: Respitose, ML 002
o Product code: 42510-7365

Consumable materials:
• 500 ml autoclaved ddH2O
• Autoclaved beakers:
o (2) 200 ml beakers
o (1) 50 ml beaker
• (10) Autoclaved 20 ml scintillation vials – plastic cap insert removed
• (3) Sterilized spatula (ethanol)
• (3) Sterilized magnetic stirrers (ethanol)
• Sterilized weigh boats large & small (ethanol)
• Autoclaved pipet tips
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1.

20 ml batch of 3% lactose  for control purposes
•
•

1.
2.
3.
4.

Actual
3 grams lactose in 100 ml ddH20 = 3% lactose solution (w/v) 3.0131 g lactose
Solubility of lactose = 210 mg/ml or 21% w/v
100.0 ml milliQ H20

Weigh 3 g (3000 mg) lactose and add to a 100 ml volumetric flask.
Add ddH20 to the fill line of the 100 ml volumetric flask.
Heat solution and stir with bar at 60 °C (lowest setting) for 5 minutes.
Aliquot 20 ml of lactose solution into new 50 ml beaker. Cover with parafilm.
a. 20 ml yields [30 mg/ml] lactose solution = 600 mg lactose solids

a. Spray-dry protocol:
4.

Spray drying conditions: (based off of previous lactose-only run)
Theoretical
i. Inlet:
190°C ± 2 °C
ii. Outlet:
50°C ±4°C
iii. Aspirator:
90%
iv. Pump:
10%
v. Filter gauge*:
- 50 mbar
vi. Nitrogen Q-flow:
vii. Filter used:

63 mmbar
PTFE (Teflon)

Actual
190 ± 2 °C
50 ± 2 °C
0%
10%
- 57 mbar initial
- 62 mbar final
63 mmbar
Teflon

* Exhaust hose connected to HEPA filter
4.

4.

Calculate powder yield percentage:

Actual

a.
b.
c.
d.

161611 mg
161998 mg
387
mg
64.5
%

Weight of vial + cap before spray drying:
Weight of vial + cap + powder after spray drying:
Weight of powder:
Percent yield: x/600 mg (100) =

Characterize particle size (Malvern Mastersizer 3000 Aero S):

Aero S particle SOP notes:
i.
Assume non-spheroid particle geometry
a. Lactose density: 1.52 g/cm3
b. Lactose absorptivity: 0.010
c. Lactose refractive index: 1.347
d. SPION density: 1.55 g/cm3
e. Dye density: 1.05 g/cm3
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2. 20 ml batch NIMs containing dye (500 mg solids or 2.5% total solids)
• Contains 20% SPIONs theoretically (50 nm diameter)
• Contains 10% FluoroSpheres™ far red dye theoretically (stock concentration: 0.02 g/ml)
• Contains 70% Lactose theoretically (6.33% lactose solution in water)
Calculation:
Lactose: 350.0 mg w/w
350/500 = 70.0% total solids
SPIONs: 100.0 mg w/v per 2 ml
(2 ml @ [50 mg/ml])  100/500 = 20.0% total solids
Dye:
50.0 mg w/v per 2.5 ml (2.5 ml @ [20 mg/ml])  50/500 = 10.0% total solids
500.0 mg total solids
500/500 = 100% total solids
 350 mg powder solids + 4.5 ml liquid solids + 15.5 ml H20 for a 20 ml final volume
• Lactose solubility in H20: 21.9 gm in 100 ml
Mass of actual amounts
1. Weigh 350 mg lactose and add to 5.0 ml ddH20 in 50 ml beaker
350.9 mg lactose
2. Add 2.5 ml dye (vortexed and sonicated)
2.5
ml dye
3. You have 5.0 ml total volume solution at this point
2.9
ml SPIONs
4. Add 2 ml SPIONs
13.0
ml milliQ water
a. You have 7 ml total volume at this point
5. QS with another 13 ml water to flask line for 20 ml final volume. Parafilm and label.
6. Weigh scintillation vial.
Spray drying
1. Spray dry conditions:
i. Inlet:
ii. Outlet:
iii. Aspirator:
iv. Pump:
v. Filter gauge:
vi. Nitrogen Q-flow:
vii. Filter used:

Theoretical
190°C
50°C ±4°C
90%
10%
- 52 mbar
63 mmbar
PTFE (Teflon)

Actual
193 ± 2 °C
55 ± 2°C
90%
10%
- 61 mbar
63 mmbar
Teflon

2.

Note powder characteristics: Particles that collect on the sides of the cyclone are nearly 100x
bigger (average: 466 µm) than particles that fall into collection vial. No longer will I scrap sides of
cyclone to retrieve any powders.

3.

Calculate powder yield percentage:
a.
b.
c.
d.

4.

Actual

Weight of vial + cap before spray drying:
Weight of vial + cap + powder after spray drying:
Weight of powder:
Percent yield: x/500 mg (100) =

Characterize particle size (Malvern Mastersizer 3000 Aero S):
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162519 mg
162722.1 mg
203.1
mg
40.6
%

TABLES
Table 1 Effect of Magnetic Field Dependent Targeting in Rat Lungs, Ex vivo
Ex Vivo Magnetic-Field-Dependent Targeting of NIMs

Tissue region
a

Rat 1

Rat 2

b

b

Intensity (RE)

Ratio

Intensity (RE)

5%

2.11E+09

Rat 3
Ratio

Intensity (RE)b

Ratio

Ratio Average

21%

2.25E+09

34%

20%

Right lung targeted

7.63E+08

Left lung

3.77E+08

2%

5.87E+08

6%

3.44E+08

5%

4%

Trachea

1.47E+10

93%

7.40E+09

73%

4.11E+09

61%

76%

Total

1.58E+10

Differential (R-L lung)

3.87E+08

28%

16% to R lung

1.01E+10
2%

6.70E+09

1.52E+09

15%

1.90E+09

Ex Vivo Absence of Magnetic-Field Dependent Targeting of NIMs

Tissue region

Rat 1

Rat 2

b

b

Intensity (RE)

Ratio

Intensity (RE)

Rat 3
Ratio

Intensity (RE)b

Ratio

Ratio Average

Right lung

8.78E+07

24%

6.63E+07

14%

9.62E+07

22%

20%

Left lung

6.58E+07

18%

9.54E+07

20%

1.35E+08

30%

23%

Trachea

2.14E+08

58%

3.10E+08

66%

2.15E+08

48%

57%

Total

3.67E+08

Differential (R-L lung)

2.20E+07

-9%

-3% to R lung

4.72E+08
6%

-2.91E+07

4.46E+08
-6%

a

NIMs were administered to excised lungs and targeted to the right lung in the presence of a magnetic field

b

Fluorescence expressed as radiant efficiency (RE) in units of [p/s]/[µW/cm2]
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-3.92E+07

Table 2 Pilot Study to Determine Air Volume Used with the Penn-Century Dry Powder Insufflator™
Absence of Magnetic-Field-Dependent Targeting of NIMs in practice mice
Tissue region

Fluorescence c

Mouse

Air volume

NIMs (mg) loaded

NIMs (mg) insufflated

Percent fluorescence

1

500 µl a

2.2

0.6

Right lung
Left lung
Trachea
Sum

1.66E+08
2.63E+07
8.10E+07
2.73E+08

13.4%
21.2%
65.4%

2

200 µl b

2.3

0.3

Right lung
Left lung
Trachea
Sum

2.04E+07
2.26E+07
1.35E+08
1.78E+08

11.5%
12.7%
75.8%

Magnetic-Field-Dependent Targeting of NIMS in practice mice d
Tissue region

Fluorescence c

Mouse

Air volume

NIMs (mg) loaded

NIMs (mg) insufflated

3

500 µl a

2.3

0.6

Right lung
Left lung
Trachea
Sum

1.33E+07
2.63E+07
4.80E+07
8.76E+07

16.5%
18.1%
65.4%

4

200 µl b

2.1

0.2

Right lung
Left lung
Trachea
Sum

9.13E+07
7.79E+07
3.56E+07
2.05E+08

17.4%
14.8%
67.8%

a

Percent fluorescence

500 µl air volume from 3 ml syringe
200 µl air volume using Penn-Century Air Pump
c
Deposition units of average Relative Efficiency (RE) in [p/s/cm2/sr]/[µW/cm2]. The IVIS Imager analyzed fluorescence.
d
When a magnetic field was applied, the magnet was placed on the ventral surface above the left lung after surgically opening the animal,
to expose the chest cavity.
b
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Table 3 Pilot Study to Determine Reproducibility of Powder Administration From the Penn-Century Dry Powder
Insufflator™
	
  
Mass balance of dry powders before and after insufflation
	
  

	
  

	
  

Mass of clean mouse insufflatora:
Mass of dry powder:
Mass of insufflator with dry powder:
Mass of dry powder after loaded into insufflator:
Mass of loaded insufflator after 10 actuations:
Mass of insufflated dry powder:
Mass of insufflator after additional 10 actuations:
Mass of powder/NIMs left in device:
Percent mass powder/NIMs not insufflated:

a

	
  

	
  
	
  
Lactose dry powder (mg)

	
  

	
  

	
  
	
  
	
  
	
  
NIMs (mg) Satarious balance (Felton lab)

	
  

	
  
	
  
	
  
NIMs (mg) Peterson balance (G89)

n=1

n=2

n=3

n=1

n=2

n=3

n=4

n=5

n=1

n=2

n=3

3492.87

3493.05

3493.08

3492.67

3492.76

3492.78

3492.70

3492.70

3492.60

3492.20

3492.40

1.59

3.38

2.30

3.10

2.03

2.41

3.20

3.23

3.70

2.40

2.50

3494.27

3495.96

3495.27

3495.57

3494.66

3494.43

3495.29

3495.26

3496.10

3494.60

3494.60

1.40

2.91

2.19

2.90

1.90

1.65

2.59

2.56

3.50

2.40

2.20

3493.20

3493.80

3493.8

3493.32

3493.40

3492.93

3493.35

3493.65

3493.20

3492.40

3493.30

1.07

2.16

1.47

2.25

1.26

1.50

1.94

1.61

2.90

2.20

1.30

3493.26

3493.80

3493.60

3493.01

3493.33

3492.93

3493.21

3493.37

3493.10

3492.40

3492.50

0.39

0.75

0.52

0.34

0.57

0.15

0.51

0.67

0.50

0.20

0.10

27.9%

25.8%

23.7%

11.7%

30.0%

9.1%

19.7%

26.2%

14.3%

8.3%

4.5%

Dry Powder InsufflatorTM Model DP-4M for mouse
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Table 4 Effect of Magnetic-Field-Dependent Targeting Quantified by Fluorescence – Intensity Values
	
  	
  
	
  	
  
	
  	
  
	
  	
  

IVIS Fluorescence Study - Intensity Values

	
  	
  

Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension

	
  	
  
	
  	
  
	
  	
  

Dry powder NIMS a

Liquid suspension a

	
  
	
   n = 1

8.34E+07

1.70E+08

1.05E+08

3.58E+08

0.50

n=2

6.50E+07

1.66E+08

1.84E+08

4.15E+08

0.40

n=3

7.69E+06

8.94E+07

9.66E+07

1.94E+08

Average

5.20E+07

1.42E+08

1.29E+08

SEM

2.28E+07

2.62E+07

2.80E+07

R lung

L lung b

Trachea

	
  	
  
	
  	
  

R lung

L lung b

Trachea

Total

Dose (mg)

	
  Total*dose

1.79E+08

	
   n = 1

1.91E+07

1.61E+07

9.39E+06

4.46E+07

0.60

2.68E+07

1.66E+08

n=2

7.61E+07

1.33E+08

1.43E+07

2.23E+08

0.60

1.34E+08

0.60

1.16E+08

n=3

2.64E+07

2.81E+07

1.07E+07

6.52E+07

0.60

3.91E+07

3.22E+08

0.50

1.54E+08

Average

4.05E+07

5.90E+07

1.15E+07

1.11E+08

0.60

6.66E+07

6.63E+07

0.06

1.92E+07

SEM

1.79E+07

3.71E+07

1.48E+06

5.64E+07

0.00

3.39E+07

Total

Dose (mg)

Total*dose

	
  	
  
	
  	
  

Absence of Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension
Dry powder NIMS a

Liquid suspension a

R lung

L lung b

Trachea

Total

Dose (mg)

Total*dose

R lung

L lung b

	
   n = 1

9.91E+07

7.78E+07

3.20E+08

4.96E+08

0.40

1.99E+08

Trachea

Total

Dose (mg)

Total*dose

	
   n = 1

1.06E+08

8.24E+07

6.61E+06

1.95E+08

0.60

1.17E+08

n=2

1.46E+07

2.92E+06

7.09E+07

8.84E+07

0.60

n=3

6.02E+07

1.03E+08

1.05E+08

2.68E+08

0.50

5.30E+07

n=2

9.92E+07

1.20E+08

2.88E+07

2.48E+08

0.60

1.49E+08

1.34E+08

n=3

6.68E+07

1.83E+07

8.90E+06

9.40E+07

0.60

5.64E+07

Average

5.79E+07

6.12E+07

1.65E+08

2.84E+08

SEM

2.44E+07

3.00E+07

7.78E+07

1.18E+08

0.50

1.29E+08

Average

9.05E+07

7.35E+07

1.48E+07

1.79E+08

0.60

1.07E+08

0.06

4.21E+07

SEM

1.20E+07

2.96E+07

7.05E+06

4.51E+07

0.00

2.71E+07

	
  	
  

	
  	
  

	
   Deposition	
   units of average
	
   Relative 	
  Efficiency (RE)
	
   in [p/s/cm	
   2/sr]/[µW/cm	
  2]. Fluorescence
	
   was
	
   analyzed	
   by the IVIS 	
  Imager II
a

b
c

	
  

	
  
	
  
	
   the chest cavity.
	
  
When a magnetic field was applied, the magnet was placed on the ventral surface above the left lung, after surgically opening the animal, to expose

NIMs or liquid suspension were administered to the lungs of mice (n = 3) with or without application of the magnetic field.

	
  

108

	
  

	
  
	
  
	
  
	
  

Table 5 Effect of magnetic-field-dependent targeting quantified by fluorescence – ratio values
IVIS Fluorescence Study - Ratio Values

	
  
Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension
Dry powder NIMS a

Liquid suspension a

R lung
(RL)

L lung b
(LL)

Trachea
(TR)

R lung
(RL)

L lung b
(LL)

Trachea
(TR)

n=1

23%

48%

29%

25%

Dye to L lung

n=1

43%

36%

21%

-7%

Dye to L lung

n=2

16%

40%

44%

24%

n=3

4%

46%

50%

42%

Dye to L lung

n=2

34%

59%

6%

25%

Dye to L lung

Dye to L lung

n=3

40%

43%

10%

3%

Dye to L lung

Average

14%

45%

41%

30%

SEM

6%

2%

6%

6%

Dye to L lung

Average

39%

46%

12%

7%

Dye to L lung

SEM

3%

7%

4%

9%

Differential (LL - RL)

Differential (LL = RL)

Absence of Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension
Dry powder NIMS a

Liquid suspension a

RL

LL b

TR

RL

LL b

n=1

20%

16%

64%

-4%

Dye to L lung

TR

Differential (LL – RL)

n=1

54%

42%

3%

-12%

Dye to L lung

n=2

17%

3%

80%

-14%

n=3

22%

38%

39%

16%

Dye to L lung

n=2

40%

48%

12%

8%

Dye to L lung

Dye to L lung

n=3

71%

19%

8%

-52%

Dye to L lung

Average

20%

19%

61%

-1%

SEM

1%

10%

12%

9%

Dye to L lung

Average

55%

36%

8%

-19%

Dye to L lung

SEM

9%

9%

3%

18%

Differential (LL - RL)

a

Deposition units of average Relative Efficiency (RE) in [p/s/cm2/sr]/[µW/cm2]. The IVIS Imager analyzed fluorescence.
When a magnetic field was applied, the magnet was placed on the ventral surface above the left lung after surgically opening the animal, to expose	
   the chest cavity.
c
NIMs or liquid suspension were administered to the lungs of mice (n = 3) with or without application of the magnetic field.
b
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Table 6 Effect of magnetic-field-dependent targeting quantified by iron – intensity values
	
  	
  
	
  	
  
	
  	
  
	
  	
  

Inductively Coupled Plasma - Optical Emission Spectroscopy - Intensity Values of Iron

Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension
Dry powder NIMS a, b

	
  
	
  

Liquid suspension a, b

R lung

L lung b

Trachea

Total Fe

n=1

7.28E+04

3.34E+05

4.14E+05

8.22E+05

n=2

2.42E+04

2.34E+05

6.73E+05

n=3

-2.13E+03

1.38E+05

Average

3.16E+04

SEM

2.19E+04

	
  	
  
	
  	
  

R lung

L lung b

Trachea

Total

n=1

5.51E+04

2.12E+04

3.72E+04

1.13E+05

9.31E+05

n=2

1.56E+05

1.64E+05

1.01E+05

4.21E+05

2.32E+05

3.68E+05

n=3

7.09E+04

5.72E+04

4.48E+04

1.73E+05

2.36E+05

4.40E+05

7.07E+05

Average

9.41E+04

8.08E+04

6.08E+04

2.36E+05

5.66E+04

1.28E+05

1.72E+05

SEM

3.15E+04

4.28E+04

2.00E+04

9.41E+04

	
  

Absence of Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension
Dry powder NIMS a

	
  

Liquid suspension a

R lung

L lung

Trachea

Total

n=1

2.77E+04

3.37E+04

3.12E+05

3.73E+05

n=2

4.74E+04

2.22E+04

6.91E+05

7.61E+05

	
  

R lung

L lung

Trachea

Total

n=1

3.01E+05

2.30E+05

6.93E+04

6.00E+05

n=2

1.36E+04

2.29E+04

3.03E+04

6.68E+04

n=3

9.76E+04

8.64E+04

4.71E+05

6.55E+05

n=3

1.00E+05

4.32E+04

1.24E+05

2.67E+05

Average

5.75E+04

4.74E+04

4.92E+05

5.96E+05

Average

1.38E+05

9.86E+04

7.44E+04

3.11E+05

SEM

2.08E+04

1.98E+04

1.10E+05

1.16E+05

SEM

8.50E+04

6.58E+04

2.71E+04

1.55E+05
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Table 6 (continuation) Effect of magnetic-field-dependent targeting quantified by iron – intensity
values
	
  	
  

Absence of Magnetic-Field-Dependent Targeting
Control: Endogenous Iron (n = 3)

	
  

R lung
Intensity

R lung
conc.
(mg/kg)

L lung
Intensity b

L lung
conc.
(mg/kg)

Trachea
Intensity

Trachea conc.
(mg/kg)

n=1

6.35E+04

100.5

4.22E+04

137.9

2.33E+04

70.8

n=2

1.30E+05

148.7

5.24E+04

140.4

1.99E+04

104.2

n=3

6.72E+04

115.1

5.91E+04

146.5

1.68E+04

74.0

Average

8.70E+04

121.4

5.12E+04

141.60

2.00E+04

83.0

SEM

2.17E+04

14.27

4.91E+03

2.55

1.88E+03

10.6

	
  	
  
a

Values normalized for endogenous iron
When a magnetic field was applied, the magnet was placed on the ventral surface above the left lung, after surgically opening the animal, to
expose the chest cavity.
b
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Table 7 Effect of magnetic-field-dependent targeting quantified by iron – ratio values
Inductively Coupled Plasma - Optical Emission Spectroscopy – Iron Ratio Values
Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension
Dry powder NIMS a

Liquid suspension a

R lung

L lung

Trachea

Outcome (L lung - R lung)

n=1

9%

42%

49%

33%

Fe to L lung

n=2

3%

25%

72%

22%

Fe to L lung

R lung

L lung

Trachea

Outcome (L lung - R lung)

n=1

49%

19%

33%

-30%

Fe to L lung

n=2

37%

39%

24%

2%

Fe to L lung

n=3

0%

38%

63%

38%

Fe to L lung

n=3

41%

33%

26%

-8%

Fe to L lung

Average

4%

35%

61%

31%

Fe to L lung

Average

42%

30%

28%

-12%

Fe to L lung

SEM

3%

5%

7%

5%

SEM

4%

6%

3%

9%

Absence of Magnetic-Field-Dependent Targeting: NIMs vs. Liquid Suspension
Dry powder NIMS a

Liquid suspension a

R lung

L lung

Trachea

Outcome (L lung - R lung)

n=1

7%

9%

82%

2%

Fe to L lung

n=2

6%

3%

87%

-3%

Fe to L lung

R lung

L lung

Trachea

Outcome (L lung - R lung)

n=1

50%

38%

21%

-12%

Fe to L lung

n=2

31%

34%

32%

3%

Fe to L lung

n=3

15%

13%

70%

-2%

Fe to L lung

n=3

38%

16%

31%

-22%

Fe to L lung

Average

9%

8%

80%

-1%

Fe to L lung

Average

40%

29%

28%

-10%

Fe to L lung

SEM

3%

3%

5%

2%

SEM

6%

7%

4%

7%

a

Deposition units of average Relative Efficiency (RE) in [p/s/cm2/sr]/[µW/cm2]. The IVIS Imager analyzed fluorescence.

b

When a magnetic field was applied, the magnet was placed on the ventral surface above the left lung after surgically opening the animal, to expose	
   the chest cavity.

c

NIMs or liquid suspension were administered to the lungs of mice (n = 3) with or without application of the magnetic field.

	
  

112

REFERENCES
Agnew, J., Pavia, D. and Clarke, S. (1981). Airways Penetration of Inhaled Radioaerosol:
an Index to Small Airways Function. European Journal of Respiratory Diseases.
62 (4): 239–55.
Ally, J. and Amirfazli, A. (2012). Targeting Magnetic Particles for Drug Delivery.
Handbook of Nanophysics: Nanomedicine and nonorobotics.
Ally, J., Martin, B., Khamesee, M., and Roa, W. (2005). Magnetic targeting of aerosol
particles for cancer therapy. Journal of Magnetism. 293, 442-449.
Ally, J., Kappl, M., and Butt J.H. (2012). Adhesion of Particles with Sharp Edges to AirLiquid Interfaces. Langmuir: the ACS Journal of Surfaces and Colloids. 28 (30):
11042–47. doi:10.1021/la300539m.
American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer
Society; (2014).
Andujar, P., Wang, J., Descatha, A., Galateau-Sallé, F., Abd-Alsamad, I., Billon-Galland,
M., Blons, H. (2010). p16INK4A Inactivation Mechanisms in Non-Small-Cell
Lung Cancer Patients Occupationally Exposed to Asbestos Lung Cancer. 67 (1):
23–30. doi:10.1016/j.lungcan.2009.03.018.
Arruebo, M., Fernández-Pacheco, R. & Ibarra, M. (2007). Magnetic nanoparticles for
drug delivery. Nano Today. 3, 22-32
Ayers, G., McKinley, E., Zhao, P., Fritz, J., Metry, R., Deal, B., Adlerz, K., Coffey, R.,
Manning, H. (2010). Volume of Preclinical Xenograft Tumors Is More
Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements.
J Ultrasound Med. 29, 891–901.
Azarmi, S., Löbenberg, R., Roa, W., Tai, S., and Finlay, W. (2008). Formulation and in
Vivo Evaluation of Effervescent Inhalable Carrier Particles for Pulmonary
Delivery of Nanoparticles. Drug Development and Industrial Pharmacy. 34 (9):
943–47. doi:10.1080/03639040802149079.
Azzoli, C., Giaccone, G., and Temin, S. (2010). American Society of Clinical Oncology
Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–SmallCell Lung Cancer. Journal of Oncology Practice. 6 (1), 39-43.
Babincova, M, and Babinec, P. (2009). Magnetic Drug Delivery and Targeting:
Principles and Applications. Biomed Papers. 153 (4), 243 – 250.

113

Bailey, M., and Berkland, C. (2009). Nanoparticle formulations in pulmonary drug
delivery. Med Res Rev. 29 (1): 196-212.
Balachandran, W., Machowski, W., and Gaura, E. and Hudson, C. (1997). Control of
Drug Aerosol in Human Airways Using Electrostatic Forces. Journal of
Electrostatics. 40 (1997): 579-584.
Balashazy, I, Martonen, TB, Hoffman, W. (1990). Fiber deposition in airway
bifurcations. Journal of Aerosol Medicine. (3): 243-60.
Beleca, R., Abbod, Balachandran, W., and Miller, P., (2010). Investigation of
Electrostatic Properties of Pharmaceutical Powders Using Phase Doppler
Anemometry. Industry Applications, IEEE Transactions. 46 (3): 1181–87.
doi:10.1109/TIA.2010.2045332.
Bengel, F., Anton, M., Richter, T., Simoes, M., Haubner, R., Henke, J., Erhardt, W.,
Reder, S., Lehner, T., Brandau, W. (2003). Noninvasive Imaging of Transgene
Expression by Use of Positron Emission Tomography in a Pig Model of
Myocardial Gene Transfer. Circulation. 108, 2127–2133.
Borgström, L., Olsson, B., and Thorsson, L. (2006). Degree of Throat Deposition Can
Explain the Variability in Lung Deposition of Inhaled Drugs. Journal of Aerosol
Medicine. Journal of Aerosols in Medicine. 19 (4): 473–83.
doi:10.1089/jam.2006.19.473.
Braber, S., Verheijden, K. (2010). A Comparison of Fixation Methods on Lung
Morphology in a Murine Model of Emphysema. American Journal of PhysiologyLung Cellular and Molecular Physiology. 299 (6), L843-L851.
Braun, M., Oschmann, R., and Schmidt, P. (1996). Influence of Excipients and Storage
Humidity on the Deposition of Disodium Cromoglycate (DSCG) in the Twin
Impinger. International Journal of Pharmaceutics. 135(1), 53-62.
Brittain, H. G., Bogdanowich, S. J., Bugay, D. E., DeVincentis, J., Lewen, G., &
Newman, A. W. (1991). Physical Characterization of Pharmaceutical Solids.
Pharmaceutical research. 8 (8), 963-973.
Cal, K., and Sollohub, K. (2010). Spray Drying Technique. I: Hardware and Process
Parameters. Journal of Pharmaceutical Sciences. 99 (2), 575-586.
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., &
Varella-Garcia, M. (2005). Epidermal growth factor receptor gene and protein and
gefitinib sensitivity in non–small-cell lung cancer. Journal of the National Cancer
Institute. 97(9), 643-655.

114

Chan, H., and Chew, N. (2003). Novel Alternative Methods for the Delivery of Drugs for
the Treatment of Asthma. Advanced Drug Delivery Reviews. 55 (7): 793–805.
Chen, Y., Kamat, V., Dougherty, E. R., Bittner, M. L., Meltzer, P. S., & Trent,
J.M. (2002). Ratio statistics of gene expression levels and applications to
microarray data analysis. Bioinformatics. 18, 1207–1215.
Chung, J.-K. (2002). Sodium Iodide Symporter: Its Role in Nuclear Medicine. Journal of
Nuclear Medicine. 43, 1188–1200.
Crowder, T., Rosati, J., Schroeter, J., and Hickey, A. (2002). Fundamental effects of
particle morphology on lung delivery: predictions of Stokes' law and the
particular relevance to dry powder inhaler formulation and
development. Pharmaceutical research. 19 (3), 239-245.
Currie, G. P., Watt, S. J., & Maskell, N. A. (2009). An overview of how asbestos
exposure affects the lung. BMJ, 339.
Curt, G. A. (1994). The Use of Animal Models in Cancer Drug Discovery and
Development. Stem Cells. 12, 23–29.
D'Arcangelo, M, and F Cappuzzo. (2012). K-Ras Mutations in Non-Small-Cell Lung
Cancer: Prognostic and Predictive Value. ISRN Molecular Biology.
Dames, P., Gleich, B., Flemmer, A., Hajek, K., Seidl, N., Wiekhorst, F., & Rudolph, C.
(2007). Targeted delivery of magnetic aerosol droplets to the lung. Nature
Nanotechnology, 2(8), 495-499. doi:10.1038/nnano.2007.217.
Darwiche, K., Zarogoulidis, P., Karamanos, N. K., Domvri, K., Chatzaki, E.,
Constantinidis, T. C., & Zarogoulidis, K. (2013). Efficacy versus safety concerns
for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for
micro-oncology. Future Oncology. 9(4), 505-525. doi:10.2217/fon.12.205.
Davidson, I. G., Langner, E. J., Plowman, S. V., & Blair, J. A. (2003). Release
mechanism of insulin encapsulated in trehalose ester derivative microparticles
delivered via inhalation. International journal of pharmaceutics. 254 (2), 211222.
Deroose, C., De, A., Loening, A., Chow, P. (2007). Multimodality Imaging of Tumor
Xenografts and Metastases in Mice with Combined Small-Animal PET, SmallAnimal CT, and Bioluminescence Imaging. Journal of Nuclear Medicine. 48 (2),
295-303.
Dobrucki, L., Sinusas, A. (2009). PET and SPECT in Cardiovascular Molecular Imaging.
Nature Reviews Cardiology. 7(1), 38-47.

115

Dohán, O., la Vieja, De, A., Paroder, V., Riedel, C., Artani, M., Reed, M., Ginter, C. S.,
Carrasco, N. (2003). The Sodium/Iodide Symporter (NIS): Characterization,
Regulation, and Medical Significance. Endocr. Rev. 24, 48–77.
Doria-Rose, N., and Haigwood. N. (2003). DNA Vaccine Strategies: Candidates for
Immune Modulation and Immunization Regimens. Methods. 31(3): 207–16.
Dunber, C., Hickey, A., and Holzner, P. (1998). Dispersion and Characterization of
Pharmaceutical Dry Powder Aerosols. KONA Powder and Particle Journal, 16
(0), 7-45
Duret, C., Wauthoz, N., Merlos, R., Goole, J., Maris, C., Roland, I., Sebti, T., Vanderbist,
F.,and Amighi. K. (2012). In Vitro and in Vivo Evaluation of a Dry Powder
Endotracheal Insufflator Device for Use in Dose-Dependent Preclinical Studies in
Mice. European journal of pharmaceutics and biopharmaceutics, 81(3), 627-634.
Field, W., and Withers, B. (2012). Occupational and Environmental Causes of Lung
Cancer. Clinics in Chest Medicine. 33(4): 681–703.
doi:10.1016/j.ccm.2012.07.001.
Foged, C., Brodin, B. Frokjaer, S. and Sundblad, A. (2005). Particle Size and Surface
Charge Affect Particle Uptake by Human Dendritic Cells in an in Vitro Model.
International Journal of Pharmaceutics. 298(2): 315–22.
doi:10.1016/j.ijpharm.2005.03.035.
Furlow, B. (2014). Uranium Mines: Lung Disease and Mistrust Among Native
Americans. The Lancet Respiratory Medicine. 2(3), 178-179.
Gagnadoux, F., Hureaux, J. Vecellio, L., Urban, T., Le Pape, A. Valo, I., Montharu, J.
(2008). Aerosolized Chemotherapy. Journal of Aerosol Medicine and Pulmonary
Drug Delivery. 21 (1): 61–70. doi:10.1089/jamp.2007.0656.
Gehr, P., Bachofen, M. & Weibel, E. R. (1978). The normal human lung: ultrastructure
and morphometric estimation of diffusion capacity. Respir Physiol. 32, 121–140.
Gerrity, T., Lee, P., Hass, F., Marinelli, A., Werner, P., and Lourenço, R. (1979).
Calculated Deposition of Inhaled Particles in the Airway Generations of Normal
Subjects. Journal of Applied Physiology: Respiratory, Environmental and
Exercise Physiology. 47 (4): 867–73.
Gilchrist, R., Medal, R., Shorey, W., Hanselman, R., Parrott, J., and Taylor. C. (1957).
Selective inductive heating of lymph nodes. Annals of surgery. 146 (4) 596.

116

Gleich, B., Hellwig, N., Bridell, H. & Jurgons, R. (2007). IEEE Xplore - Design and
Evaluation of Magnetic Fields for Nanoparticle Drug Targeting in Cancer.
Nanotechnology. 6, 164-170.
Goffin, J., Lacchetti, C., Ellis, P., Ung, Y., Evans, W. (2010). First-Line Systemic
Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer: a
Systematic Review. Journal of Thoracic Oncology. Official Publication of the
International Association for the Study of Lung Cancer. 5 (2): 260–74.
doi:10.1097/JTO.0b013e3181c6f035.
Guillon, A, Montharu, J, Vecellio, L, Schubnel, V, Roseau, G, Guillemain, J, Diot, P, de
Monte, M. (2012). Pulmonary delivery of dry powders to rats: Tolerability limits
of an intra-tracheal administration model, International Journal of Pharmaceutics.
434(1-2): 481-87.
Guo, R., Zhang, Y., Liang, S., Xu, H., Zhang, M., Li, B. (2010). Sodium Butyrate
Enhances the Expression of Baculovirus-Mediated Sodium/Iodide Symporter
Gene in A549 Lung Adenocarcinoma Cells. Nucl Med Commun., 31, 916–921.
Gupta, A., and Gupta, M. (2005). Synthesis and Surface Engineering of Iron Oxide
Nanoparticles for Biomedical Applications. Biomaterials. 26 (18): 3995–4021.
doi:10.1016/j.biomaterials.2004.10.012.
Hickey, A. J. (2014). Controlled delivery of inhaled therapeutic agents. J Control
Release.
Hasenpusch, G, Geiger, J, Wagner, K, Mykhaylyk, O, Wiekhorst, F, Trahms, L,
Heidsieck, A, Gleich, B, Rudolph, C. (2012). Magnetized aerosols comprising
superparamagnetic iron oxide nanoparticles improve targeted drug and gene
delivery to the lung. Pharmaceutical Research. 29(5): 1308-18.
doi:10.1007/s11095-012-0682-z.
Hershey, A. E., Kurzman, I., Forrest, L., Bohling, C., Stonerook, M., Placke, M., Imondi,
A., Vail, M. (1999). Inhalation chemotherapy for macroscopic primary or
metastatic lung tumors: proof of principle using dogs with spontaneously
occurring tumors as a model. Clinical Cancer Research. 5, 2653-9.
Hitzman, C J, and W F Elmquist. (2006). Development of a Respirable, Sustained
Release Microcarrier for 5‐Fluorouracil I: in Vitro Assessment of Liposomes,
Microspheres, and Lipid Coated Nanoparticles. Journal of Journal of
Pharmaceutical Sciences. 95(5), 1114-1126.
Hoppentocht, M, C Hoste, P Hagedoorn, H W Frijlink, and A H de Boer. (2014). In Vitro
Evaluation of the DP-4M PennCentury™ Insufflator. European Journal of
Pharmaceutics and Biopharmaceutics. Official Journal of Arbeitsgemeinschaft

117

Für Pharmazeutische Verfahrenstechnik E.V, June.
doi:10.1016/j.ejpb.2014.06.014.
Hoppentocht, M, P Hagedoorn, H W Frijlink, and A H de Boer. (2014). Technological
and Practical Challenges of Dry Powder Inhalers and Formulations. Advanced
Drug Delivery Reviews. April. doi:10.1016/j.addr.2014.04.004.
Häfeli, U O. (2004). Magnetically Modulated Therapeutic Systems. International Journal
of Pharmaceutics.
Ichite, N.; Chougule, M. B.; Jackson, T.; Fulzele, S. V.; Safe, S.; Singh, M. (2009).
Enhancement of Docetaxel Anticancer Activity by a Novel Diindolylmethane
Compound in Human Non-Small Cell Lung Cancer. Clinical Cancer Research.
15, 543–552.
Inubushi, M., Wu, J. C., Gambhir, S. S., Sundaresan, G., Satyamurthy, N., Namavari, M.,
Yee, S., Barrio, J. R., Stout, D., Chatziioannou, A. F., et al. (2003). PositronEmission Tomography Reporter Gene Expression Imaging in Rat Myocardium.
Circulation. 107, 326–332.
Jemal, A., Bray, F., Center, M., Ferlay, J., Ward, E., Forman, D. (2011). Global cancer
statistics. CA Cancer J Clin. 61, 69–90.
Jänne, P A, and J A Engelman. (2005). Epidermal Growth Factor Receptor Mutations in
Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology.
Journal of Clinical. Journal of Clinical Oncology. 23(14), 3227-3234.
Kakar, S, D Batra, and R Singh. (2013). A Review on Target Drug Delivery: Magnetic
Microspheres. Journal of Acute Disease. 189, 195.
Kang, Y., Omura, M., Suzuki, A., Theeraladanon, C., Oka, T., Nakagami, Y., Suzuki, A.,
Nagashima, Y., Inoue, T. (2010). Proliferation of Human Lung Cancer in an
Orthotopic Transplantation Mouse Model. Exp Ther Med. 1, 471–475.
Koshkina, N., Yang, V., and Kleinerman, E. (2013). Inhibition of Cdc42-Interacting
Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression. Current Cancer Drug
Targets 13 (1): 48–56.
Krapcho, M., Neyman, N., Aminou, R. & Howlader, N. (209). SEER Cancer Statistics
Review. 1975-2006, National Cancer Institute. Bethesda, MD.
Krewski, D, J H Lubin, J M Zielinski, and M Alavanja. (2005). Residential Radon and
Risk of Lung Cancer: a Combined Analysis of 7 North American Case-Control
Studies.

118

Kris, M G, R B Natale, R S Herbst, and T J Lynch Jr. (2003). Efficacy of Gefitinib, an
Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in
Symptomatic Patients with Non–Small Cell Lung Cancer: a Randomized Trial.
Jama. 290(16), 2149-2158.
Kunda, Nitesh K, Satyanarayana Somavarapu, Stephen B Gordon, Gillian A Hutcheon,
and Imran Y Saleem. (2012). Nanocarriers Targeting Dendritic Cells for
Pulmonary Vaccine Delivery. Pharmaceutical Research 30 (2). Springer US: 325–
41. doi:10.1007/s11095-012-0891-5.
Kyriazis, A. A., Kyriazis, A. P. (1980). Preferential Sites of Growth of Human Tumors in
Nude Mice Following Subcutaneous Transplantation. Cancer research, 40(12),
4509-4511.
Labiris, N R, and M B Dolovich. (2003). Pulmonary Drug Delivery. Part I: Physiological
Factors Affecting Therapeutic Effectiveness of Aerosolized Medications. British
Journal of Clinical pharmacology, 56(6), 588-599
Lemarie, E., Vecellio, L., Hureaux, J., Prunier, C., Valat, C., Grimbert, D., BoidronCelle, M. (2011). Aerosolized Gemcitabine in Patients with Carcinoma of the
Lung: Feasibility and Safety Study. Journal of Aerosol Medicine and Pulmonary
Drug Delivery. 24 (6): 261–70. doi:10.1089/jamp.2010.0872.
Li, A, and G Ahmadi. (1995). Computer Simulation of Particle Deposition in the Upper
Tracheobronchial Tree. Aerosol Science and Technology. 23(2), 201-223.
Li, B., Torossian, A., Li, W., Schleicher, S., Niu, K., Giacalone, N. J., Kim, S. J., Chen,
H., Gonzalez, A., Moretti, L. (2011). A Novel Bioluminescence Orthotopic
Mouse Model for Advanced Lung Cancer. Radiat. Res. 176, 486–493.
Lippmann, M, D B Yeates, and R E Albert. (1980). Deposition, Retention, and Clearance
of Inhaled Particles. British Journal of Industrial Medicine. 37 (4): 337–62.
Locher, C., Debieuvre, D., Coëtmeur, D., Goupil, F., Molinier, O., Collon, T., & Grivaux,
M. (2013). Major changes in lung cancer over the last ten years in France: the
KBP-CPHG studies. Lung Cancer, 81(1), 32-38.
doi:10.1016/j.lungcan.2013.03.001.
Louey, M. D., Van Oort, M. & Hickey, A. J. (2004). Aerosol dispersion of respirable
particles in narrow size distributions using drug-alone and lactose-blend
formulations. Pharm Res. 21, 1207–1213.
Luo, H Y, Y Liu, and X L Yang. (2007). Particle Deposition in Obstructed Airways.
Journal of Biomechanics. 40 (14), 3096-3104.

119

March, T. H.; Marron-Terada, P. G.; Belinsky, S. A. (2001). Refinement of an Orthotopic
Lung Cancer Model in the Nude Rat. Vet. Pathol. 38, 483–490.
Mazzone, Peter, and Tarek Mekhail. (2012). Current and Emerging Medical Treatments
for Non-Small Cell Lung Cancer: a Primer for Pulmonologists. Respiratory
Medicine. 106 (4): 473–92. doi:10.1016/j.rmed.2011.10.016.
McBride, A. A. Price, D., Lamoureux, L. & Muttil, P. (2013). Preparation and
characterization of novel magnetic nano-in-microparticles for site-specific
pulmonary drug delivery. Mol. Pharm. 10, 3574–3581
McBride, A.A, Price, D., Lamoureux, L. & Muttil, P. (2012). Novel Preparation and
Characterization of Magnetic Nano-in-Microparticle Dry Powders for Directed
Drug Delivery: An Application to Lung Cancer. Respiratory Drug Delivery
Conference.
McBride, A.A. & Muttil, P. (2013). A Pilot study Targeting Nano-in-Microparticles
(NIMs) in Rat Lungs Ex Vivo.” Respiratory Drug Delivery 2013, Davis
Healthcare International Publishing. River Grove, IL. R.N. Dalby and J. Cone,
editors. RDD Europe 2013 Vol 2, pp 423 – 428. ISBN: 1-933722-70-3
McConville, J.T. Use of A Novel Modified TSI for the Evaluation of Controlled-release
Aerosol Formulations. Drug Dev. Ind. Pharm. Vol 26, No 11, pp. 1191 – 1198.
McLemore, T. L., Liu, M. C., Blacker, P. C., Gregg, M., Alley, M. C., Abbott, B. J., &
Boyd, M. R. (1987). Novel intrapulmonary model for orthotopic propagation of
human lung cancers in athymic nude mice. Cancer research,47(19), 5132-5140.
Cancer research. 47(19), 5132-5140.
Meyers, P H, F Cronic, and C Nice Jr. (1963). Experimental Approach in the Use and
Magnetic Control of Metallic Iron Particles in the Lymphatic and Vascular
System of Dogs as a Contrast and Isotropic. Am. J. Roentgenol., Radium Therapy
Nucl. Med., 90.
Mikan, A., Martinez Lanao, J., Gonzalez Lopez, F. & Dominguez-Gil Hurle, A. (1990).
High performance liquid chromatography determination of doxorubicin and
daunorubicin in plasma using UV detection and column switching. Biomed.
Chromatogr. 4, 154–156.
Minchinton, Andrew I, and Ian F Tannock. (2006). Drug Penetration in Solid Tumours.
Nat Rev Cancer 6 (8): 583–92. doi:10.1038/nrc1893.
Miyagawa, M., Anton, M., Wagner, B., Haubner, R., Souvatzoglou, M., Gansbacher, B.,
& Bengel, F. M. (2005). Non-Invasive Imaging of Cardiac Transgene Expression
with PET: Comparison of the Human Sodium/Iodide Symporter Gene and HSV1Tk as the Reporter Gene. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 1108–1114.

120

Mogi, A, and H Kuwano. (2011). TP53 Mutations in Nonsmall Cell Lung Cancer.
BioMed Research International.
Morello, M. et al. (2009). Dry-powder pulmonary insufflation in the mouse for
application to vaccine or drug studies. Tuberculosis. (Edinb) 89, 371–377
Mortensen, N. P., P. Durham and A. J. Hickey (2014). The role of particle physicochemical properties in pulmonary drug delivery for tuberculosis therapy. J
Microencapsul: 1-11.
Muttil, P., Pulliam, B., Garcia-Contreras, L., Fallon, J., Wang, C., Hickey, A., and
Edwards, D. (2010). Pulmonary Immunization of Guinea Pigs with Diphtheria
CRM-197 Antigen as Nanoparticle Aggregate Dry Powders Enhance Local and
Systemic Immune Responses. The AAPS Journal. 12 (4): 699–707.
doi:10.1208/s12248-010-9229-6.
Nakamoto, Y., Saga, T., Misaki, T., Kobayashi, H., Sato, N., Ishimori, T., Kosugi, S.,
Sakahara, H., Konishi, J. (2000). Establishment and Characterization of a Breast
Cancer Cell Line Expressing Na+/I- Symporters for Radioiodide Concentrator
Gene Therapy. J. Nucl. Med. 41, 1898–1904.
O'Hagan, D., Rahman, D., McGee, J., Jeffery, H., Davies, M., Williams, P., Davis, S.,
and Challacombe, S. (1991). Biodegradable Microparticles as Controlled Release
Antigen Delivery Systems. Immunology. 73 (2): 239–42.
O'Hagan, Derek T, and Rino Rappuoli. (2004). Novel Approaches to Vaccine Delivery.
Pharmaceutical Research 21 (9). Kluwer Academic Publishers-Plenum
Publishers: 21(9), 1519-1530.doi:10.1023/B:PHAM.0000041443.17935.33.
Olive, K. P.; Tuveson, D. A. (2006). The Use of Targeted Mouse Models for Preclinical
Testing of Novel Cancer Therapeutics. Clin. Cancer Res. 12, 5277–5287.
Otsu, N. A Threshold Selection Method From Gray-Level Histograms. Systems, Man and
Cybernetics, IEEE Transactions. 1979, 9, 62–66.
Otterson, Gregory A, Miguel A Villalona-Calero, Sunil Sharma, Mark G Kris, Anthony
Imondi, Mirjam Gerber, Dorothy A White, et al. (2007). Phase I Study of Inhaled
Doxorubicin for Patients with Metastatic Tumors to the Lungs. Clinical Cancer
Research. Official Journal of the American Association for Cancer Research 13
(4): 1246–52. doi:10.1158/1078-0432.CCR-06-1096.
Otterson, G. A., Villalona-Calero, M. A., Hicks, W., Pan, X., Ellerton, J. A., Gettinger, S.
N., & Murren, J. R. (2010). Phase I/II Study of inhaled doxorubicin combined
with platinum-based therapy for advanced non–small cell lung cancer. Clinical
Cancer Research, 16(8), 2466-2473. doi:10.1158/1078-0432.CCR-09-3015.

121

Patton, John S, and Peter R Byron. (2007). Inhaling Medicines: Delivering Drugs to the
Body Through the Lungs. Nature Reviews. Drug Discovery 6 (1): 67–74.
doi:10.1038/nrd2153.
Phalen, R. F.; Oldham, M. J.; Wolff, R. K. (2008). The Relevance of Animal Models for
Aerosol Studies. J Aerosol Med Pulm Drug Deliv. 21, 113–124.
Podczeck, F. (1997). The Relationship Between Particulate Properties of Carrier
Materials and the Adhesion Force of Drug Particles in Interactive Powder
Mixtures. Journal of Adhesion Science and Technology. 11(8), 1089-1104.
Polyakt, B. and G. Friedman. (2009). Magnetic targeting for site-specific drug delivery:
applications and clinical potential.
Price, D., McBride, A.A. & Muttil, P. (2011). Pulmonary immunization for TB with live
cell-based vaccines: the importance of the delivery route. Ther Deliv. 2, 1519–
1522
Raaschou-Nielsen, Ole, Zorana J Andersen, Martin Hvidberg, Steen S Jensen, Matthias
Ketzel, Mette Sørensen, Johnni Hansen, Steffen Loft, Kim Overvad, and Anne
Tjønneland. (2011). Air Pollution From Traffic and Cancer Incidence: a Danish
Cohort Study. Environmental Health: a Global Access Science Source 10: 67.
doi:10.1186/1476-069X-10-67.
Raaschou-Nielsen, O., Andersen, Z. J., Beelen, R., Samoli, E., Stafoggia, M., Weinmayr,
G., & Cesaroni, G. 2013. Air Pollution and Lung Cancer Incidence in 17
European Cohorts: Prospective Analyses From the European Study of Cohorts for
Air Pollution Effects (ESCAPE). The Lancet Oncology, 14 (9), 813-822.
Rao, R. D., Markovic, S. N. & Anderson, P. M. (2003). Aerosol therapy for malignancy
involving the lungs. Curr Cancer Drug Targets. 3, 239–250.
Redman, GES, Martin, A, Waszak, P, Thompson, R, Cheung, P, Thebaud, B, Finlay, W.
(2011). Pilot study of inhaled aerosols targeted via magnetic alignment of high
aspect ratio particles in rabbits, Journal of Nanomaterials. 1-7,
doi:10.1155/2011/130721.
Riesco-Eizaguirre, G.; Santisteban, P. (2006). A Perspective View of Sodium Iodide
Symporter Research and Its Clinical Implications. Eur. J. Endocrinol. 155, 495–
512.
Roa, Wilson H, Shirzad Azarmi, M H D Kamal Al-Hallak, Warren H Finlay, Anthony M
Magliocco, and Raimar Löbenberg. (2011). Inhalable Nanoparticles, a NonInvasive Approach to Treat Lung Cancer in a Mouse Model. Journal of

122

Controlled Release. Official Journal of the Controlled Release Society 150 (1):
49–55. doi:10.1016/j.jconrel.2010.10.035.
Rodriguez, C O, Jr, and T A Crabbs. (2010). Aerosol Gemcitabine: Preclinical Safety and
in Vivo Antitumor Activity in Osteosarcoma-Bearing Dogs. Journal of Aerosol
medicine and pulmonary drug delivery, 23(4), 197-206.
Rudge, S R, T L Kurtz, C R Vessely, L G Catterall, and D L Williamson. (2000).
Preparation, Characterization, and Performance of Magnetic Iron-Carbon
Composite Microparticles for Chemotherapy. Biomaterials. 21 (14): 1411–20.
Rudolph, C., Gleich, B. & Flemmer, A. W. Magnetic aerosol targeting of nanoparticles to
cancer: nanomagnetosols. Methods Mol. Biol. (2010). 624, 267–280.
Sadhukha, T., Wiedmann, T., and Panyam, J. (2013). Inhalable Magnetic Nanoparticles
for Targeted Hyperthermia in Lung Cancer Therapy. Biomaterials. 34 (21): 5163–
71. doi:10.1016/j.biomaterials.2013.03.061.
Saha, D.; Watkins, L.; Yin, Y.; Thorpe, P.; Story, M. D.; Song, K.; Raghavan, P.;
Timmerman, R.; Chen, B.; Minna, J. D.; et al. (2010) An Orthotopic Lung Tumor
Model for Image-Guided Microirradiation in Rats. Radiat. Res. 174, 62–71.
Sakagami, M. (2006). In vivo, in vitro and ex vivo models to assess pulmonary
absorption and disposition of inhaled therapeutics for systemic delivery.
Advanced drug delivery reviews, 58(9), 1030-1060.
Samet, J. M., Avila-Tang, E., Boffetta, P., Hannan, L. M., Olivo-Marston, S., Thun, M.
J., & Rudin, C. M. (2009). Lung cancer in never smokers: clinical epidemiology
and environmental risk factors. Clinical Cancer Research, 15(18), 5626-5645.
doi:10.1158/1078-0432.CCR-09-0376.
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., ... &
Johnson, D. H. (2002). Comparison of four chemotherapy regimens for advanced
non–small-cell lung cancer. New England Journal of Medicine. 346(2), 9298.doi:10.1056/NEJMoa011954.
Schüle, S, T Schulz-Fademrecht, P Garidel, K Bechtold-Peters, and W Frieb. (2008).
Stabilization of IgG1 in Spray-Dried Powders for Inhalation. European Journal of
Pharmaceutics and Biopharmaceutics. 69 (3): 793–807.
doi:10.1016/j.ejpb.2008.02.010.
Sham, J. O.-H., Y. Zhang, W. H. Finlay, W. H. Roa and R. Löbenberg (2004).
Formulation and characterization of spray-dried powders containing nanoparticles
for aerosol delivery to the lung. International Journal of Pharmaceutics 269(2):
457-467.

123

Sharma, S, D White, A R Imondi, M E Placke, D M Vail, and M G Kris. (2001).
Development of Inhalational Agents for Oncologic Use. Journal of Clinical
Oncology: Official Journal of the American Society of Clinical Oncology. 19 (6):
1839–47.
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert,
S., & Seymour, L. (2005). Erlotinib in previously treated non–small-cell lung
cancer. New England Journal of Medicine, 353(2), 123-132.
Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014). Cancer Statistics, 2014. CA: a Cancer
Journal for Clinicians 64 (1): 9–29. doi:10.3322/caac.21208.
Son, Y.-J., Mitchell, J., McConville. In Vitro Performance Testing for Pulmonary Drug
Delivery. In Controlled pulmonary drug delivery. Smyth, H. & Hickey A; 1st ed.;
Springer Publishing Co.: New York, 2011; pp. 383-415.
Son, Y.-J. and McConville, J. T. , (2011). A new respirable form of rifampicin. Eur J
Pharm Biopharm 78; pp. 366–376.
Son, Y.-J. and McConville, J. T. Preparation of sustained release rifampicin
microparticles for inhalation. (2012) J. Pharm. Pharmacol. 64; pp. 1291–1302.
Sood, A. and Panchagnula, R., (1999). Role of dissolution studies in controlled release
drug delivery systems. S.T.P. Pharma Sciences 9; pp. 157 – 168.
Sou, T., Meeusen, E., de Veer, M., Morton, D., Kaminskas, L., and Michelle P McIntosh.
(2011). New Developments in Dry Powder Pulmonary Vaccine Delivery. Trends
in Biotechnology. 29(4): 191–98. doi:10.1016/j.tibtech.2010.12.009.
Sridhar, S., Seymour, L. and Shepherd, F. (2003). Inhibitors of Epidermal-Growth-Factor
Receptors: a Review of Clinical Research with a Focus on Non-Small-Cell Lung
Cancer. The Lancet Oncology. 4(7), 397-406.
Strable, E., Bulte, J. & Moskowitz, B. (2001). Synthesis and characterization of soluble
iron oxide-dendrimer composites. Chem. Mater. 13: 2201-2209.
Stahlhofen, W. and W. Möller (1993). Behaviour of magnetic micro-particles in the
human lung. Radiation and Environmental Biophysics. 32(3): 221-238.
Subramanian, J., Waqar, S. N., & Govindan, R. (2011). Targeted therapy in lung cancer:
lessons learned from past experiences. Journal of Thoracic Oncology, 6(11),
S1786-S1788. doi:10.1097/01.JTO.0000407558.38416.c5.
Svartengren, K., Anderson, M., Svartengren, M., Philipson, K., and Camner, P. (1996).
Oropharyngeal Deposition of 3.5 Microns Particles Inhaled Through an Elongated
Mouthpiece. The European Respiratory Journal. 9(7): 1556–59.

124

Syrigos, K. N., Nutting, C. M., Roussos, C. Tumors of the Chest: Biology, Diagnosis and
Management. (2006). Springer Science & Business Media.
Tatsumura, T, S Koyama, M Tsujimoto, M Kitagawa, and S Kagamimori. (1993). Further
Study of Nebulisation Chemotherapy, a New Chemotherapeutic Method in the
Treatment of Lung Carcinomas: Fundamental and Clinical. British Journal of
Cancer 68(6): 1146–49.
Tatsumura, T., Yamamoto, K. & Murakami, A. (1983) New chemotherapeutic method
for the treatment of tracheal and bronchial cancers--nebulization chemotherapy.
Japan journal of cancer clinics, 29(7), 765-770.
Tazebay, U. H.; Wapnir, I. L.; Levy, O.; Dohan, O.; Zuckier, L. S.; Zhao, Q. H.; Deng,
H. F.; Amenta, P. S.; Fineberg, S.; Pestell, R. G. (2000). The Mammary Gland
Iodide Transporter Is Expressed During Lactation and in Breast Cancer.” Nat.
Med. 6, 871–878.
Telko, M., and Hickey, A. (2005). Dry Powder Inhaler Formulation. Respiratory Care.
50(9): 1209–27.
Terrovitis, J.; Kwok, K., Lautamäki, R., Engles, J. M., Barth, A. S., Kizana, E.; Miake, J.;
Leppo, M. K.; Fox, J.; Seidel, J. (2008). Ectopic Expression of the Sodium-Iodide
Symporter Enables Imaging of Transplanted Cardiac Stem Cells in Vivo by
Single-Photon Emission Computed Tomography or Positron Emission
Tomography. J. Am. Coll. Cardiol. 52, 1652–1660.
Thatcher, N., Chang, A., Parikh, P., and Rodrigues Pereira, J. (2005). Gefitinib plus best
supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: results from a randomised, placebo-controlled, multicentre study
(Iressa Survival Evaluation in Lung Cancer). The Lancet, 366(9496), 1527-1537.
Thun, M., Henley, S., Burns, D., and Jemal, A. (2006). Lung Cancer Death Rates in
Lifelong Nonsmokers. Journal of the National Cancer Institute, 98(10), 691-699.
Tomayko, M. Reynolds, C. Determination of Subcutaneous Tumor Size in Athymic
(Nude) Mice. (1989). Cancer chemotherapy and pharmacology. 24(3), 148-154.
Torchilin, V. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature
reviews Drug discovery 4.2:145-160.
Tseng, C. L., Su, W. Y., Yen, K. C., Yang, K. C., & Lin, F. H. (2009). The use of
biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin
accumulation in cancerous lungs via inhalation. Biomaterials, 30(20), 3476-3485.
doi:10.1016/j.biomaterials.2009.03.010.

125

Urva, S. R., Shin, B. S., Yang, V. C. & Balthasar, J. P. (2009) Sensitive high performance
liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in
mouse plasma and tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
877, 837–841.
van Kuppevelt, T. H.; Robbesom, A. A.; Versteeg, E. M.; Veerkamp, J. E.; van
Herwaarden, C. L.; Dekhuijzen, P. N. (2000) Restoration by Vacuum Inflation of
Original Alveolar Dimensions in Small Human Lung Specimens. Eur. Respir. J.,
15, 771–777.
Vargas, J. M., McBride, A. A., Plumley, J. B., Fichou, Y., Memon, T. A., Shah, V.,
Osiński, M. (2011). Synthesis and characterization of core/shell Fe3O4/ZnSe
fluorescent magnetic nanoparticles. Journal of applied physics,109(7), 07B536.
Wangari-Talbot, J. and Hopper-Borge, E. (2013). Drug Resistance Mechanisms in NonSmall Cell Lung Carcinoma. Journal of Cancer Research Updates. 2 (4). NIH
Public Access: 265. doi:10.6000/1929-2279.2013.02.04.5.
Wang, Y., Schmid-Bindert, G. and Zhou, C. (2012). Erlotinib in the Treatment of
Advanced Non-Small Cell Lung Cancer: an Update for Clinicians. Therapeutic
Advances in Medical Oncology, 4 (1): 19–29. doi:10.1177/1758834011427927.
Weers, J., Tarara, T., Clark, A. (2007). Design of Fine Particles for Pulmonary Drug
Delivery. Expert Opinion on Drug Delivery. 4 (3): 297–313.
doi:10.1517/17425247.4.3.297.
Widder, K., Senyei, A., and Ranney, D. (1979). Magnetically Responsive Microspheres
and Other Carriers for the Biophysical Targeting of Antitumor Agents. Advances
in Pharmacology and Chemotherapy. 16: 213–71.
Wild, P, Bourgkard, E., and Paris, C. (2009). Lung Cancer and Exposure to Metals: the
Epidemiological Evidence. Cancer Epidemiology. 139-167.
Wolff, R K. (1998). Safety of Inhaled Proteins for Therapeutic Use. Journal of Aerosol
Medicine. 11(4), 197-219.
World Health Organization. Lung Cancer Fact sheet, 2014.
Xie, Y., Longest, P. W., Xu, Y. H., Wang, J. P. & Wiedmann, T. S. (2010). In vitro and
in vivo lung deposition of coated magnetic aerosol particles. J Pharm Sci. 99,
4658–4668.
Yamaura, T.; Murakami, K.; Doki, Y.; Sugiyama, S.; Misaki, T.; Yamada, Y.; Saiki, I.
(2000). Solitary Lung Tumors and Their Spontaneous Metastasis in Athymic
Nude Mice Orthotopically Implanted with Human Non-Small Cell Lung Cancer.
Neoplasia. 2, 315–324.

126

Yang, X., Yang, K., & Kuang, K. (2014). The Efficacy and Safety of EGFR Inhibitor
Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review. Current
oncology reports, 16(6), 1-10. doi:10.1007/s11912-014-0390-4.
Yi, D., & Wiedmann, T. S. (2010). Inhalation adjuvant therapy for lung cancer. Journal
of aerosol medicine and pulmonary drug delivery, 23(4), 181-187.
doi:10.1089/jamp.2009.0787.
Zak, A., Feldman, Y., Lyakhovitskaya, V., Leitus, G., Popovitz-Biro, R., Wachtel, E., &
Tenne, R. (2002). Alkali metal intercalated fullerene-like MS2 (M= W, Mo)
nanoparticles and their properties. Journal of the American Chemical
Society, 124(17), 4747-4758.
Zarogoulidis, P, Darwiche, K., Krauss, L., and Huang, H. (2013). Inhaled Cisplatin
Deposition and Distribution in Lymph Nodes in Stage II Lung Cancer Patients.
Future Medicine. 9(9), 1307-1313.
Zeng, Ming, X., Martin, G., and Marriott, C. (2000). Particulate Interactions in Dry
Powder Formulation for Inhalation. Taylor & Francis.

127

